user_input,reference_contexts,reference,synthesizer_name,answer,source_content,source_document_info,LLMContextPrecisionWithReference_score,ResponseRelevancy_score,NoiseSensitivity_score,Faithfulness_score
"Whats the neuro status of the pashent with systmic murmer at RUSB, especaily ther alertness and cranial nerve intactness?","['0070a23b-dc9f-483f-a66d-a8d84a4b995b\n\nCARDIOVASCULAR: Regular rate and rhythm with late ___ systolic\nmurmur at RUSB, no rubs or gallops\nLUNGS: clear to auscultation bilaterally without rhonchi,\nwheezes, or crackles\nGI: soft, nontender, without rebounding or guarding, \nnondistended\nwith normal active bowel sounds, no hepatomegaly\nEXTREMITIES: no clubbing, cyanosis, or edema\nGU: no foley\nSKIN: no rashes, petechia, lesions, or echymoses; warm to\npalpation\nNEURO: Alert and interactive to person, ___ (daughters\nstated that this is a hospital before pt named it), ___, but\nthinks that it is ___, cranial nerves II-XII intact, strength \nis\n___ in RUE, RLE, LLE, ___ in LUE elbow flexion/extension and\nhand grip. Gait is WNL, negative Romberg, negative pronator\ndrift.\nPSYCH: normal mood and affect\nDISCHARGE EXAM\nVS: 97.9 PO 151 / 65 64 18 99 RA \nGEN: Alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor', '688ac351-3658-4804-8bb2-2bd5b3e5aaac\n\nEXTREMITIES: 2+ pitting edema bilaterally in lower extremities.\nPulses 2+ bilaterally. \nNEURO: Alert & oriented x3. Non-focal neuro exam.\nDISCHARGE PHYSICAL EXAMINATION:  \n===============================\n24 HR Data (last updated ___ @ 809)\n    Temp: 98.1 (Tm 99.0), BP: 168/75 (142-168/69-79), HR: 88\n(87-95), RR: 18 (___), O2 sat: 97% (94-97)  \n___ Total Intake: 720ml PO Amt: 720ml \n___ Total Output: 1100ml Urine Amt: 1100ml \nFluid balance: -380\n___ Total Intake: 180ml PO Amt: 180ml \n___ Total Output: 900ml Urine Amt: 900ml \nFluid balance: -720\nGENERAL: Sitting up comfortably at edge of bed, in NAD\nHEENT: NC/AT\nNECK: Supple. unable to appreciate JVD at 90 degrees\nCARDIAC: RRR, no rubs/gallops\nLUNGS: Faint bibasilar crackles on auscultation\nABDOMEN: Soft, NTND\nEXTREMITIES: 2+ pitting edema bilaterally to knees in ___. Pulses\n2+ bilaterally. WARM']","The patient is Alert and interactive to person, with some memory or recognition issues (as indicated by the patient initially not naming the hospital correctly but later doing so). The patient thinks it is a different time/frame than actual (exact details not specified). Cranial nerves II-XII are intact. Strength is noted as being 5/5 in Right Upper Extremity (RUE), Right Lower Extremity (RLE), Left Lower Extremity (LLE), and 4/5 in Left Upper Extremity (LUE) for elbow flexion/extension and hand grip. Gait is Within Normal Limits (WNL), with a negative Romberg and negative pronator drift.",custom_multi_hop_query_synthesizer,"To answer the question accurately, let's break down the information needed and where to find it:

1. **Patient ID with Systolic Murmur**: We need to identify documents mentioning a systolic murmur and note the patient ID from the **METADATA**.
2. **Neuro Status, Alertness, and Cranial Nerve Intactness**: Once we've identified the relevant document(s) with the systolic murmur, we'll look for neuro status, alertness, and cranial nerve information in the **CONTENT**.

**Analysis**:

- **Systolic Murmur & Patient ID**:
	* Document 3 mentions a ""Systolic murmur"" under **Cardiovascular (CV)**.
	* According to the **METADATA** of Document 3, the **Patient/Subject ID** is: **13180007**
	* **Note**: This Patient ID is consistent across all provided documents (1 through 5), indicating all documents pertain to the same patient.

- **Neuro Status, Alertness, and Cranial Nerve Intactness for Patient 13180007 with Systolic Murmur**:
	* **Alertness**: Document 3 mentions the patient is ""**Alert and Oriented x3**"" under **Neurological (Neuro)**.
	* **Cranial Nerve Intactness**: While Document 3 does not specifically mention cranial nerve status, Document 1 and Document 4 provide complementary information:
		+ Document 1: ""**CN (Cranial Nerves) intact**"" under **Neuro**.
		+ Document 4: ""**Cranial Nerves (CN) [intact, but specific CN not listed]**"" under **Neurological (Neuro)**.

**Answer**:

* **Patient ID with Systolic Murmur at RUSB (Right Upper Sternal Border, implied by ""RUSB"" though not explicitly mentioned in the documents)**: **13180007** (consistent across all documents)
* **Neuro Status**:
	+ **Alertness**: **Alert and Oriented x3** (Document 3, also supported by other documents)
	+ **Cranial Nerve Intactness**: **Intact** (Documents 1 and 4, though specific cranial nerves are not detailed in Document 4)","['* **Msk**:\n\t+ No spine tenderness\n\t+ Moving all 4 extremities\n\t+ 2+ edema\n* **Neuro**:\n\t+ A&O x3 (Alert and Oriented to person, place, and time)\n\t+ CN (Cranial Nerves) intact\n\t+ Normal strength and se', '* **Initial Vital Signs (VS):**\n\t+ Temperature (T): 98.5Â°F\n\t+ Heart Rate (HR): 102 bpm\n\t+ Blood Pressure (BP): 178/76 mmHg\n\t+ Respiratory Rate (RR): 22 breaths/min\n\t+ Oxygen Saturation (SpO2): 98% on ', '- Normal oropharynx\n\t+ Lungs: Non-labored breathing, Clear to Auscultation Bilaterally (CTAB)\n\t+ Cardiovascular (CV):\n\t\t- Regular Rate and Rhythm (RRR)\n\t\t- Systolic murmur\n\t\t- Normal S1, S2\n\t+ Abdomen', '- Alert and Oriented x3\n\t\t- Cranial Nerves (CN) [intact, but specific CN not listed]\n\t\t- Normal strength and sensation in all extremities\n\t\t- Normal speech and gait\n\t+ Skin: No rash\n\t+ Psych: Normal m', '* **Admission Physical Exam**\n\t+ **Vital Signs (VS)**: \n\t\t- Temp: 97.8\n\t\t- BP: 144/69\n\t\t- HR: 86\n\t\t- RR: 18\n\t\t- O2 sat: 96%\n\t\t- O2 delivery: RA\n\t+ **General**: NAD (No Acute Distress), Oriented x3, Mo']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
What were the initial presentation and immediate interventions for the patient with acute Heart Failure with preserved Ejection Fraction (HFpEF) exacerbation in the Emergency Department (ED)?,"['595bbed3-a542-444b-b48a-e6edf79ac096\n\nHistory of Present Illness:\n___ year old man with numerous cardiac risk factors, prior CVA\npresented with sudden onset worsening of subacute dyspnea found\nto have flash pulmonary edema admitted for acute HFpEF\nexacerbation. \n Per EMS and confirmed with family, patient was found on the\ncouch by his family was minimally responsive. Patient described\nsubacute shortness of breath over the last two weeks (e.g.,\nhaving to sit down multiple times when going to grocery store or\nup steps at home).  He has also had a cough, rhinorrhea but no\nfever, no sputum.  This worsened acutely this morning when he\nwoke-up struggling to breath.  EMS was called, SBP to 176 per ED\ndocumentation, patient was given nitro x2 and started on CPAP. \n In the ED, he was started on bipap diuresed with OV Lasix,\nstarted on home BP medications and then transferred to floor. \n - Initial vitals: HR 109 BP 176/67 RR 26 ___ 90, patient was\ntachypneic, unable to speak in full sentences, crackles L>R, no\nfocal deficits\n - EKG:  not commented upon\n - Labs/studies notable for: Patient was given: NG x2. Lasix IV\n40mg (at 4:30am), Zosyn/Vanc  \n Amlodipine 10mg, Carvedilol 25mg, Lisinopril 2.5mg,\nlevothyroxine, insulin 10U regular,  \n - Vitals on transfer:  ___ 1040 Temp: 98.4 PO BP: 115/45 R', ""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin.""]","The patient, a man with numerous cardiac risk factors and a prior CVA, presented to the ED with sudden onset worsening of subacute dyspnea, leading to flash pulmonary edema. Initial vitals in the ED showed HR 109, BP 176/67, RR 26, with the patient being tachypneic. Immediate interventions included administration of nitro x2 by EMS, initiation of CPAP, which was later switched to BiPAP in the ED, diuresis with IV Lasix (40mg), and the continuation of home BP medications (Amlodipine 10mg, Carvedilol 25mg, Lisinopril 2.5mg).",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Identification (from METADATA, consistent across all documents):**
* **Patient/Subject ID:** 13180007
* **Note ID:** 13180007-DS-19 (consistent across all documents, indicating these documents are related to the same note/event)
* **Admission ID:** 20774429 (consistent across all documents, confirming the event/admission is the same)

**Initial Presentation in the Emergency Department (ED):**
* **Symptoms (from Document 1 & Document 2):** 1 day of dyspnea and discomfort
* **Vital Signs at Initial Assessment in ED (from Document 4):**
	+ Temperature (T): 98.5
	+ Heart Rate (HR): 102
	+ Blood Pressure (BP): 178/76
	+ Respiratory Rate (RR): 22
	+ Oxygen Saturation (SpO2): 98% on Room Air (RA)

**Immediate Interventions for HFpEF Exacerbation:**
* **Initial Treatment (from Document 1 & Document 2):** Diuresed with several doses of IV Lasix 80mg, leading to improvement in symptoms.
* **Discharge Medication for Ongoing Management (from Document 1 & Document 2):** Torsemide 100mg daily for active diuresis.

**Additional Context Relevant to the ED Presentation:**
* **Notable Labs at Time of Initial Assessment (from Document 4):**
	- Hemoglobin (Hgb): 7.4
	- Blood Urea Nitrogen (BUN): 39
	- Creatinine (Cr): 2.6
	- proBNP: 784
	- Troponin T (TropT): 0.03
* **Trigger for Exacerbation (from Document 1 & Document 2):** Unclear, with possible medication non-compliance mentioned, though the patient endorses compliance (Document 4).","['* **Summary**: \n\t+ Patient with HFpEF (EF 55-60%) admitted for HF exacerbation with dyspnea and discomfort\n\t+ Trigger unclear, possibly medication non-compliance\n\t+ Symptoms improved with IV Lasix; di', '* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa', '* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi', '+ 2 hospitalizations in the past year for HF exacerbations\n* **Medication Compliance**:\n\t+ Typically on Lasix 80mg daily\n\t+ Endorses compliance with medications\n* **Initial Assessment in ED**:\n\t+ Init', '**ACUTE PROBLEMS**\n=====================\n\n### 1. **Acute on Chronic HFpEF (Heart Failure with Preserved Ejection Fraction)**']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"Whats the relevent med list for DM managment in a pateint with Hx of CAD, ischemic CVA, CKD, and Hypothyroidism, with med speling dont mater?","['8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY', '8d31665e-700b-4b64-8af5-51456ad55ff5\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-140 \nK-4.6 Cl-99 HCO3-25 AnGap-16\n___ 06:35AM BLOOD Calcium-8.4 Phos-6.0* Mg-2.1\n \nBrief Hospital Course:\nSUMMARY\n=======\n___ male with history of HFpEF (EF 55-60% in ___,\nprior CVA, CKD, DM, hypertension, and carotid artery disease\nwho presented with 1 day of dyspnea and discomfort, and was\nadmitted for HF exacerbation. The trigger was unclear, possible \nmedication non-compliance. He was diuresed with several doses of \nIV Lasix 80 and by time of discharge symptoms had improved. He \nwas still slightly volume up on exam, with JVP ~12 and 1+ edema \nto ankles.\nTRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally and JVP of 12cm. He is being \ndischarged on torsemide 100 daily for active diuresis, with \nabout 3lb of fluid still left to lose.']","Based on the provided context, for a patient with a history of CAD, ischemic CVA, CKD, Hypothyroidism, and specifically focusing on Diabetes Mellitus (DM) management, the relevant medications from the admission list are:  1. **Jardiance (empagliflozin) 10 mg oral DAILY** - an SGLT2 inhibitor used in the treatment of type 2 diabetes. 2. **Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY** - a GLP-1 receptor agonist used for type 2 diabetes management. Additionally, medications indirectly beneficial for DM management due to their effects on related conditions include: - **CARVedilol 37.5 mg PO BID** and **amLODIPine 10 mg PO DAILY** for hypertension, a common comorbidity with DM. - **sevelamer CARBONATE 800 mg PO TID W/MEALS** for CKD, which can be influenced by DM management.",custom_multi_hop_query_synthesizer,"Based on the provided documents, I'll attempt to answer your question while following the instructions.

**Question:** What's the relevant med list for DM (Diabetes Mellitus) management in a patient with Hx (History) of CAD (Coronary Artery Disease), ischemic CVA (Cerebrovascular Accident), CKD (Chronic Kidney Disease), and Hypothyroidism, with medication spelling variations not mattering?

**Relevant IDs (as per instruction 2 & 3):**
- **Patient/Subject ID:** 13180007 (appears in all documents: 1, 2, 3, 4, 5)
- **Note ID:** 13180007-DS-19 (appears in all documents: 1, 2, 3, 4, 5)
- **Admission ID:** 20774429 (appears in all documents: 1, 2, 3, 4, 5)

**DM Management Medication List:**
Based on the provided documents, the following medications are relevant to the patient's conditions, including Diabetes Mellitus Type 2 management, considering the history of CAD, ischemic CVA, CKD, and Hypothyroidism:

1. **For Diabetes Mellitus Type 2 (DM):**
   - **No specific anti-diabetic medications** are listed in the provided documents. However, the patient's **%HbA1c is 11.4*** (High), indicating poorly controlled diabetes. Typically, medications for DM might include Metformin, Sulfonylureas, DPP-4 inhibitors, etc., but none are mentioned here.

2. **For CAD and ischemic CVA:**
   - **Aspirin** (81 mg PO DAILY) - for antiplatelet therapy
   - **Atorvastatin** (80 mg PO QPM) - for managing dyslipidemia and reducing cardiovascular risk

3. **For CKD (Chronic Kidney Disease):**
   - **No specific medications for CKD management** are highlighted in the documents. However, the patient's lab results (e.g., elevated Phos, cTropnT levels) suggest the need for CKD management, which might typically include medications like ACE inhibitors, ARBs, phosphate binders, etc., but none are listed here.

4. **For Hypothyroidism:**
   - **Levothyroxine** (100 mcg PO DAILY) - for managing hypothyroidism

**Summary for DM Management in Context:**
Given the patient's complex medical history, the absence of specific anti-diabetic medications in the provided documents is notable. The management of DM in this patient, especially with a history of CAD, ischemic CVA, CKD, and Hypothyroidism, would typically require a more comprehensive approach, including:
- **Unlisted Anti-diabetic medications** (e.g., Metformin, etc.)
- **Aspirin** and **Atorvastatin** for cardiovascular protection
- **Levothyroxine** for hypothyroidism management
- **Unlisted CKD management medications** (the patient's CKD stage and specific needs are not detailed in the provided documents)

**Recommendation:**
For accurate and comprehensive DM management, consult the patient's full medical record, including any additional medications not listed in these documents, and consider a multidisciplinary approach given the patient's complex health profile.","['#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri', '* **Related Information from Other Sections (for context):**\n\t+ **Family History:** Parents have heart disease; Mother has heart problems and diabetes; Father has diabetes\n\t+ **Chronic Problems Sectio', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '**PAST MEDICAL HISTORY**\n\n* **Conditions:**\n\t1. **Hypertension**\n\t2. **Dyslipidemia**\n\t3. **Diabetes Mellitus Type 2**\n\t4. **Cerebrovascular Disease**, status post CVA (date: **[REDACTED]**)\n\t5. **Ext', '- AnGap: 13\n\t\t- **05:53 AM**\n\t\t\t- Calcium: 8.4\n\t\t\t- Phos: 4.9* (High)\n\t\t\t- Mg: 2.0\n\t\t\t- Iron: 28*\n\t\t\t- calTIBC: 294\n\t\t\t- Ferritn: 73\n\t\t\t- TRF: 226\n\t\t\t- %HbA1c: 11.4* (High)\n\t\t\t- eAG: 280*\n\t\t\t- TSH: 4.']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
Whats the comon complictions of uncontrolld DM2 in patiants with exsisting CVA and HTN?,"['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', 'e2f22eea-f842-4b4c-8542-dfd4f8a519ce\n\n___ yo M with IDDM, HTN, CVA, asthma who presents to the ED after\nvomiting multiple times last night. He notes he ate taco bell at\n5, then at 6pm ate dinner and vomited all his rice at that time.\nContinued to vomit multiple times and decided to come to the ED.\nNon bilious non bloody. Doesn\'t have vomiting often. Denies any\nproblems with bowel movements. \nHe notes that he has been having problems with his BPs at home.\nNotes compliance and uses a pill box that his wife helps him\nfill. Notes that he tries to eat healthy (although he did have\ntacobell last night around 5pm). He also notes feeling ""off\nbalance"" when his BPs are raised but doesn\'t check them often at\nhome. Has been trying to check blood sugars more recently.\nDoesn\'t have a log here. \nNotes he sometimes has chest pain. Currently without chest pain.\nNotes that he doesn\'t get it with walking unless walking long\ndistance. Can walk up about 20 steps without stopping. \n \nPast Medical History:\n- DM2\n- Diabetic Retinopathy\n- Hypothyroidism\n- CKD Stage IIIa\n- HLD\n- HTN']","Based on the provided context, common complications or associated conditions with uncontrolled DM2 (Diabetes Mellitus Type 2) in patients with existing CVA (Cerebrovascular Accident) and HTN (Hypertension) include:               - **Chronic Infarcts**: As seen in the CT HEAD results, indicating potential previous brain tissue damage due to lack of blood supply.              - **Cognitive Impairment**: Mentioned in the brief hospital course, suggesting a decline in cognitive function.              - **Chronic Lacunar Infarcts**: Within the basal ganglia, indicative of small vessel disease, common in diabetes and hypertension.              - **CKD (Chronic Kidney Disease)**: Stage IIIa noted in the past medical history, a known complication of long-standing diabetes and hypertension.              - **Diabetic Retinopathy**: Listed in the past medical history, a common complication of diabetes affecting the eyes.              - **Emotional Lability and Dysarthria**: Residual effects from the CVA, potentially exacerbated by the metabolic and vascular stress of uncontrolled DM2 and HTN.",custom_multi_hop_query_synthesizer,"**Answering the Question with Available Information**

Given the complexity of the question, which inquires about common complications of uncontrolled Diabetes Mellitus Type 2 (DM2) in patients with existing Cerebrovascular Accident (CVA) and Hypertension (HTN), we'll analyze the provided documents to extract relevant information. However, please note that the documents primarily offer a snapshot of a patient's medical history and current conditions rather than directly answering the question about common complications in similar patient profiles.

**Relevant Extracted Information from Documents:**

- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Conditions Relevant to the Question:**
  - **Diabetes Mellitus Type 2 (DM2):** Mentioned in Document 1 under ""PAST MEDICAL HISTORY"" and in Document 2 as a ""Secondary Diagnosis"" upon discharge, indicating its active management.
  - **Cerebrovascular Accident (CVA):** Document 1 lists ""Cerebrovascular Disease, status post CVA"" with a redacted date, and Document 2 mentions ""History of CVA"" under ""CHRONIC PROBLEMS"".
  - **Hypertension (HTN):** Listed in Document 1 under ""PAST MEDICAL HISTORY"".

**Common Complications of Uncontrolled DM2 in Patients with Existing CVA and HTN (Inferred from General Medical Knowledge, as Specifics are Not Provided in the Documents):**

Given the documents do not directly address the question of common complications, we rely on general medical knowledge for this part:

- **Cardiovascular Diseases:** Exacerbation of existing heart conditions (e.g., heart failure, as seen in Document 2's ""Primary Diagnosis"").
- **Kidney Damage (Nephropathy):** Acute kidney injury is listed in Document 2, which could be a complication of uncontrolled DM2, further exacerbated by HTN.
- **Neurological Decline:** Increased risk of further CVAs or worsening of existing neurological deficits due to uncontrolled HTN and DM2.
- **Vision Impairment (Diabetic Retinopathy):** Not mentioned in the documents but a known complication of uncontrolled DM2.
- **Foot Ulcers/Gangrene:** Not mentioned; however, a common complication of poorly managed DM2.

**Limitations and Conclusion:**

- The documents provide a comprehensive view of a patient's medical history and current conditions but do not directly answer the question about common complications in similar patient profiles.
- The answer regarding common complications is inferred from general medical knowledge, highlighting the need for specific studies or medical literature for a detailed and accurate response.

**Metadata Summary (as per instruction 3):**
- **Patient/Subject ID:** 13180007 (appears in all documents: 1, 2, 3, 4, 5)
- **Note ID, Admission ID, Chart Time, and Store Time** are consistent across all documents, indicating they pertain to the same patient event.","['**PAST MEDICAL HISTORY**\n\n* **Conditions:**\n\t1. **Hypertension**\n\t2. **Dyslipidemia**\n\t3. **Diabetes Mellitus Type 2**\n\t4. **Cerebrovascular Disease**, status post CVA (date: **[REDACTED]**)\n\t5. **Ext', '#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri', '**PERTINENT STUDIES/RESULTS**', '### **PERTINENT STUDIES/RESULTS**', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"Whats the perscribd dose of Aspirin for a patiant with NSTEMI and hypertension, and whats its role in ther care plan?","['5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","For a patient with NSTEMI and hypertension, as observed in the provided medical context, the prescribed dose of Aspirin is 81 mg PO DAILY. The role of Aspirin in this care plan is consistent with managing Non-ST Elevation Myocardial Infarction (NSTEMI), where Aspirin is standard for its antiplatelet effects to reduce the risk of further cardiac events. Additionally, its anti-inflammatory properties may indirectly support the management of the patient's overall cardiovascular health, including hypertension, although its primary role in this context is related to the patient's CAD with inducible ischemia and NSTEMI rather than directly lowering blood pressure.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's the answer to your question:

**Prescribed Dose of Aspirin for the Patient:**
The prescribed dose of Aspirin for the patient is **81 mg PO DAILY**.

**Source Documents for Aspirin Dose:**
This information can be found in:
- **Document 1**: Under ""CONTENT"" > ""12. Aspirin 81 mg PO DAILY""
- **Document 2**: Under ""CONTENT"" > ""**Chronic Problems Section:**"" > ""**History of CVA**"" > ""Aspirin and atorvastatin 80"" (Note: The dose is not explicitly mentioned here, making Document 1 the primary source for the dose.)
- **Document 4**: Under ""CONTENT"" > ""**CHRONIC PROBLEMS**"" > ""2. **History of CVA (Cerebrovascular Accident)**"" > ""Aspirin 81 mg PO DAILY (continued from home)""

**Role in the Care Plan:**
Based on the context provided across the documents, Aspirin plays a role in managing two aspects of the patient's health:

1. **History of CVA (Cerebrovascular Accident)**: Aspirin is used as an antiplatelet agent to reduce the risk of another cerebrovascular event.
2. **Family History of Heart Disease and Patient's Own History**: While not explicitly stated as a treatment for hypertension or a specific condition like NSTEMI (which is not mentioned in the provided documents), aspirin's general role in cardiovascular health is well-established. It helps in preventing blood clots that could lead to heart attacks and strokes, aligning with the management of patients with heart disease and hypertension.

**IDs Consistency:**
- **Patient/Subject ID**: Consistently listed as **13180007** across all documents (Documents 1 through 5).
- **Note ID**: Consistently listed as **13180007-DS-19** across all documents (Documents 1 through 5).
- **Admission ID**: Consistently listed as **20774429** across all documents (Documents 1 through 5).
- **Chart Time** and **Store Time**: Consistent across all documents, indicating the information was charted and stored at the same times for this patient's admission.","['11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '* **Related Information from Other Sections (for context):**\n\t+ **Family History:** Parents have heart disease; Mother has heart problems and diabetes; Father has diabetes\n\t+ **Chronic Problems Sectio', '* **VS (Vital Signs)**:\n\t+ Temp: 97.8\n\t+ BP: 144/69\n\t+ HR: 86\n\t+ RR: 18\n\t+ O2 sat: 96% RA\n* **General**: NAD, Oriented x3, Mood and affect appropriate\n* **HEENT**:\n\t+ Normocephalic atraumatic\n\t+ Scler', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '+ 2 hospitalizations in the past year for HF exacerbations\n* **Medication Compliance**:\n\t+ Typically on Lasix 80mg daily\n\t+ Endorses compliance with medications\n* **Initial Assessment in ED**:\n\t+ Init']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What specific insulin regimen should a discharged patient, who was hospitalized for worsening shortness of breath and leg swelling, continue to follow as part of their post-discharge care, considering their pre-admission insulin schedule?","['cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!', ""fd49a2e0-9612-4cbf-91c3-bbfc765fb300\n\n[ ] Changed medications: Insulin (lantus 40 qam and 10 qpm w/ \nNovolog ___ w/ SSI with meals; discharged w/ insulin pens), \ncoreg was increased to 37.5 mg BID. Amlodipine was switched from \nqod to everyday.\n[ ] Please monitor BP as an outpatient and consider starting \nimdur.\n[ ] HFpEF - Consider initiation of spironolactone once Cr is \ndowntrending.\n[ ] ?COPD - Consider PFTs to see if patient has COPD. Started on \nadvair as an inpatient.\n[ ] DM: Please monitor his blood glucose as an outpatient as his \nblood glucoses ran elevated as an inpatient. He should follow-up \nwith ___ as an outpatient.\n[ ] Lung cancer screening - Given patient's smoking history, \nconsider outpatient CT Chest.\n[ ] Hyperlipidemia - Per prior cardiology note, patient approved \nfor PCSK9 inhibitor.\n[ ] Iron deficiency anemia: Will need a colonoscopy as an \noutpatient\n[ ] CKD - Anticipate he may need dialysis in the future. K on \ndischarge was 4.8 and Cr on discharge was 3.7.\n[ ] Labs: Please recheck a BMP at his next follow-up appointment \nto monitor K and Cr.\n[ ] Discharge weight: 72.7 kg\n==============""]","The patient should continue taking insulin according to the regimen they were following before this admission, which specifically includes: Insulin (Lantus 40 qam and 10 qpm with Novolog, with Sliding Scale Insulin (SSI) adjustments with meals), now discharged with insulin pens for administration.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's the analysis to answer the question about the specific insulin regimen for the discharged patient:

**Patient Identification for Context:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, 2, 3, 4, and 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Insulin Regimen Analysis:**

* **Pre-admission Insulin Schedule (Document 5 - Medications on Admission):**
	+ **Insulin (70/30):**
		- 30 Units at Breakfast
		- 10 Units at Lunch

* **Post-discharge Insulin Schedule (as per various documents):**
	+ **Document 2 (Discharge Medications):**
		- **Insulin (70/30):**
			- 30 Units Breakfast
			- 10 Units Lunch (noted as ""continued, with adjustments"")
	+ **Documents 3 and 4 (Discharge Medications Lists):**
		- Only mention ""70/30 Insulin"" without specifying the dosage and timing, implying reliance on previous specifications for detailed administration instructions.

**Conclusion:**
Given the information, the discharged patient should continue with the **70/30 Insulin** regimen as follows, considering the pre-admission schedule and the note on adjustments in the post-discharge instructions:

* **30 Units at Breakfast**
* **10 Units at Lunch** (with the understanding that there might be **adjustments** to this schedule as noted in Document 2, but the exact nature of these adjustments is not specified in the provided documents)

**Recommendation for Clinical Practice:**
Due to the mention of ""adjustments"" in Document 2 without clear specifications, it is recommended that the patient clarifies these adjustments with their healthcare provider to ensure accurate insulin administration post-discharge.","['Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula', '* **Discharge Medications:**\n\t1. **Torsemide**: 100 mg PO DAILY (newly prescribed)\n\t2. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath (continued)\n\t3. **Amlodipine**: 10 mg PO DAILY (cont', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ', '* **Medications on Admission (Pre-admission List):**\n\t1. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath\n\t2. **Amlodipine**: 10 mg PO DAILY\n\t3. **Atorvastatin**: 80 mg PO QPM\n\t4. **Carved']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What ar the commen causis of Congestive Heart Failure (CHF) exaserbation in pashents with a history of hypertension and diabetis, and how do sympoms like shortness of breath and lower extremity edema relait to the condishun?","['6ca6759d-052d-4b9a-b47d-014a869a41be\n\nechocardiographic evidence of tamponade.\nIMPRESSION: Mild symmetric biventricular hypetrophy with \npreserved biventricular systolic function. No clinically \nsignificant valvular disease. Small, predominantly anterior \npericardial effusion\nwithout echocardiographic evidence of tamponade.\n \nBrief Hospital Course:\n___ M w/ PMH significant for HTN, HLD, T2DM, and CVA in ___ \nwho presents w/ increased SOB and volume retention, concerning \nfor CHF exacerbation. \nACTIVE ISSUES: \n==============\n#Acute HF exacerbation (preserved EF 65% on stress echo in ___, \nunknown current EF)\n#Hypertension\nPatient presented with worsening shortness of breath, lower \nextremity edema and was hypervolemic on exam w/ diffuse rhonchi \non lung auscultation, as well as elevated BNP, all concerning \nfor CHF exacerbation. Stress echo in ___ showed \npreserved EF. Etiology could be either uncontrolled hypertension \nvs ischemia (especially given history of positive stress echo). \nExacerbation could be due to medication/dietary non-compliance.', 'e0673342-03d7-4e47-9dd2-f1d0eaafa133\n\n___ (PORTABLE AP)\nIMPRESSION: \nIn comparison with the study of earlier in this date, the \nendotracheal tube\nhas been pulled back so that the tip now lies approximately 5 cm \nabove the\ncarina.  Cardiomediastinal silhouette is stable.  The vascular \ncongestion\nsuggested previously is no longer appreciated.\n \nBrief Hospital Course:\n___ year old male w history of diastolic CHF, diabetes type 2 \nrecent admission for CHF exacerbation, re-admitted ___ \nwith hyperglycemia and respiratory distress requiring \nintubation, status post treatment of acute diastolic CHF, \nsubsequently optimizing glucose control, able to be discharged \nhome with ___ for medication assistance.  \nTRANSITIONAL ISSUES:\n====================\n[ ] Will need repeat Cr at his ___ appointment on ___, \n___, to ensure stability.\n[ ] Repeat CMP within 1 week of discharge, to ensure stability \nin electrolytes \n[ ] Patient has now had multiple presentations the hospital with']","Based on the provided context, CHF exacerbation in patients with a history of hypertension and diabetes can be attributed to two main etiologies: **1. Uncontrolled Hypertension** and **2. Ischemia** (especially in patients with a history of positive stress echo). Symptoms such as **worsening shortness of breath (SOB)**, **lower extremity edema**, and being **hypervolemic on exam** along with **diffuse rhonchi on lung auscultation** and **elevated BNP**, are all concerning for CHF exacerbation. Additionally, **medication/dietary non-compliance** can also contribute to the exacerbation of CHF. In patients with diastolic CHF, optimizing glucose control (for those with diabetes) and managing the underlying causes are crucial for stabilization and discharge.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Common Causes of Congestive Heart Failure (CHF) Exacerbation in Patients with a History of Hypertension and Diabetes:**

While the provided documents do not explicitly list common causes of CHF exacerbation, based on medical knowledge, the following are typical triggers in patients with a history of hypertension and diabetes:

1. **Medication Non-compliance**: As hinted at in Document 1, not adhering to prescribed medications for CHF, hypertension, or diabetes can lead to exacerbation.
2. **Poor Glycemic Control**: Elevated blood sugar levels (e.g., A1c 11.4% in Document 5) can increase blood pressure and worsen heart failure.
3. **Hypertension**: Uncontrolled high blood pressure (though described as ""well-controlled"" in Document 5 for this patient) can exacerbate CHF.
4. **Fluid Overload**: Consuming too much fluid or retaining fluid due to renal issues (like CKD mentioned in all documents) can worsen CHF symptoms.
5. **Infections or Other Illnesses**: Not directly mentioned but commonly known to exacerbate CHF.

**Relationship Between Symptoms and Condition:**

1. **Shortness of Breath (Dyspnea)**: 
   - **Relation to CHF**: Indicates fluid buildup in the lungs (pulmonary congestion), a common symptom of CHF exacerbation.
   - **Document References**: Document 1 (Presentation), Document 3 (Chief Complaint), and Document 2 (Presenting Symptoms).

2. **Lower Extremity Edema**:
   - **Relation to CHF**: Suggests fluid buildup due to the heart's reduced ability to pump blood effectively, leading to increased venous pressure and fluid leakage into tissues.
   - **Document References**: Document 2 (Presenting Symptoms) and Document 3 (Additional Symptoms).

**Metadata Observations (as per instructions):**

- **Patient/Subject ID**: Consistently listed as **13180007** across all documents (Documents 1 through 5).
- **Note ID**: Identical across all documents as **13180007-DS-19**.
- **Admission ID**: Uniformly **20774429** in all provided documents.
- **Chart Time and Store Time**: Same for all documents, **20/06/62 0:00** and **21/06/62 9:56**, respectively.","['* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa', '* **Patient Profile**: ___ male with history of:\n\t+ HFpEF (EF 55-60%)\n\t+ Prior CVA\n\t+ CKD\n\t+ DM\n\t+ Hypertension\n\t+ Carotid artery disease\n* **Presenting Symptoms**:\n\t+ 2 days of dyspnea on exertion\n\t+', 'Here is the extracted and summarized information for the subheading ""* CHIEF COMPLAINT"":\n\n**Chief Complaint:**\n\n* **Primary Complaints:**\n\t1. **Dyspnea** (shortness of breath)\n\t2. **Chest Pain**\n* **A', '* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
Whats the perscribed dose of CARVedilol for the patient with Hx of CAD and CKD stage III?,"['4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:', 'dc9c33c0-6523-4835-a02f-162ecaa61776\n\n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. Minoxidil 10 mg PO DAILY \n5. CARVedilol 50 mg PO BID \n6. Levothyroxine Sodium 100 mcg PO DAILY \n7. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n8. sevelamer CARBONATE 800 mg PO TID W/MEALS \n9. Vitamin D 1000 UNIT PO DAILY \n10. Torsemide 100 mg PO DAILY \n11. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n12. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n13. Aspirin 81 mg PO DAILY \n \nDischarge Medications:\n1.  Acetaminophen 650 mg PO Q6H:PRN Pain - Mild/Fever  \n2.  70/30 30 Units Breakfast\n70/30 20 Units Dinner \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID']","The prescribed dose of CARVedilol for the patient is 50 mg PO BID (twice a day). This is part of the patient's medically optimized regimen for CAD, alongside other medications such as aspirin, atorvastatin, and with careful management due to CKD stage III-IV.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the answer to the question:

**Question:** What's the prescribed dose of Carvedilol for the patient with Hx of CAD and CKD stage III?

**Note:** 
- The patient's medical history (Hx) of CAD (Coronary Artery Disease) is not explicitly mentioned in the provided documents, but CKD (Chronic Kidney Disease) is mentioned in Document 1.
- Since the question specifically asks for the dose of Carvedilol, we'll focus on finding that information.

**Answer:**

* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Prescribed Dose of Carvedilol:**
	+ **Dose:** 50 mg
	+ **Frequency:** PO BID (Orally, Twice a Day)

**Source Documents for Carvedilol Dose:**
- Document 1: Under **Hypertension** medications
- Document 2: **Medications on Admission** list, item 4
- Document 3: Listed as **Carvedilol**
- Document 4: **Discharge Medications**, item 6 (continued from admission)
- Document 5: **Medications to Take as Prescribed**, item 7","['1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '* **Medications on Admission (Pre-admission List):**\n\t1. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath\n\t2. **Amlodipine**: 10 mg PO DAILY\n\t3. **Atorvastatin**: 80 mg PO QPM\n\t4. **Carved', '1. **Albuterol Inhaler**\n\t* Dose: 2 PUFF IH Q8H\n\t* Indication: PRN shortness of breath\n2. **Amlodipine**\n\t* Dose: 10 mg PO DAILY\n3. **Atorvastatin**\n\t* Dose: 80 mg PO QPM\n4. **Carvedilol**\n\t* Dose: 50', '* **Discharge Medications:**\n\t1. **Torsemide**: 100 mg PO DAILY (newly prescribed)\n\t2. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath (continued)\n\t3. **Amlodipine**: 10 mg PO DAILY (cont', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the standard dosage of Levothyroxine for a patient with Hypothyroidism in the context of multiple comorbidities (e.g., Hypertension, IDDM, CKD) as observed in clinical care coordination?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided medical context, for patients with Hypothyroidism, alongside multiple comorbidities such as Hypertension, IDDM (Insulin-Dependent Diabetes Mellitus), and CKD (Chronic Kidney Disease), the continued home dosage of Levothyroxine is consistently noted as 100mcg daily. This dosage is mentioned across different patient scenarios, suggesting a standard approach for Hypothyroidism management in these complex cases, under the care coordination observed.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Standard Dosage of Levothyroxine for Hypothyroidism in the Context of Multiple Comorbidities:**

Based on the provided documents, the standard dosage of Levothyroxine for the patient with Hypothyroidism (Patient/Subject ID: **13180007**, consistently across all documents) and multiple comorbidities (e.g., Hypertension, IDDM, CKD) is:

* **Levothyroxine Sodium: 100 mcg PO DAILY**

This dosage is consistently mentioned across the documents as follows:

- **Document 1 (CONTENT, #26. CHRONIC PROBLEMS):** Levothyroxine 100mcg daily
- **Document 2 (CONTENT, CHRONIC PROBLEMS):** Levothyroxine Sodium 100 mcg PO DAILY
- **Document 3 (CONTENT, Chronic Problems Section):** levothyroxine 100mcg daily
- **Document 4 (CONTENT, Medications on Admission):** Levothyroxine Sodium: 100 mcg PO DAILY

**Metadata Consistency for Patient/Subject ID:**
The **Patient/Subject ID: 13180007** is consistently mentioned across all documents (**Document 1**, **Document 2**, **Document 3**, **Document 4**, and **Document 5**), indicating that all information pertains to the same patient.

**Note on Comorbidities and Dosage:**
While the question asks about the dosage in the context of multiple comorbidities (Hypertension, IDDM, CKD), the provided documents do not indicate an adjustment of the Levothyroxine dosage based on these comorbidities. The dosage remains consistent at 100 mcg PO DAILY across all mentions.","['#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '* **Related Information from Other Sections (for context):**\n\t+ **Family History:** Parents have heart disease; Mother has heart problems and diabetes; Father has diabetes\n\t+ **Chronic Problems Sectio', '* **Medications on Admission (Pre-admission List):**\n\t1. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath\n\t2. **Amlodipine**: 10 mg PO DAILY\n\t3. **Atorvastatin**: 80 mg PO QPM\n\t4. **Carved', '1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the relevent medicashuns and ther underlaying efectivness for a pashent with a Hx of CAD, ischemic CVA, CKD (likely due to HTN, DM), and Hypothyroidism, consiederin the pashent is alredy on carvedilol, ASA, and high dose atorvastatin?","['8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided context, the patient's relevant medications and their underlying effectiveness for the mentioned conditions are as follows:  - **For CAD and Ischemic CVA Prevention:**   - **Carvedilol (CARVedilol 37.5 mg PO BID):** Continued for heart-related conditions, indicating its ongoing effectiveness.   - **ASA (Aspirin, dosage not specified in the context but mentioned as continued):** For antiplatelet effects to prevent further ischemic events.   - **Atorvastatin (dosage not specified, but mentioned as high dose):** For managing cholesterol, crucial in CAD management.  - **For CKD (with likely underlying etiology of HTN, DM):**   - **Furosemide 40 mg PO 3X/WEEK:** For fluid management in CKD.   - **Sevelamer CARBONATE 800 mg PO TID W/MEALS:** To control phosphorus levels in CKD patients.   - **Minoxidil 2.5 mg PO DAILY:** For blood pressure management (HTN).   - **AmLODIPine 10 mg PO DAILY:** Also for HTN management.   - **Jardiance (Empagliflozin) 10 mg oral DAILY:** Specifically for DM management, with the added benefit of renal protection in CKD.  - **For Hypothyroidism:**   - **Levothyroxine Sodium 100 mcg PO DAILY:** Continued for thyroid hormone replacement.  - **Additional for DM (as part of the themes):**   - **Victoza 3-Pak (Liraglutide) 1.2 mg subcutaneous DAILY:** For DM management, helping with glucose control and possibly aiding in weight management, which can be beneficial for overall cardiovascular health.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I'll address the current question to the best of my abilities, given the constraints and the information available in the documents.

**Current Question Analysis:**
The question pertains to a patient's relevant medications and their underlying effectiveness, considering the patient's history of:
1. CAD (Coronary Artery Disease)
2. Ischemic CVA (Cerebrovascular Accident)
3. CKD (Chronic Kidney Disease), likely due to HTN (Hypertension) and DM (Diabetes Mellitus)
4. Hypothyroidism

**Given Medications:**
The patient is already on:
1. Carvedilol (not explicitly mentioned in the provided documents but stated in the question)
2. ASA (Aspirin) - **Confirmed in Documents 1, 2, and 3**
3. High-dose Atorvastatin - **Confirmed in Documents 1, 2, and 3 (80 mg)**

**Relevant Medications and Effectiveness for the Conditions (based on the question and documents):**

1. **Hypothyroidism:**
	* Medication: Levothyroxine Sodium 100 mcg PO DAILY - **Confirmed in Documents 1, 2, and 3**
	* Effectiveness: Generally effective for managing hypothyroidism; no direct information on effectiveness in these documents.

2. **CAD and Ischemic CVA:**
	* Medications:
		+ ASA (Aspirin) - **Antiplatelet, effective for secondary prevention**
		+ Atorvastatin (high dose) - **Effective for lowering cholesterol, thereby reducing CAD risk**
	* **Carvedilol** (though not in documents, as per the question) - **Typically used for HTN, CAD, and heart failure; effective for these conditions**

3. **CKD (likely due to HTN, DM):**
	* **Direct Medications for CKD in Documents:** None explicitly mentioned for CKD treatment.
	* **Indirect:**
		- **ASA and Atorvastatin:** While primarily for CAD and CVA, they indirectly benefit by reducing cardiovascular risk factors that can worsen CKD.
		- **Carvedilol (as per the question):** Can help with HTN management, which is beneficial for CKD patients.
	* **Missing but Relevant for CKD Management:** Medications for HTN (other than Carvedilol, which is not in the documents), DM (e.g., for Type 2 Diabetes Mellitus mentioned in Document 3), and specific CKD treatments are not detailed.

**Metadata Observations:**
- **Patient/Subject ID:** Consistently **13180007** across all documents.
- **Note ID, Admission ID, Chart Time, and Store Time:** Consistent across all documents, indicating these documents pertain to the same patient event.
	+ **Note ID:** 13180007-DS-19
	+ **Admission ID:** 20774429
	+ **Chart Time:** 20/06/62 0:00
	+ **Store Time:** 21/06/62 9:56

**Limitations and Recommendations:**
- **Direct CKD and HTN Management Medications:** Not explicitly mentioned; recommend reviewing the patient's full medical record for comprehensive management strategies.
- **Effectiveness Assessment:** The documents do not provide outcomes or effectiveness assessments for the mentioned medications. Clinical evaluation and follow-up records would be necessary for a thorough effectiveness analysis.","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '* **Related Information from Other Sections (for context):**\n\t+ **Family History:** Parents have heart disease; Mother has heart problems and diabetes; Father has diabetes\n\t+ **Chronic Problems Sectio', '#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri', '**PAST MEDICAL HISTORY**\n\n* **Conditions:**\n\t1. **Hypertension**\n\t2. **Dyslipidemia**\n\t3. **Diabetes Mellitus Type 2**\n\t4. **Cerebrovascular Disease**, status post CVA (date: **[REDACTED]**)\n\t5. **Ext', '### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What changes, if any, occurred in the patient's Furosemide dosage from admission to discharge, and what could be the clinical rationale behind such adjustments for a patient initially presenting with worsening shortness of breath, increased leg swelling, and weight gain?","['8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","Upon admission, the patient was taking Furosemide 80 mg PO DAILY. At discharge, the medication regimen was adjusted to Furosemide 40mg twice daily. The initial presentation of worsening shortness of breath, increased leg swelling, and weight gain suggests fluid overload, for which IV diuretic medications were effectively administered during the hospital stay. The adjustment to a twice-daily regimen at a lower cumulative daily dose (40mg twice daily equals 80mg total daily) might reflect a clinical decision to maintain diuretic efficacy while minimizing potential side effects, considering the patient's improved condition following in-hospital diuretic treatment. This adjustment could also be tailored to manage outpatient fluid balance, given the patient's response to diuretics during the hospitalization.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, 2, 3, 4, and 5)
**Note ID and Admission ID:** Also consistent across all documents (13180007-DS-19 and 20774429, respectively), indicating these documents pertain to the same hospital admission.

**Changes in Furosemide Dosage from Admission to Discharge:**

* **Admission Dosage (Document 4 - Medications on Admission):**
	+ **Furosemide (Lasix):** 80 mg PO DAILY
* **Discharge Dosage:**
	+ **No direct mention of Furosemide in the discharge documents (2, 3, and 5).** Instead, **Torsemide** is mentioned as a discharge medication:
		- **Document 2:** Torsemide 100mg daily for active diuresis.
		- **Document 3:** Torsemide 100 mg PO DAILY (listed as New/Changed).
		- **Document 5:** Diuretic: Torsemide 100mg daily.

**Clinical Rationale for the Adjustment:**

1. **Switch from Furosemide to Torsemide:**
	* **Efficacy and Potency:** Torsemide is often considered more potent than Furosemide, with a longer duration of action. This switch might have been made to more effectively manage the patient's volume overload, as indicated by the initial presentation of swelling in legs due to fluid accumulation caused by heart failure.
	* **Tolerability and Side Effects:** The change could also be due to differences in side effect profiles or patient tolerance. Torsemide might offer a more favorable profile for this patient, potentially reducing the risk of hypokalemia or other adverse effects associated with Furosemide.
2. **Dosage Adjustment (from 80mg Furosemide to 100mg Torsemide):**
	* **Equivalency and Efficacy:** The dosage adjustment might reflect an attempt to achieve a similar or enhanced diuretic effect with Torsemide, considering its pharmacokinetic and pharmacodynamic properties compared to Furosemide.
3. **Clinical Context:**
	* The patient's condition at discharge (e.g., slightly volume up, 1+ edema to ankles bilaterally, elevated Creatinine) suggests that while there was improvement, ongoing management of fluid status and renal function was necessary. The switch to Torsemide could be part of optimizing this management.

**Limitations in Answering:**
- The exact reason for the medication change (e.g., patient tolerance, efficacy, side effects) isn't explicitly stated in the provided documents.
- Direct comparison of Furosemide and Torsemide dosages requires consideration of their respective potencies and the patient's specific response, which is not fully detailed here.","['Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '* **Medications on Admission (Pre-admission List):**\n\t1. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath\n\t2. **Amlodipine**: 10 mg PO DAILY\n\t3. **Atorvastatin**: 80 mg PO QPM\n\t4. **Carved', '**Key Metrics at Discharge**\n\n* **Weight**: 166.6lb\n* **Creatinine (Cr)**: 2.9 (elevated from baseline 1.8-2.2)\n* **Diuretic**: Torsemide 100mg daily\n\n**Action Items**\n\n* **Follow-up Labs**: To be dra']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the role of Hydralazine in the treatment regimen for a patient discharged with a primary diagnosis of Acute on chronic heart failure with preserved ejection fraction, and how is its dosage administered?","['5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia', 'ab26554b-50b4-4fe8-adc0-d18910279c6b\n\n=============== \n#Acute exacerbation of HFpEF (EF 57%)\nLikely ___s possible ischemia given his \npositive stress in ___. Also possibly triggered by \npneumonia. Did endorse occasional angina symptoms, but trop was \nflat with no EKG changes. TTE showed no regional wall motion \nabnormalities and no mitral regurgitation. He was actively \ndiuresed. His lisinopril was held due to ___. His heart failure \nregimen upon discharge:\nDIURESIS: Torsemide 40 mg QD\nAFTERLOAD: Hydralazine 100 mg TID\nClonidine 0.2 mg BID\nHeld lisinopril given ___\nAmlodipine 10 mg QD\nNHBK: Carvedilol 37.5 mg BID; \n- Discharge weight: 72.7 kg (160.27 lb) \n- Discharge Cr: 3.7\n___ on CKD:\n#Hyperkalemia:\nInitially due to venous congestion, then likely due to \noverdiuresis. He had underlying CKD and his creatinine did not \nreturn to his baseline upon discharge. We suspect that he will \nneed to initiate HD in the near future. His K rose to about 5.8 \nthe week prior to discharge, but this improved with Lasix IV, \nkayexelate, and low potassium diet.']","According to the patient's discharge information, Hydralazine plays a role in the 'AFTERLOAD' component of the heart failure treatment regimen. The dosage of Hydralazine is specifically 100 mg, administered three times a day (TID). This is part of a broader regimen that includes DIURESIS with Torsemide, additional blood pressure management with Clonidine and Amlodipine, and NHBK (likely referring to Neurohormonal Blockade) with Carvedilol. The use of Hydralazine in this context suggests its application in managing afterload reduction, crucial for heart failure management, especially in a patient with preserved ejection fraction and other complicating factors like coronary artery disease and hyperkalemia.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Role of Hydralazine in the Treatment Regimen:**
* **Not Mentioned**: Hydralazine is not mentioned at all in the provided documents (Document 1 through Document 5) as part of the treatment regimen for the patient with a primary diagnosis of Acute on chronic diastolic heart failure exacerbation (indicative of Heart Failure with Preserved Ejection Fraction, HFpEF, as noted with an ejection fraction of 55-60%).

**Dosage Administration:**
* **Not Applicable (N/A)**: Since Hydralazine is not mentioned in any of the documents as part of the patient's treatment, there is no dosage administration information available.

**Additional Observations Relevant to the Patient's Treatment:**

* **Diuretic Use Mentioned**: The patient was treated with diuretics for fluid accumulation due to heart failure. Specifically, IV Lasix (Furosemide) was administered during the hospital stay, and upon discharge, the patient was prescribed Torsemide 100mg daily for ongoing diuresis (as mentioned in Document 5).
* **Consistency in Patient and Admission IDs Across Documents**: All documents (1 through 5) share the same:
	+ **Patient/Subject ID**: 13180007
	+ **Note ID**: 13180007-DS-19
	+ **Admission ID**: 20774429
	+ **Chart Time** and **Store Time**, indicating they pertain to the same patient event.","['Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula', '### **DISCHARGE DIAGNOSIS & CONDITION**\n\n* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation\n* **Secondary Diagnoses:**\n\t1. Acute kidney injury\n\t2. Acute on chronic anemia\n\t', '* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', '* **Summary**: \n\t+ Patient with HFpEF (EF 55-60%) admitted for HF exacerbation with dyspnea and discomfort\n\t+ Trigger unclear, possibly medication non-compliance\n\t+ Symptoms improved with IV Lasix; di']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
Whats the ushual dose of Vitimin D prescribd to pashents in thes hospitl recrds?,"['080dba33-29e9-4409-89cb-54a03af0e470\n\n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Torsemide 100 mg PO DAILY  \n13.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n14.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNSOIS:\n==================\nAcute Hypoxemic Respiratory Failure\nAcute on Chronic Diastolic Heart Failure\nHyperglycemia, Type 2 Diabetes \n___ on CKD \nSECONDARY DIAGNOSIS:', '9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0\n\n11.  Tresiba U-100 Insulin (insulin degludec) 50 units \nsubcutaneous DAILY  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  \n14. HELD- CloNIDine 0.4 mg PO BID  This medication was held. Do \nnot restart CloNIDine until see what BP is at PCP visit, to see \nif need more meds\n15. HELD- Gabapentin 400 mg PO TID  This medication was held. Do \nnot restart Gabapentin until you discuss with PCP the need for \nit, was not needed during this hospital stay\n16. HELD- HydrALAZINE 100 mg PO TID  This medication was held. \nDo not restart HydrALAZINE until discuss with primary care \ndoctor\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nType II diabetes']","Based on the provided hospital records, two different dosages of Vitamin D are mentioned for patients:               1. **1000 UNIT PO DAILY** (Record: 080dba33-29e9-4409-89cb-54a03af0e470)              2. **___ UNIT PO 1X/WEEK (WE)** (Record: 9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0) - *Note: The exact unit dosage is not specified in this record.*",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the answer to the question:

**Question:** What's the usual dose of Vitamin D prescribed to patients in these hospital records?

**Answer Analysis:**

* Since the question pertains to medication dosage, we'll rely on the **CONTENT** of the documents (as metadata primarily contains ID and time-related information).
* We'll scan through the content of all provided documents for Vitamin D dosage mentions.

**Findings Across Documents:**

* **Document 1:** Vitamin D 1000 UNIT PO DAILY
* **Document 2:** **Vitamin D** * Dose: 1000 UNIT PO DAILY
* **Document 3:** Vitamin D 1000 UNIT PO DAILY
* **Document 4:** **Vitamin D** * Dose: 1000 UNIT * Frequency: PO DAILY
* **Document 5:** Does not specifically mention Vitamin D in the provided excerpt, but the question focuses on usual dosage across records, not the absence in one.

**Conclusion:**
The usual dose of Vitamin D prescribed to patients in these hospital records, based on the consistent information across **Documents 1, 2, 3**, and **4**, is:

* **Dose:** 1000 UNIT
* **Frequency:** PO (Per Os, meaning by mouth) DAILY

**Note on IDs (for contextual clarity, though not directly asked):**
- **Patient/Subject ID:** Consistently **13180007** across all documents.
- **Note ID, Admission ID, Chart Time, and Store Time** are also consistent across all documents, indicating these entries likely pertain to the same patient visit/episode.","['9. Minoxidil 10 mg PO DAILY\n\t10. Polyethylene Glycol 17 g PO DAILY:PRN\n\t11. Sevelamer CARBONATE 800 mg PO TID W/MEALS\n\t12. Victoza (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY\n\t13. Vita', '8. **Liraglutide (Victoza)**\n\t* Dose: 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY\n9. **Minoxidil**\n\t* Dose: 10 mg PO DAILY\n10. **Polyethylene Glycol**\n\t* Dose: 17 g PO DAILY\n\t* Indication: PRN Const', '11. Sevelamer CARBONATE 800 mg PO TID W/MEALS\n\t12. Victoza (Liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Follow-up Appointments:**\n\t+ **Lab Follow-u', '10. **Polyethylene Glycol**\n\t* Dose: 17 g\n\t* Frequency: PO DAILY:PRN (as needed) for Constipation - First Line\n11. **Sevelamer Carbonate**\n\t* Dose: 800 mg\n\t* Frequency: PO TID (three times a day) W/ME', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
Whats the perscribd dose of Asprin for the pashent in the givn clinikal kontext?,"['5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1', 'c91e9f73-a3db-4de7-b32b-2595064882de\n\ndose inhaled twice a day Disp #*1 Disk Refills:*0 \n3.  sevelamer CARBONATE 800 mg PO TID W/MEALS \nRX *sevelamer carbonate 800 mg 1 tablet(s) by mouth three times \na day with meals Disp #*90 Tablet Refills:*0 \n4.  Torsemide 40 mg PO DAILY \nRX *torsemide 20 mg 2 tablet(s) by mouth once a day Disp #*60 \nTablet Refills:*0 \n5.  amLODIPine 10 mg PO DAILY  \n6.  CARVedilol 37.5 mg PO BID \nRX *carvedilol 25 mg 1.5 tablet(s) by mouth twice a day Disp \n#*90 Tablet Refills:*0 \n7.  Glargine 30 Units Breakfast\nGlargine 10 Units Bedtime\nHumalog 5 Units Breakfast\nHumalog 5 Units Lunch\nHumalog 5 Units Dinner\nInsulin SC Sliding Scale using HUM Insulin \n8.  Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB  \n9.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n10.  Atorvastatin 80 mg PO QPM \nRX *atorvastatin 80 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n11.  CloNIDine 0.2 mg PO BID \nRX *clonidine HCl 0.2 mg 1 tablet(s) by mouth twice a day Disp']","According to the provided clinical context, the prescribed dose of Aspirin is 81 mg PO (orally) DAILY. This is consistent across both the preadmission medication list (context node: 5a643f48-aebd-476f-bd5e-af9cd241686d, item 5) and the discharge medications (context node: c91e9f73-a3db-4de7-b32b-2595064882de, item 9), with the latter specifying a dispensing quantity of *30 tablets with 0 refills.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the answer to the question:

**Question:** What's the prescribed dose of Aspirin for the patient in the given clinical context?

**Answer:**

* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Prescribed Dose of Aspirin:**
	+ According to **Document 1: CONTENT** (under the section for ongoing medications, similar to admission with specified changes):
		- **Aspirin 81 mg PO DAILY**

**Response:**
The prescribed dose of Aspirin for patient **13180007** (as consistently identified across all provided documents) is **81 mg PO DAILY**.","['11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '- **Glucose:** 287* (09:01 AM)\n\t\t- **UreaN:** 39* (09:01 AM), 51* (Discharge)\n\t\t- **Creat:** 2.6 (Admission), 2.9 (Discharge)\n\t\t- **CK(CPK):** 257 (02:28 PM)\n\t\t- **ALT:** 9 (05:53 AM)\n\t\t- **AST:** 13 ', '* **VS (Vital Signs)**:\n\t+ Temp: 97.8\n\t+ BP: 144/69\n\t+ HR: 86\n\t+ RR: 18\n\t+ O2 sat: 96% RA\n* **General**: NAD, Oriented x3, Mood and affect appropriate\n* **HEENT**:\n\t+ Normocephalic atraumatic\n\t+ Scler', '* **Admission Physical Exam**\n\t+ **Vital Signs (VS)**: \n\t\t- Temp: 97.8\n\t\t- BP: 144/69\n\t\t- HR: 86\n\t\t- RR: 18\n\t\t- O2 sat: 96%\n\t\t- O2 delivery: RA\n\t+ **General**: NAD (No Acute Distress), Oriented x3, Mo', '* **Discharge Physical Exam**\n\t+ **General**: NAD, Mood and affect appropriate\n\t+ **HEENT**: (same as Admission Physical Exam)\n\t+ **Neck**: JVP 12 cm\n\t+ **Cardiac**: (same as Admission Physical Exam, ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
What is the prescribed dosage and administration schedule for CloNIDine upon admission and at discharge?,"['44d8d766-27ad-43f8-9511-d17ad9f10f4d\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. amLODIPine 10 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.2 mg PO BID \n4. Gabapentin 400 mg PO TID \n5. Lisinopril 40 mg PO DAILY \n6. MetFORMIN (Glucophage) 850 mg PO TID \n7. Metoprolol Tartrate 25 mg PO BID \n8. Basaglar (Glargine) 30 Units Breakfast\n9. Albuterol Inhaler 2 PUFF IH Q4H \n10. Levothyroxine Sodium 100 mcg PO DAILY \n11. Vitamin D ___ UNIT PO WEEKLY \n \nDischarge Medications:\n1.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once daily Disp #*30 \nTablet Refills:*0 \n2.  Carvedilol 25 mg PO BID \nRX *carvedilol 25 mg 1 tablet(s) by mouth twice daily Disp #*60 \nTablet Refills:*0 \n3.  Furosemide 40 mg PO BID \nRX *furosemide 40 mg 1 tablet(s) by mouth twice daily Disp #*60 \nTablet Refills:*0', 'c91e9f73-a3db-4de7-b32b-2595064882de\n\ndose inhaled twice a day Disp #*1 Disk Refills:*0 \n3.  sevelamer CARBONATE 800 mg PO TID W/MEALS \nRX *sevelamer carbonate 800 mg 1 tablet(s) by mouth three times \na day with meals Disp #*90 Tablet Refills:*0 \n4.  Torsemide 40 mg PO DAILY \nRX *torsemide 20 mg 2 tablet(s) by mouth once a day Disp #*60 \nTablet Refills:*0 \n5.  amLODIPine 10 mg PO DAILY  \n6.  CARVedilol 37.5 mg PO BID \nRX *carvedilol 25 mg 1.5 tablet(s) by mouth twice a day Disp \n#*90 Tablet Refills:*0 \n7.  Glargine 30 Units Breakfast\nGlargine 10 Units Bedtime\nHumalog 5 Units Breakfast\nHumalog 5 Units Lunch\nHumalog 5 Units Dinner\nInsulin SC Sliding Scale using HUM Insulin \n8.  Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB  \n9.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n10.  Atorvastatin 80 mg PO QPM \nRX *atorvastatin 80 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n11.  CloNIDine 0.2 mg PO BID \nRX *clonidine HCl 0.2 mg 1 tablet(s) by mouth twice a day Disp']","According to the provided medication lists, the prescribed dosage and administration schedule for CloNIDine are consistent across both admission and discharge: **CloNIDine 0.2 mg PO (orally) BID (twice a day)**. No changes in dosage or administration schedule are noted between admission and discharge medications.",custom_multi_hop_query_synthesizer,"**Answer to the Question**

**Prescribed Dosage and Administration Schedule for Clonidine upon Admission and at Discharge:**

* **Admission:**
	+ **Dosage:** 0.1 mg (implied, as the unit is not explicitly mentioned but commonly associated with Clonidine) **OR** 10 mg (if considering the format of other medications, but this seems unusually high for Clonidine)
	+ **Administration Schedule:** Not explicitly mentioned in the provided documents for Clonidine upon admission. However, based on the formatting of other medications:
		- **Possible Administration Schedule (Inferred, Not Explicit for Clonidine):** Assuming a common schedule for Clonidine, it might be PO (orally) with a frequency such as BID (twice daily), TID (three times daily), or DAILY, but **THIS IS PURELY INFERENTIAL AND NOT SUPPORTED BY THE PROVIDED DOCUMENTS**.
* **Discharge:**
	+ **Dosage:** Not Mentioned
	+ **Administration Schedule:** Not Mentioned

**Key Observations and Limitations:**

1. **Clonidine is Not Explicitly Mentioned** in any of the provided documents (Document 1 through Document 5) under either admission or discharge medications.
2. **Minoxidil is Mentioned** in Document 2 under Admission Medications, which might be confused with Clonidine due to similar names, but they are different medications. Minoxidil's dosage and administration schedule upon admission are: **10 mg PO DAILY**.
3. Given the instructions to prioritize metadata over content for ID values, **there's no relevant ID information to report for Clonidine** since it's not mentioned in the documents.
4. The same Note ID, Admission ID, and Patient/Subject ID appear across all documents, indicating they pertain to the same patient and admission event:
	* **Patient/Subject ID:** 13180007
	* **Note ID:** 13180007-DS-19
	* **Admission ID:** 20774429","['11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '* **Admission Medications:**\n\t1. Albuterol Inhaler\n\t2. Amlodipine 10 mg PO DAILY\n\t3. Atorvastatin 80 mg PO QPM\n\t4. Carvedilol 50 mg PO BID\n\t5. Furosemide 80 mg PO DAILY\n\t6. Insulin (70/30) 30 Units Br', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ', 'Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula', '22. BRIEF HOSPITAL COURSE\n23. SUMMARY\n24. TRANSITIONAL ISSUES\n25. ACUTE PROBLEMS\n26. CHRONIC PROBLEMS\n27. MEDICATIONS ON ADMISSION\n28. DISCHARGE MEDICATIONS\n29. DISCHARGE DISPOSITION\n30. DISCHARGE DIA']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the role of Aspirin in the treatment of a patient with multiple conditions including hypertension, CAD with inducible ischemia, and NSTEMI, based on the provided medical context?","['5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1', '5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,']","Based on the provided context, Aspirin (81 mg PO DAILY) is continued as part of the patient's treatment regimen for CAD with inducible ischemia and NSTEMI. Specifically, for NSTEMI, which was considered type 2 due to volume overload (with a troponin peak at 0.02), Aspirin is maintained alongside atorvastatin and carvedilol. This indicates its importance in managing cardiac conditions, likely for antiplatelet effects to prevent further cardiac events, although the context does not explicitly state its rationale beyond continuation in treatment.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and medical context, I'll address the question to the best of my abilities. However, please note the following:

1. **The question's context doesn't fully match the provided documents' content**: The question mentions conditions (hypertension, CAD with inducible ischemia, and NSTEMI) not explicitly listed in the documents as the primary focus, except for hypertension. CAD (Coronary Artery Disease) and NSTEMI (Non-ST Elevation Myocardial Infarction) are not directly mentioned in the provided documents.
2. **Aspirin's role is inferred from the context of provided conditions**: Given the conditions explicitly mentioned in the documents (e.g., History of CVA, Hypertension, Cerebrovascular Disease), we can infer a common use of Aspirin.

**Answer to the Question:**

* **Patient/Subject ID (as per metadata across all documents, which is consistent)**: 13180007
* **Note ID, Admission ID (consistent across all documents)**: 13180007-DS-19, 20774429, respectively

**Role of Aspirin in the Treatment (based on provided documents and general medical knowledge)**:

Given the patient's conditions as described in the documents, particularly:
- **History of CVA (Cerebrovascular Accident)**
- **Cerebrovascular Disease**
- **Hypertension** (among others like Dyslipidemia, which is often managed in conjunction with these conditions)

**Aspirin's Role**:
- **Antiplatelet Therapy**: Primarily, Aspirin is used for its antiplatelet effects to reduce the risk of further cerebrovascular events (like another CVA) in patients with a history of CVA or cerebrovascular disease.
- **Cardiovascular Protection**: In the context of hypertension and dyslipidemia (mentioned in Document 2), Aspirin may also contribute to the overall strategy of reducing cardiovascular risk, although its use specifically for hypertension or dyslipidemia alone is not the primary indication.

**Important Note**: The documents do not explicitly mention CAD or NSTEMI, which are conditions where Aspirin is commonly used for acute management and secondary prevention. The answer is tailored to the conditions explicitly mentioned in the documents.

**Additional Recommendations for Complete Assessment**:
- For a comprehensive understanding of Aspirin's role in this patient's treatment, especially concerning CAD and NSTEMI (if diagnosed), additional medical records or context would be necessary.
- Consultation with the patient's healthcare provider or access to more detailed medical history would provide a clearer picture of Aspirin's specific indications in this case.","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '**PAST MEDICAL HISTORY**\n\n* **Conditions:**\n\t1. **Hypertension**\n\t2. **Dyslipidemia**\n\t3. **Diabetes Mellitus Type 2**\n\t4. **Cerebrovascular Disease**, status post CVA (date: **[REDACTED]**)\n\t5. **Ext', '* **Related Information from Other Sections (for context):**\n\t+ **Family History:** Parents have heart disease; Mother has heart problems and diabetes; Father has diabetes\n\t+ **Chronic Problems Sectio', '#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the primary reasons for hospital admission and the corresponding in-hospital treatments for patients with conditions related to uncontrolled diabetes and heart failure, based on recent discharge summaries?","['462328c3-90c8-4169-90f0-27fed5e6b04f\n\nDischarge Instructions:\nDear ___, \nIt was a pleasure caring for you here at ___ \n___!\nWHY WAS I IN THE HOSPITAL?\n================================\n- You were admitted to the hospital due to uncontrolled diabetes \nwith blood glucose in a dangerous range. \nWHAT HAPPENED IN THE HOSPITAL?\n================================\n- You were given an insulin drip acutely to lower your glucose, \nfollowed by observation/stabilization on the medicine floor.\n- The ___ diabetes doctors came to help you with your insulin \nregimen; we gave you long acting insulin and insulin with your \ndaily meals. The ___ diabetes doctors talked with your \ndaughters and you to continue 2 medications at home with 2 \ninjections. We monitored your blood sugars here and made sure \nyou ate a healthy diet.\n- You were also given medication to lower your total volume in \nthe body.   \nWHAT SHOULD I DO WHEN I LEAVE THE HOSPITAL?', 'bc70aec9-8d49-462b-9afd-e5bb15b22e94\n\nDischarge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n \nDischarge Instructions:\nDear ___,  \nIt was a pleasure participating in your care. Please read \nthrough the following information.\nWHY WAS I ADMITTED TO THE HOSPITAL? \n- You were admitted to the hospital because you had been feeling \nshort of breath and you were found to have fluid on your lungs. \nThis was felt to be due to a condition called heart failure, \nwhere your heart does not pump hard enough and fluid backs up \ninto your lungs. \nWHAT HAPPENED WHILE I WAS IN THE HOSPITAL? \n- You were given a diuretic medication through the IV to help \nget the fluid out. You improved considerably and were ready to \nleave the hospital.  \n- You underwent an echocardiogram, which is an ultrasound of']","Based on recent discharge summaries, two primary reasons for hospital admission and their corresponding in-hospital treatments are as follows: nn1. **Uncontrolled Diabetes:**n   - **Reason for Admission:** Uncontrolled diabetes with blood glucose in a dangerous range.n   - **In-Hospital Treatment:** Patients were given an insulin drip to lower glucose levels, followed by observation and stabilization. Specialist diabetes doctors adjusted the patient's insulin regimen, including long-acting insulin and mealtime insulin, with educational support for patients and their families.nn2. **Heart Failure (leading to fluid on the lungs):**n   - **Reason for Admission:** Shortness of breath due to fluid buildup in the lungs, attributed to heart failure where the heart doesn't pump sufficiently.n   - **In-Hospital Treatment:** Administration of diuretic medication intravenously to reduce fluid, significantly improving the patient's condition. Additionally, an echocardiogram (ultrasound of the heart) was performed for further assessment.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Primary Reasons for Hospital Admission and Corresponding In-Hospital Treatments**

Based on the provided discharge summaries (Documents 1-5), all pertaining to the same patient due to matching metadata IDs, we can deduce the following information relevant to the question:

### **Patient Identification and Admission Details**

* **Patient/Subject ID**: 13180007 (consistent across all documents)
* **Admission ID**: 20774429 (consistent across all documents)
* **Chart Time**: 20/06/62 0:00 (indicating the start of the hospital stay)

### **Primary Reasons for Hospital Admission**

1. **Swelling in legs due to fluid accumulation caused by heart failure** (Document 1: DISCHARGE INSTRUCTIONS)
2. **Specifically diagnosed as:** 
	* **Acute on chronic diastolic heart failure exacerbation** (Primary Diagnosis in Documents 2 and 3)
	* **Associated conditions:** Acute kidney injury, Acute on chronic anemia, and Type 2 diabetes mellitus (Secondary Diagnoses in Documents 2 and 3)

### **Corresponding In-Hospital Treatments for Mentioned Conditions**

1. **Heart Failure (Acute on chronic diastolic heart failure exacerbation)**:
	* **Treatment Outcome Mentioned**: Medications were administered to reduce fluid accumulation, leading to improved symptoms (Document 1)
	* **Specific Treatment Not Detailed** in provided documents, but improvement noted.
2. **Uncontrolled Diabetes (Type 2 diabetes mellitus, mentioned as IDDM in Document 5 with poorly controlled A1c 11.4%)**:
	* **No Direct Treatment Mentioned** in the context of diabetes management within the provided documents.
3. **Acute on Chronic Anemia**:
	* **Treatment Mentioned**: Received 3 doses of Ferric Gluconate 250 mg IV (Document 5)
	* **Treatment Outcome**: Hb increased from 7.4 on admission to 7.6 at discharge (Document 5)

**Observations and Limitations**

- All documents share the same Patient/Subject ID, Note ID, Admission ID, Chart Time, and Store Time, indicating they pertain to the same hospital admission event.
- The primary reason for admission is heart failure, with associated conditions including uncontrolled diabetes.
- While in-hospital treatment for anemia is detailed, specific treatments for heart failure and diabetes management during the hospital stay are not explicitly mentioned in the provided documents.","['Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula', '### **DISCHARGE DIAGNOSIS & CONDITION**\n\n* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation\n* **Secondary Diagnoses:**\n\t1. Acute kidney injury\n\t2. Acute on chronic anemia\n\t', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '### 5. **Acute on Chronic Anemia**\n\n* **Presentation:** Hb 7.4 on admission\n* **Possible Causes:** Worsening renal function or dilutional iso heart failure\n* **Management:**\n\t+ Received 3 doses of Fer']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
What are the notable trends and abnormalities in the patient's calcium levels based on the provided lab results?,"[""88b52764-61ad-4740-9004-35da4cf9a996\n\nAbsMono-0.42 AbsEos-0.09 AbsBaso-0.03\n___ 11:00AM BLOOD Glucose-98 UreaN-32* Creat-2.3* Na-139 \nK-4.1 Cl-100 HCO3-25 AnGap-14\n___ 11:00AM BLOOD ALT-8 AST-9 CK(CPK)-110 AlkPhos-144* \nTotBili-<0.2\n___ 11:00AM BLOOD Albumin-3.5 Calcium-9.2 Mg-2.3\nDISCHARGE LABS:\n___ 06:22AM BLOOD WBC-5.6 RBC-3.86* Hgb-10.1* Hct-32.1* \nMCV-83 MCH-26.2 MCHC-31.5* RDW-14.3 RDWSD-43.4 Plt ___\n___ 06:08AM BLOOD Glucose-157* UreaN-33* Creat-1.9* Na-138 \nK-4.5 Cl-100 HCO3-22 AnGap-16\nIMPORTANT RESULTS:\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 09:00PM BLOOD TSH-1.3\n___ 11:11AM BLOOD Lactate-1.6\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\nChest X-ray: \nComparison to ___.  On today's radiograph, a small\npleural left-sided calcification is seen.  There also is a small"", '9a673ed7-18d2-4d47-9b22-110fb9514b9b\n\nK-4.2 Cl-103 HCO3-22 AnGap-18\n___ 03:10PM BLOOD Glucose-236* UreaN-29* Creat-2.2* Na-135 \nK-4.1 Cl-96 HCO3-25 AnGap-14\n___ 07:27AM BLOOD Glucose-185* UreaN-27* Creat-2.1* Na-137 \nK-4.3 Cl-97 HCO3-27 AnGap-13\n___ 02:50PM BLOOD Glucose-248* UreaN-31* Creat-2.1* Na-137 \nK-4.6 Cl-97 HCO3-27 AnGap-13\n___ 06:45AM BLOOD Glucose-165* UreaN-27* Creat-2.0* Na-138 \nK-4.3 Cl-98 HCO3-26 AnGap-14\n___ 07:44AM BLOOD Calcium-9.0 Phos-4.4 Mg-1.7\n___ 05:00PM BLOOD Calcium-9.2 Phos-4.8* Mg-3.2*\n___ 07:00AM BLOOD Calcium-8.9 Phos-5.0* Mg-2.3\n___ 02:48PM BLOOD Calcium-9.0 Phos-5.3* Mg-2.2\n___ 07:35AM BLOOD Calcium-8.4 Phos-5.1* Mg-2.0\n___ 03:10PM BLOOD Calcium-8.8 Phos-5.0* Mg-2.1\n___ 07:27AM BLOOD Calcium-8.9 Phos-4.4 Mg-2.0\n___ 02:50PM BLOOD Calcium-8.5 Phos-4.4 Mg-2.1\n___ 06:45AM BLOOD Calcium-8.6 Phos-4.0 Mg-2.0\nLFTs\n___ 09:10AM BLOOD ALT-31 AST-25 AlkPhos-111 TotBili-<0.2\n___ 07:44AM BLOOD CK(CPK)-531*\n___ 07:00AM BLOOD CK(CPK)-509*\nCARDIAC ENZYMES:\n___ 09:10AM BLOOD proBNP-1140*']","Based on the lab results, here are the notable trends and abnormalities in the patient's calcium levels:      - **Variation in Calcium Levels:** Calcium levels fluctuated between 8.4 mg/dL (07:35 AM) and 9.2 mg/dL (05:00 PM and 11:00 AM in the first context node), indicating some variability throughout the day.     - **Abnormalities:** None of the calcium levels provided fall outside the typical normal range (approximately 8.6 to 10.2 mg/dL, though reference ranges may slightly vary). However, it's crucial to consider these in the context of the patient's overall health and other lab results.     - **Associated Abnormalities:** Notably, Phosphate (Phos) levels were occasionally elevated (* denotes abnormality), which can be related to calcium metabolism and may warrant further investigation. For example, a Phos level of 5.3* mg/dL at 02:48 PM is above the normal range (typically about 2.5 to 4.5 mg/dL for adults), which might suggest an imbalance in calcium-phosphate homeostasis.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Notable Trends and Abnormalities in Patient's Calcium Levels:**

Based on the provided lab results across multiple documents for **Patient/Subject ID: 13180007** (consistent across all documents), the notable trends and abnormalities in the patient's calcium levels are as follows:

* **Consistency Across Documents:** The patient's calcium levels are reported in two documents, **Document 2** and **Document 3**, with consistent results.
* **Calcium Levels:**
	+ **Document 2:** Calcium: **8.4** (no indication of abnormality)
	+ **Document 3 (Electrolytes and Minerals):** Calcium: **8.4** (no indication of abnormality)
* **Notable Trends:** None observed. The calcium levels remain consistent at **8.4** across the two reports, with no indication of a trend upwards or downwards.
* **Abnormalities:** None reported. Both documents indicate a calcium level of **8.4**, which, based on the provided information, does not appear to be flagged as abnormal. Typically, normal calcium levels range from about 8.6 to 10.2 mg/dL, but since **8.4** is not explicitly marked as abnormal in the context of these documents, and considering potential slight variations in reference ranges, it is not highlighted as an abnormality here without further clinical context.

**Metadata Consistency for Patient ID:**
- The **Patient/Subject ID: 13180007** is consistently reported across all documents (**Document 1** through **Document 5**).
- The **Note ID (13180007-DS-19)** and **Admission ID (20774429)** also remain consistent across all documents, reinforcing the connection of these lab results to the same patient encounter.","['+ Diastolic dysfunction (grade indeterminate)\n\t+ Small pericardial effusion\n\t+ Other findings: Detailed in the original document under ""PERTINENT STUDIES/RESULTS""\n* **Laboratory Results - mentioned in', '- Glucose: 164*\n\t\t- UreaN (BUN): 51*\n\t\t- Creat (Cr): 2.9* (elevated from baseline 1.8-2.2)\n\t\t- Na: 140\n\t\t- K: 4.6\n\t\t- Cl: 99\n\t\t- HCO3: 25\n\t\t- AnGap: 16\n\t+ **Electrolytes & Minerals:**\n\t\t- Calcium: 8.4', '### **Electrolytes and Minerals**\n\n* **Date/Time:** ___ 05:53AM\n* **Results:**\n\t+ Calcium: 8.4\n\t+ Phos: 4.9* (flagged as abnormal)\n\t+ Mg (Magnesium): 2.0\n\t+ Iron: 28*\n\t+ calTIBC: 294\n\t+ Ferritn: 73\n\t+', '11. Sevelamer CARBONATE 800 mg PO TID W/MEALS\n\t12. Victoza (Liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Follow-up Appointments:**\n\t+ **Lab Follow-u', '+ **Diagnostic Procedures:** Various lab tests, imaging studies (e.g., CXR, TTE), and EKG were performed (detailed under ""Labs notable for:"", ""Studies notable for:"", ""PERTINENT RESULTS:"", and ""DISCHAR']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
Whats the perscribed dose of HydrALAZINE for this patient??,"['058d90f2-3d7b-4d29-bca6-e70e3cb19e4d\n\n4.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times daily \nDisp #*90 Tablet Refills:*0 \n5.  Glargine 30 Units Breakfast \n6.  Albuterol Inhaler 2 PUFF IH Q4H  \n7.  amLODIPine 10 mg PO DAILY  \n8.  Atorvastatin 80 mg PO QPM  \n9.  CloNIDine 0.2 mg PO BID  \n10.  Gabapentin 400 mg PO TID  \n11.  Levothyroxine Sodium 100 mcg PO DAILY  \n12.  MetFORMIN (Glucophage) 850 mg PO TID  \n13.  Vitamin D ___ UNIT PO WEEKLY  \n14. HELD- Lisinopril 40 mg PO DAILY  This medication was held. \nDo not restart Lisinopril until told to do so by your doctor\n15.Outpatient Lab Work\nChem-7 to be draw ___\nICD 10: I50.3: Diastolic (congestive) heart failure\nFax results to: ___ ATTN: ___\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___', '5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1']","According to the medical records, the prescribed dose of HydrALAZINE for this patient is 100 mg, taken orally (PO) three times daily (TID). This is consistent across both the initial medication list (context ID: 058d90f2-3d7b-4d29-bca6-e70e3cb19e4d, item 4) and the CORE MEASURES list (context ID: 5a643f48-aebd-476f-bd5e-af9cd241686d, item 4).",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the answer to the question:

**Question:** What's the prescribed dose of HydrALAZINE for this patient??

**Answer:** **NOT MENTIONED**

**Rationale:**

1. **Metadata Review**: None of the metadata fields across all documents (1 to 5) mention ""HydrALAZINE"" or any related information.
2. **Content Review**: A thorough review of the content across all documents (1 to 5) does not yield any mention of ""HydrALAZINE"", its prescription, or dosage for the patient.
3. **Medication Mentions**: The documents do mention other medications, such as:
	* Torsemide (100mg daily, Document 1 and mentioned in context in others)
	* Ferric Gluconate (250mg IV, Documents 2 and 3)
	* IV Lasix (Furosemide, 80mg, Document 5)
	* **No HydrALAZINE is listed**.

**IDs for Context (as per instruction 2 & 3)**:
- **Patient/Subject ID**: 13180007 (consistent across all documents)
- **Note ID**: 13180007-DS-19 (consistent across all documents)
- **Admission ID**: 20774429 (consistent across all documents)","['* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '### 5. **Acute on Chronic Anemia**\n\n* **Presentation:** Hb 7.4 on admission\n* **Possible Causes:** Worsening renal function or dilutional iso heart failure\n* **Management:**\n\t+ Received 3 doses of Fer', '* **Additional Recommendations:**\n\t+ Consider completing the 4-day course of **ferric gluconate** (started during admission; received 2 doses of 250mg IV on **[NOT PROVIDED]**).\n\t+ One additional infu', '* **Summary**: \n\t+ Patient with HFpEF (EF 55-60%) admitted for HF exacerbation with dyspnea and discomfort\n\t+ Trigger unclear, possibly medication non-compliance\n\t+ Symptoms improved with IV Lasix; di', '- Creatinine (Cr): 2.6\n\t\t- pro-B-type Natriuretic Peptide (proBNP): 784\n\t\t- Troponin T (TropT): 0.03\n\t+ **Imaging:**\n\t\t- **Chest X-Ray (CXR):** Mild pulmonary vascular congestion with small bilateral ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the key findings and management strategies for a patient with a history of Coronary Artery Disease (CAD) and other comorbidities, as evident from recent hospital admissions and medication lists?","['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', '8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided context, key findings for the patient with a history of CAD include:    - **History of CAD** with a past stress test showing inducible ischemia in the LCx distribution, managed with carvedilol, ASA, and high-dose atorvastatin.   - **Comorbidities**: History of ischemic CVA, HFpEF, uncontrolled DM2, HTN, CKD, possible hypothyroidism, asthma, and mild cognitive impairment.   - **Recent Hospital Findings**: No acute intracranial abnormalities on CT HEAD, chronic infarcts in the right frontal and left occipital lobes, and unchanged calcifications within the pons.   - **Medication Management**: The patient is on a comprehensive medication regimen including diuretics (furosemide), sevelamer carbonate for CKD, minoxidil, levothyroxine for hypothyroidism, carvedilol and amlodipine for CAD and HTN, inhalers for asthma, and empagliflozin and liraglutide for DM2 management.   - **Urine Culture**: Showed < 10,000 CFU/mL, indicating no significant urinary tract infection.   Management strategies appear to focus on multifaceted pharmacological intervention to control the patientâs various comorbid conditions, alongside monitoring for any progression of CAD or other diseases.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Key Findings and Management Strategies for Patient with History Suggestive of CAD and Comorbidities:**

**Patient Identification:**
- **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)
- **Chart Time:** 20/06/62 0:00 (consistent across all documents)
- **Store Time:** 21/06/62 9:56 (consistent across all documents)

**Observation:** While the question specifically asks about Coronary Artery Disease (CAD), the provided documents directly mention **Dyslipidemia**, **Carotid Artery Disease**, **Extensive Intracranial Atherosclerosis**, and **Mild Aortic Regurgitation (AR)**, which are related to or can increase the risk of CAD, but CAD itself is not explicitly mentioned. **Hypertension** and **Diabetes Mellitus Type 2** are also noted, which are common comorbidities with CAD.

**Key Findings:**

1. **Conditions Related to or Increasing Risk of CAD:**
	* Dyslipidemia (Document 3)
	* Carotid Artery Disease (Document 3)
	* Extensive Intracranial Atherosclerosis (Document 3)
	* Mild Aortic Regurgitation (AR) (Document 3)
2. **Other Comorbidities:**
	* Hypertension (Document 3)
	* Diabetes Mellitus Type 2 (Documents 1, 3)
	* Hypothyroidism (Documents 1, 2, 4)
	* History of CVA (Cerebrovascular Accident) (Documents 1, 2, 4)
	* Acute on chronic diastolic heart failure exacerbation (Document 1)
	* Acute kidney injury, Acute on chronic anemia (Document 1)
	* Chronic Kidney Disease (CKD) (Document 5)
	* Asthma, Osteoarthritis (Documents 3, 5)

**Management Strategies (as per medications listed):**

1. **For Conditions Related to CAD Risk:**
	* Dyslipidemia: **Atorvastatin 80 mg** (Documents 1, 2, 4)
2. **For Other Comorbidities:**
	* Hypothyroidism: **Levothyroxine 100mcg daily** (Documents 1, 2, 4)
	* History of CVA: **Aspirin 81 mg daily**, **Atorvastatin 80 mg** (Documents 1, 2, 4)
	* Diabetes Mellitus Type 2: No specific medication listed in provided documents
	* CKD: **Sevelamer Carbonate 800 mg PO TID** (Document 5)
	* Asthma: **Albuterol Inhaler 2 PUFF IH Q8H:PRN** (Document 5)
	* Osteoarthritis: No medication listed (Document 5)
	* Heart Failure, Acute Kidney Injury, Anemia: No specific medications listed in provided documents; managed as per **Primary and Secondary Diagnoses** in Document 1.","['#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '**PAST MEDICAL HISTORY**\n\n* **Conditions:**\n\t1. **Hypertension**\n\t2. **Dyslipidemia**\n\t3. **Diabetes Mellitus Type 2**\n\t4. **Cerebrovascular Disease**, status post CVA (date: **[REDACTED]**)\n\t5. **Ext', '* **Related Information from Other Sections (for context):**\n\t+ **Family History:** Parents have heart disease; Mother has heart problems and diabetes; Father has diabetes\n\t+ **Chronic Problems Sectio', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What lab values indicate poor management of Diabetes Mellitus (DM) in the hospitalized male patient with HFpEF, and how might these relate to his discharge medication for diuresis?","['8d31665e-700b-4b64-8af5-51456ad55ff5\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-140 \nK-4.6 Cl-99 HCO3-25 AnGap-16\n___ 06:35AM BLOOD Calcium-8.4 Phos-6.0* Mg-2.1\n \nBrief Hospital Course:\nSUMMARY\n=======\n___ male with history of HFpEF (EF 55-60% in ___,\nprior CVA, CKD, DM, hypertension, and carotid artery disease\nwho presented with 1 day of dyspnea and discomfort, and was\nadmitted for HF exacerbation. The trigger was unclear, possible \nmedication non-compliance. He was diuresed with several doses of \nIV Lasix 80 and by time of discharge symptoms had improved. He \nwas still slightly volume up on exam, with JVP ~12 and 1+ edema \nto ankles.\nTRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally and JVP of 12cm. He is being \ndischarged on torsemide 100 daily for active diuresis, with \nabout 3lb of fluid still left to lose.']","Based on the provided context, lab values indicating poor management of Diabetes Mellitus (DM) include: Glucose-164* (elevated, suggesting hyperglycemia), Hgb-7.6* and Hct-24.3* (indicating anemia, which can be a complication of poorly managed DM), and Phos-6.0* (elevated phosphate, which can be seen in diabetic patients due to kidney impairment, as hinted at by CKD in the patient's history). The discharge medication, torsemide 100 daily for active diuresis, aims to reduce volume overload (noted by 1+ edema to ankles and JVP of 12cm at discharge). While torsemide does not directly manage DM, effective diuresis can help in managing fluid overload associated with diabetic nephropathy, indirectly benefiting DM management by reducing the body's fluid volume and, consequently, the workload on the kidneys.",custom_multi_hop_query_synthesizer,"**Answer:**

**Lab Values Indicating Poor Management of Diabetes Mellitus (DM):**

Based on the provided documents, the lab value that indicates poor management of Diabetes Mellitus (DM) in the hospitalized male patient with HFpEF is:

* **A1c (Hemoglobin A1c) level of 11.4%** (mentioned in **Document 3** under **IDDM (Insulin-Dependent Diabetes Mellitus)** as ""poorly controlled, A1c 11.4%"")
* **Abnormal glucose level of 164** (mentioned in **Document 4** under **Key Findings**, with a note that it is consistent with the patient's known Diabetes Mellitus Type 2)

**Relation to Discharge Medication for Diuresis:**

The discharge medication for diuresis is **torsemide 100mg daily** (mentioned in **Document 1** under **Summary** and **Document 2** under **Treatment Outcome**). The relationship between the poor management of DM (as indicated by high A1c and glucose levels) and the discharge medication for diuresis (torsemide) can be considered in two aspects:

1. **Increased Risk of Hypoglycemia with Certain Diuretics:** While torsemide is primarily used for its diuretic effects in managing fluid overload in heart failure, patients with poorly controlled diabetes might experience fluctuations in blood glucose levels. However, torsemide itself is less commonly associated with hypoglycemia compared to other diuretics. Close monitoring of blood glucose levels is still advisable.

2. **Impact of Diuretics on Renal Function in Diabetic Patients:** Patients with diabetes are at increased risk of renal impairment. The elevated creatinine (Cr) levels at discharge (2.9, as mentioned in **Document 4**) indicate persistent renal impairment. Diuretics like torsemide can affect renal function, particularly in patients with pre-existing kidney issues or those with diabetes. Therefore, monitoring renal function (through regular Cr and possibly eGFR checks) is crucial in managing this patient's heart failure while minimizing risks to his renal health.

**Metadata Observations:**

* The **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)** are consistent across all five documents, indicating they pertain to the same patient's single admission and care episode.
* The **Chart Time** and **Store Time** are also identical across all documents, suggesting that these documents were generated or updated at the same time, reflecting the patient's status at discharge.","['* **Summary**: \n\t+ Patient with HFpEF (EF 55-60%) admitted for HF exacerbation with dyspnea and discomfort\n\t+ Trigger unclear, possibly medication non-compliance\n\t+ Symptoms improved with IV Lasix; di', '* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the current management and recommendation for the patient's hypertension, specifically regarding the use of hydralazine, given its prior discontinuation by the primary care physician before admission?","['71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:', '9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0\n\n11.  Tresiba U-100 Insulin (insulin degludec) 50 units \nsubcutaneous DAILY  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  \n14. HELD- CloNIDine 0.4 mg PO BID  This medication was held. Do \nnot restart CloNIDine until see what BP is at PCP visit, to see \nif need more meds\n15. HELD- Gabapentin 400 mg PO TID  This medication was held. Do \nnot restart Gabapentin until you discuss with PCP the need for \nit, was not needed during this hospital stay\n16. HELD- HydrALAZINE 100 mg PO TID  This medication was held. \nDo not restart HydrALAZINE until discuss with primary care \ndoctor\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nType II diabetes']","According to the provided context, hydralazine (100 mg PO TID) was held during the hospital stay. The patient's hypertension management was adjusted by increasing carvedilol to 50 mg BID and minoxidil to 5 mg, continuing amlodipine 10 mg QD, which resulted in mostly normotensive readings, though aiming for SBP <130. The recommendation is not to restart hydralazine until discussed with the primary care doctor, implying that outpatient follow-up will determine the necessity of its reinitiation or alternative adjustments to achieve the desired blood pressure goal.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I'll do my best to answer the question. However, please note that the question specifically asks about the current management and recommendation for the patient's hypertension, particularly regarding the use of hydralazine, which is not mentioned in the provided documents except for the question itself implying a prior discontinuation (not shown in the documents).

**Answer:**

* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Note ID and Admission ID:** Since these are not directly relevant to the question about hypertension management, they are noted as consistent but not further analyzed here. (Note ID: 13180007-DS-19, Admission ID: 20774429, consistent across all documents)

**Current Management of Hypertension (as per the documents):**

* **Status:** History of hypertension, currently well controlled (Document 2)
* **Management:** Continued on home:
	1. **Amlodipine** 10 mg
	2. **Coreg (Carvedilol)** 50 mg BID
	3. **Minoxidil** 10 mg daily (Document 2)

**Regarding Hydralazine:**

* **Mention in Documents:** None. The documents provided do not mention hydralazine at all, neither its use, discontinuation, nor any recommendations related to it.
* **Implication from the Question:** It is implied that hydralazine was discontinued by the primary care physician before admission, but this information is not found in the provided documents.

**Conclusion:**

Given the information in the documents, there is no data to provide a recommendation or insight into the management of the patient's hypertension with regards to hydralazine, as it is not mentioned. The current management of hypertension, as stated in Document 2, involves Amlodipine, Coreg (Carvedilol), and Minoxidil, with no reference to hydralazine.","['11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', 'Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '* **Medications on Admission (Pre-admission List):**\n\t1. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath\n\t2. **Amlodipine**: 10 mg PO DAILY\n\t3. **Atorvastatin**: 80 mg PO QPM\n\t4. **Carved']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the key considerations and potential complications for a patient with asthma, presenting with no current respiratory distress, but having a complex past medical history including cardiac risk factors and cerebrovascular disease, in a long-term healthcare management context?","['281ec1ee-1c32-43a3-8667-6c9eaa2f4734\n\nEKG:  SR, NL axis, NIs, TWIs laterally (c/w prior) \nLabs/studies notable for:  proBNP: 1140, Cr 1.9\nPatient was given:  IV Furosemide 10mg\nOn the floor...  \n---------------\nStates that he feels better than he did when he came to the\nhospital. No SOB, CP, or palpitations. Only complaint is the\nburning/itching in his lower extremities. \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '3a943d1f-0e52-4cc8-939c-42f2386be179\n\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis\n \nSocial History:\n___\nFamily History:\nBoth parents have heart disease. Mother-___ w/ heart problems and\ndiabetes & father is ___ w/ diabetes. 16 brothers and sisters. No\nknown hx of early coronary artery disease or sudden cardiac \ndeath.\n \nPhysical Exam:\nADMISSION EXAM:\nVS: ___ Temp: 97.3 PO BP: 168/78 HR: 85 RR: 18 O2 sat:\n97% O2 delivery: RA Dyspnea: 0 RASS: 0 Pain Score: ___ \nGEN: alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor\napparent trauma\nLYMPH: no anterior/posterior cervical, supraclavicular \nadenopathy']","Based on the provided context, key considerations for managing a patient with asthma, like the one described, include monitoring for potential exacerbations, especially given the patient's complex past medical history. Notably, the patient's current presentation without SOB (shortness of breath), CP (chest pain), or palpitations, but with a complaint of burning/itching in lower extremities, suggests that asthma is not currently the primary acute concern. However, the patient's history of cardiac risk factors (Type 2 Diabetes Mellitus, Hypertension, Dyslipidemia, Coronary artery disease), cardiac history (Secondum ASD, Mild AR), and cerebrovascular disease (status post CVA), alongside extensive intracranial atherosclerosis, necessitates a holistic approach. This includes careful management of medications (e.g., the IV Furosemide given for an unspecified but likely cardiac-related issue, given the proBNP and Cr levels), regular monitoring for signs of cardiac decompensation or stroke, and adjusting asthma management to prevent triggering other conditions. The patient's family history of heart disease and diabetes also warrants close long-term monitoring for early signs of these conditions. Physical exams, like the one documented, are crucial for ongoing assessment, particularly focusing on the patient's comfort, distress levels, and specific systemic evaluations (e.g., HEENT, Lymphatic).",custom_multi_hop_query_synthesizer,"**Analysis and Response**

**Patient Identification:**
Based on the provided metadata, the patient's key identifiers are consistent across all documents:
* **Patient/Subject ID:** 13180007 (consistent across Documents 1-5)
* **Note ID:** 13180007-DS-19 (consistent across Documents 1-5)
* **Admission ID:** 20774429 (consistent across Documents 1-5)

**Key Considerations for Asthma Management in the Context of Complex Past Medical History:**

1. **Cardiac Risk Factors:**
	* **Relevance to Asthma:** Certain asthma medications (e.g., non-selective beta-agonists) can potentially exacerbate cardiac conditions. The patient's history of **Hypertension**, **Dyslipidemia**, **Mild Aortic Regurgitation (AR)**, and **Secundum Atrial Septal Defect (ASD)** (Document 1) necessitates careful medication selection to avoid worsening cardiac function.
	* **Action:** Prefer asthma medications with minimal to no cardiac side effects. Monitor cardiac function during asthma treatment adjustments.

2. **Cerebrovascular Disease:**
	* **Relevance to Asthma:** While direct interactions between asthma treatments and cerebrovascular disease are less common, overall vascular health is crucial. The patient's **Extensive Intracranial Atherosclerosis** and **History of CVA** (Document 1) highlight the importance of maintaining optimal vascular risk factor control.
	* **Action:** Ensure that asthma management does not neglect or compromise the patient's cerebrovascular disease management (e.g., continue Aspirin and Atorvastatin as indicated in Documents 2 and 4 for CVA history).

3. **Polypharmacy and Medication Interactions:**
	* Given the patient's complex medical history and multiple medications (e.g., for Hypothyroidism, CVA, CKD, Asthma as seen across Documents 2-5), there's a heightened risk of drug interactions.
	* **Action:** Regularly review the patient's entire medication regimen to identify potential interactions, especially when adjusting asthma treatments.

4. **Comorbid Conditions Influencing Asthma:**
	* **Chronic Kidney Disease (CKD):** May affect the metabolism and excretion of certain asthma medications. (Document 3 mentions CKD with Sevelamer Carbonate treatment.)
	* **Action:** Choose asthma medications that are safe for patients with CKD. Monitor renal function during treatment.

5. **Family History of Heart Disease and Diabetes:**
	* While not directly influencing asthma management, this highlights a predisposition to metabolic and cardiac conditions, which can be exacerbated by certain asthma treatments or poor asthma control.
	* **Action:** Encourage lifestyle modifications that benefit both asthma control and the reduction of metabolic and cardiac risks (e.g., diet, exercise, smoking cessation if applicable).

**Potential Complications to Monitor:**

1. **Cardiac Events:** Due to the patient's cardiac risk factors and the potential cardiac side effects of some asthma medications.
2. **Stroke or TIA:** Given the patient's history of CVA and extensive intracranial atherosclerosis.
3. **Renal Function Decline:** Due to CKD and the potential nephrotoxic effects of certain medications.
4. **Metabolic Syndrome Development:** Considering the family history of diabetes and heart disease.

**Recommendations for Long-term Healthcare Management:**

1. **Multidisciplinary Care Team:** Involve cardiologists, neurologists, nephrologists, endocrinologists, and a primary care physician to manage the patient's complex conditions holistically.
2. **Regular Review of Medications:** To minimize interactions and ensure the safest, most effective treatments for all conditions.
3. **Patient Education:** Emphasize the importance of adherence to the prescribed medication regimen, lifestyle modifications, and regular follow-ups.
4. **Monitoring Schedule:** Establish a frequent monitoring schedule for cardiac, renal, and metabolic parameters, alongside regular asthma control assessments.","['**PAST MEDICAL HISTORY**\n\n* **Conditions:**\n\t1. **Hypertension**\n\t2. **Dyslipidemia**\n\t3. **Diabetes Mellitus Type 2**\n\t4. **Cerebrovascular Disease**, status post CVA (date: **[REDACTED]**)\n\t5. **Ext', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri', '* **Related Information from Other Sections (for context):**\n\t+ **Family History:** Parents have heart disease; Mother has heart problems and diabetes; Father has diabetes\n\t+ **Chronic Problems Sectio']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
What is the prescribed dosage of Hydralazine for a patient post-hospital discharge for managing hypertension alongside other conditions?,"['71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","According to the discharge instructions, the patient is prescribed Hydralazine 100mg three times daily, in addition to other medications such as Carvedilol and Furosemide, for managing conditions that include hypertension, indicating a return to this medication after it was stopped by the PCP just prior to the hospital admission.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

* **Prescribed Dosage of Hydralazine for Patient Post-Hospital Discharge:** 
**NOT MENTIONED** in any of the provided documents (Document 1 through Document 5).

**Rationale:**
1. **Metadata Consistency:** All documents share the same Patient/Subject ID (13180007), Note ID (13180007-DS-19), and Admission ID (20774429), indicating they pertain to the same patient event.
2. **Content Review:** A thorough review of the CONTENT sections across all documents reveals:
	* Detailed discharge instructions, diagnoses, conditions, and medications.
	* Specific medications listed in Documents 3, 4, and summarized in others, but **Hydralazine is not mentioned**.
3. **Priority to Metadata for IDs:** While the question doesn't directly ask for an ID, the consistency in metadata reinforces that the search for Hydralazine's dosage is indeed within the context of the same patient/admission. However, the key takeaway is the absence of Hydralazine in the medication lists.

**Additional Observations Relevant to the Patient's Context (Hypertension Management alongside Other Conditions):**

* Medications that might relate to hypertension or heart failure management are mentioned, such as:
	+ Torsemide (a diuretic, useful in managing fluid overload in heart failure)
	+ Amlodipine (a calcium channel blocker, commonly used for hypertension)
	+ Carvedilol (a beta-blocker, used in heart failure and sometimes hypertension)
* However, **Hydralazine**, specifically, is not listed among the discharge medications in any document.","['Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', '11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ', '### **DISCHARGE DIAGNOSIS & CONDITION**\n\n* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation\n* **Secondary Diagnoses:**\n\t1. Acute kidney injury\n\t2. Acute on chronic anemia\n\t']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What treatment approach was taken for patient with CAD w/ inducible ischemia & NSTEMI, considering kidney function?","['5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,', 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","For the patient with CAD w/ inducible ischemia & NSTEMI, the decision was made to hold off on coronary angiogram due to kidney function concerns and the suspicion that the NSTEMI was type 2 (likely due to volume overload, as troponin peaked at 0.02). The patient was continued on aspirin, atorvastatin, and carvedilol.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I must point out that the question's specifics (CAD w/ inducible ischemia & NSTEMI, considering kidney function) are not directly addressed in the content of the documents as described. However, I will provide an analysis based on the information available, adhering to the instructions:

**Direct Answers Based on Provided Documents and Instructions:**

1. **Patient/Subject ID**: 13180007 (Consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
2. **Note ID**: 13180007-DS-19 (Consistent across all documents)
3. **Admission ID**: 20774429 (Consistent across all documents)
4. **Chart Time & Store Time**: Chart Time: 20/06/62 0:00, Store Time: 21/06/62 9:56 (Consistent across all documents)

**Treatment Approach for Conditions Mentioned in Question (Inferred from Available Documents):**

- **Condition in Question**: CAD with inducible ischemia & NSTEMI, considering kidney function.
- **Available Information**:
  - **CAD with Inducible Ischemia & NSTEMI**: Not explicitly mentioned in the documents. However, there is mention of:
    - **Chest Pain** with mild troponin elevation (0.03) in Document 2, but it's noted as possibly not indicative of ischemia due to CKD.
    - **Cardiac Enzymes** in Document 1, including CK(CPK) and cTropnT, but the context of NSTEMI or inducible ischemia is not provided.
  - **Considering Kidney Function**: The patient has **CKD (Chronic Kidney Disease)** mentioned in all documents, with implications on various treatments and interpretations.

**Treatment Approach as Per Documents (Not Directly Answering the Question but Providing Relevant Info):**

- For **Chest Pain** (potentially related to cardiac issues but complicated by CKD), the management was to continue on **ASA and Atorvastatin**, with no further workup pursued (Document 2).
- For **CKD**, there's mention of the patient receiving **IV Lasix 80mg for diuresis** (Document 3), indicating management of fluid overload, a common complication in CKD.

**Conclusion**:
Given the documents do not explicitly address ""CAD w/ inducible ischemia & NSTEMI, considering kidney function,"" the direct treatment approach for this specific condition cannot be accurately provided from the information available. The management mentioned (continuation of ASA and Atorvastatin for chest pain, and IV Lasix for diuresis in the context of CKD) does not directly relate to the question's specifics about CAD with inducible ischemia and NSTEMI.","['- AnGap: 13\n\t\t- **05:53 AM**\n\t\t\t- Calcium: 8.4\n\t\t\t- Phos: 4.9* (High)\n\t\t\t- Mg: 2.0\n\t\t\t- Iron: 28*\n\t\t\t- calTIBC: 294\n\t\t\t- Ferritn: 73\n\t\t\t- TRF: 226\n\t\t\t- %HbA1c: 11.4* (High)\n\t\t\t- eAG: 280*\n\t\t\t- TSH: 4.', '### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d', '* **Procedure Performed:** *None*\n* **Details:** No major surgical or invasive procedure was performed during this hospital admission.\n* **Related Information:** \n\t+ **Alternative Treatments:** Patien', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '* **Patient Profile**: ___ male with history of:\n\t+ HFpEF (EF 55-60%)\n\t+ Prior CVA\n\t+ CKD\n\t+ DM\n\t+ Hypertension\n\t+ Carotid artery disease\n* **Presenting Symptoms**:\n\t+ 2 days of dyspnea on exertion\n\t+']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the key findigns from the CT scans (head, abd/pelvis, C spine) for a patient with edema, and how do these relait to possibl aspiration or pneumonia, based on the providd medikal imagig reports?","['a0523bf3-a15e-4abc-bd78-1c98b6c5dc7e\n\nedema.  No\nevidence of displaced fracture.\nCT head ___:\nThere is no evidence of infarction, hemorrhage, edema,or midline \nshift.  There\nis prominence of the ventricles and sulci suggestive of \ninvolutional changes.\n \nThere is no evidence of fracture.  Opacification of the mastoid \nair cells. \nThe visualized portion of the paranasal sinuses, mastoid air \ncells, and middle\near cavities are clear.  The visualized portion of the orbits \nare\nunremarkable.\nCT abd/pelvis ___:\n1. Bilateral lower lobe opacities, concerning for aspiration or \npneumonia.\n2. No acute finding in the abdomen or pelvis.\nCT C spine ___:\nNG tube and endotracheal tube are noted.  Alignment is normal. \nNo fractures\nare identified. There is no evidence of high-grade spinal canal', 'dd2587c0-7ebc-4cd2-878e-f8cd5d8d0c1b\n\nBMP - Na 135, K 5, Cr 2.0 (baseline ___, HCO3 20, BG 625, AG 16\nCa 8, phos 6.6\nUA - neg leuk, neg nitr, 7 WBC, neg ketone, 1000 glucose\nUrine tox negative\nTSH pending\nBCx, UCx\nTrop 0.03 -> 0.06\nEKG with T-wave inversion in lateral leads, unchanged from prior\nImaging:  \n- CT head w/o contrast:\n1. No evidence of intracranial bleed. No evidence of acute\nintracranial abnormality.\n2. Opacification of the mastoid air cells.\n- CT C-spine w/o contrast\nNo evidence of acute fracture or malalignment\n- CT A/P w/o contrast\n1. No evidence of acute abdominal or pelvic abnormality. \n2. Extensive bibasilar atelectasis. \n3. Small left pleural effusion. \n- CXR\nSmall left pleural effusion. Opacities likely represent\natelectasis however pneumonia cannot be excluded in the correct\nclinical setting. \nConsults: none']","Based on the provided medical imaging reports, here are the key findings from the CT scans and their relation to possible aspiration or pneumonia:       1. **CT Head**: No evidence of infarction, hemorrhage, edema, or midline shift. Prominence of ventricles and sulci suggests involutional changes. No fracture, but opacification of mastoid air cells is noted.       2. **CT Abd/Pelvis**: **Key Finding Relevant to Aspiration/Pneumonia**: Bilateral lower lobe opacities, concerning for **aspiration or pneumonia**. No acute findings in the abdomen or pelvis.       3. **CT C Spine**: Normal alignment, no fractures, and no evidence of high-grade spinal canal stenosis. NG and endotracheal tubes are noted, which might relate to the patient's condition leading to or resulting from aspiration or pneumonia, but the CT C Spine itself does not directly indicate aspiration or pneumonia.       **Relation to Aspiration/Pneumonia**: The primary indicator from the CT scans for aspiration or pneumonia comes from the **CT Abd/Pelvis**, highlighting bilateral lower lobe opacities. This finding, coupled with the clinical context (e.g., edema, the presence of endotracheal tubes suggesting respiratory support), supports the concern for aspiration or pneumonia. The **CXR** from the second report further supports this with small left pleural effusion and opacities likely representing atelectasis, though it also cannot exclude pneumonia without the correct clinical setting.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the response to the current question:

**Answer:**

* **Key Findings from CT Scans (Head, Abd/Pelvis, C Spine):** 
	+ **NOT AVAILABLE** in the provided documents (1 through 5). None of the documents mention CT scans or provide medical imaging reports for head, abdomen/pelvis, or C spine.

* **Relation to Possible Aspiration or Pneumonia:**
	+ **NOT APPLICABLE** due to the absence of CT scan findings in the provided documents.
	+ However, based on the clinical examination findings across the documents:
		- **Pneumonia Indicators:** There are no explicit indicators of pneumonia in the provided documents. Document 1, 3, and 5 all mention ""Clear to Auscultation Bilaterally (CTAB)"" or equivalent lung findings (""No crackles, wheezes, or rhonchi""), which suggest no overt signs of pneumonia were detected during these examinations.
		- **Aspiration Indicators:** There are no direct mentions or implications of aspiration in the provided documents.
		- **Edema:** Consistently noted across documents (e.g., Document 1, 2, 3, and 5) with varying descriptions, indicating the presence of lower extremity edema, more pronounced on the left side.

**Metadata Observations (as per instruction 3):**
* The **Patient/Subject ID**, **Note ID**, and **Admission ID** are identical across all five documents:
	+ **Patient/Subject ID:** 13180007
	+ **Note ID:** 13180007-DS-19
	+ **Admission ID:** 20774429
	+ **Chart Time** and **Store Time** are also consistent, suggesting these documents pertain to the same patient's single admission episode, recorded and stored at the same times.","['- Normal oropharynx\n\t+ Lungs: Non-labored breathing, Clear to Auscultation Bilaterally (CTAB)\n\t+ Cardiovascular (CV):\n\t\t- Regular Rate and Rhythm (RRR)\n\t\t- Systolic murmur\n\t\t- Normal S1, S2\n\t+ Abdomen', '* **Discharge Physical Exam**\n\t+ **General**: NAD, Mood and affect appropriate\n\t+ **HEENT**: (same as Admission Physical Exam)\n\t+ **Neck**: JVP 12 cm\n\t+ **Cardiac**: (same as Admission Physical Exam, ', '+ No chest wall deformities or tenderness\n\t+ Respiration: Unlabored, no accessory muscle use\n\t+ No crackles, wheezes, or rhonchi\n* **ABDOMEN:**\n\t+ Soft, non-tender, non-distended\n* **EXTREMITIES:**\n\t+', '+ **Symptoms to Report (Danger Signs)**: Not explicitly listed under Discharge Condition, but implied to be monitored based on hospital course (e.g., worsening edema, shortness of breath, chest pain)', '+ No crackles, wheezes, or rhonchi\n* **Abdomen**:\n\t+ Soft\n\t+ Non-tender\n\t+ Non-distended\n* **Extremities**:\n\t+ Warm\n\t+ Well perfused\n\t+ ___ lower extremity edema to ankles (L>R)\n* **Skin**: No signifi']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the current treatment plan for a patient with Hypothyroidism, and how does it relate to their other chronic conditions like Hypertension and IDDM, considering their recent discharge diagnosis and condition?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '8ffe5463-ba8e-4c92-be15-e075478499d9\n\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY:\n=======================================\nHyperglycemic hyperosmolar syndrome \nType 2 diabetes mellitus\nSECONDARY: \n=======================================\nCoronary artery disease\nChronic kidney disease\nHypertension\nHeart failure preserved ejection fraction\nNormocytic Anemia\nHypothyroidism\n \nDischarge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.']","According to the patient's records, for Hypothyroidism, the patient is continued on home levothyroxine 100mcg daily. This treatment plan is managed alongside other chronic conditions. For Hypertension, the patient is on home amlodipine 10, Coreg 50 BID, and minoxidil 10 daily, with the condition currently well controlled. For IDDM (Poorly controlled with an A1c of 14.4, later improved to 11.4%), the patient was transitioned from Lantus 30u at night of admission to home insulin with 70/30 30u with breakfast and 20u with lunch, also utilizing ISS while inpatient. At discharge, the patient's mental status was clear and coherent, alert, interactive, and ambulatory-independent, with Hypothyroidism listed among the secondary discharge diagnoses, indicating its ongoing management as part of the patient's overall care plan.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)
* **Chart Time:** 20/06/62 0:00 (consistent across all documents)
* **Store Time:** 21/06/62 9:56 (consistent across all documents)

**Current Treatment Plan for Hypothyroidism and Relation to Other Conditions:**

1. **Hypothyroidism Treatment:**
	* **Medication:** Levothyroxine (Sodium) 100 mcg PO DAILY (Document 1, Document 2, Document 3, and Document 5 confirm this dosage consistently)

2. **Relation to Hypertension:**
	* **Indirect Mention:** While ""Hypertension"" is not explicitly listed as a chronic problem, medications commonly used to manage hypertension are prescribed:
		+ **Amlodipine 10 mg PO DAILY** (Document 3 and Document 5) - a calcium channel blocker used in hypertension treatment.
		+ **Carvedilol 50 mg PO BID** (Document 3 and Document 5) - a beta-blocker used in managing hypertension among other conditions.
	* **Diastolic Heart Failure Exacerbation** (Document 1, Primary Discharge Diagnosis) implies the presence of hypertension, given its role in heart failure.

3. **Relation to IDDM (Insulin-Dependent Diabetes Mellitus) or Type 1 Diabetes:**
	* **Misalignment in Question:** The documents actually mention **Type 2 Diabetes Mellitus** (Document 1, Secondary Discharge Diagnosis), not IDDM/Type 1 Diabetes.
	* **Management of Type 2 Diabetes Mellitus:**
		+ **70/30 Insulin** with specified dosages (Document 3 and Document 5) indicates management of diabetes with insulin therapy.

**Summary:**
- The patient's Hypothyroidism is managed with Levothyroxine 100 mcg daily.
- Hypertension, while not explicitly listed, is implied through the management of diastolic heart failure and the prescription of hypertensive medications (Amlodipine, Carvedilol).
- The patient has Type 2 Diabetes Mellitus, managed with 70/30 Insulin, not IDDM/Type 1 Diabetes as queried.","['#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '* **Related Information from Other Sections (for context):**\n\t+ **Family History:** Parents have heart disease; Mother has heart problems and diabetes; Father has diabetes\n\t+ **Chronic Problems Sectio', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What specific adjustments were made to the patient's medication regimen during the recent hospitalization to manage poorly-controlled Type 2 Diabetes Mellitus (T2DM) with Hyperosmolar Hyperglycemic State (HHS), and what follow-up actions are recommended for the Clinical Care Coordinator to ensure the patient's continued care?","['386e4975-89d1-411a-99a3-9d225138df6c\n\n[] Ensure that patient was able to adhere to a diabetic diet\nPCP:\n[] Had elevated SBP in 130s-150s. Increased minoxidil to 5mg and \ncarvedilol to 50 mg BID. Please follow-up on blood pressures. \n[] Follow up on diuretics and volume status. Please get \nfollow-up labs BUN/Cr at follow-up appointment.\nNew meds: 70-30 novolog (30 units in AM, 20 units at dinner)\nStopped meds: none\nChanged meds: Carvedilol 50 mg twice a day, increased minoxidil \n5 mg daily \nACUTE ISSUES: \n=============== \n# HHS\n# T2DM\nPatient has history of poorly-controlled DM w/ A1c ~14. Based on \nlabs, determined to be in HHS likely precipitated by med \nnon-adherence or difficulty understanding multi-step process. No \nclear infection was identified. Of note, he tends to have high \ninsulin requirements. Pt was continued on insulin basal/bolus \nwhile inpatient. There was significant efforts to have him bring \nin home Victoza but he only had a half dose so he was continued \non basal/bolus course and made a plan for close outpatient \nfollow up and home 2 injections (Victoza and pre-mixed insulin).']","During the hospitalization, adjustments to the patient's medication regimen included increasing carvedilol to 50 mg twice a day and minoxidil to 5 mg daily. The patient was also continued on insulin basal/bolus. For discharge, a plan was made for close outpatient follow-up with the patient administering two injections at home: Victoza and pre-mixed insulin (70-30 novolog, with 30 units in the AM and 20 units at dinner). As the Clinical Care Coordinator, recommended follow-up actions include: (1) ensuring the patient adheres to the diabetic diet, (2) following up on blood pressures given the recent medication changes, (3) monitoring diuretics and volume status, and (4) obtaining follow-up labs (BUN/Cr) at the next appointment to assess the effectiveness of the current regimen and make any necessary adjustments.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)
* **Chart Time and Store Time:** Indicate documentation around the same hospitalization event (20/06/62 0:00 to 21/06/62 9:56)

**Adjustments to Medication Regimen for Poorly-Controlled T2DM:**

1. **Insulin Adjustment:**
	* **Initial Treatment:** Lantus 30u (night of admission, as per Document 1 and Document 5)
	* **Adjustment:** Transitioned to home insulin regimen - 70/30, 30u with breakfast, 20u with lunch (Document 1 and reinforced in Document 2 and Document 4)
2. **Additional Medication Changes:**
	* **New/Changed Medication:** Torsemide 100 mg PO DAILY (added as per Document 2 and listed in Document 4 as part of discharge medications)
	* **Continued Medications:** Aspirin 81 mg PO DAILY, Vitamin D 1000 UNIT PO DAILY (mentioned in Document 2 as continued from admission), along with others listed in Document 4 that were not explicitly mentioned as changed or new.

**Follow-up Actions for Clinical Care Coordinator:**

1. **Schedule Follow-up Appointments:**
	* **Action:** Arrange for the patient to have follow-up appointments with their healthcare provider to monitor the effectiveness of the adjusted insulin regimen and overall diabetes management. **Status:** Follow-up appointments were [NOT PROVIDED] (Document 4).
	* **Recommendation:** Coordinate with the patient and healthcare provider to schedule these appointments as soon as possible.
2. **Monitor Renal Impairment and Adjust Medications as Necessary:**
	* **Basis:** Elevated Creatinine (Cr) level at discharge indicating persistent renal impairment (Document 3).
	* **Action:** Ensure that the patient's renal function is closely monitored, and work with the healthcare provider to adjust medications (e.g., Torsemide) based on the patient's evolving renal status.
3. **Educate Patient on Home Insulin Regimen and Medication Adherence:**
	* **Action:** Organize or facilitate patient education on the proper administration of the 70/30 insulin regimen and the importance of adherence to all prescribed medications, including Torsemide, to manage both diabetes and renal impairment effectively.
4. **Regular Review of Lab Results:**
	* **Action:** Schedule regular lab tests (e.g., A1c, eAG, Hgb, Cr) to monitor the patient's response to the adjusted treatment plan, and adjust the plan as necessary based on the results.","['* **Status:** Poorly controlled\n* **Lab Results:**\n\t+ A1c 14.4 (prior) and 11.4% (current)\n\t+ eAG 280\n* **Management:**\n\t+ Given Lantus 30u night of admission, then transitioned to home insulin regime', '11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '* **Medications Administered During Hospital Stay:**\n\t1. **IV Lasix**: 80mg (received during ED stay)\n\t2. **Ferric Gluconate**: 250 mg IV (received 3 doses on specified dates, not provided)\n\t3. **Lant']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the ussage of Minoxidil in a patient with Hypertension (HTN) and other comorbidities, and what dose ajustments were made?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:']","Minoxidil was prescribed for a patient with a history of hypertension, among other conditions (Acute on chronic anemia, IDDM, Hypothyroidism, History of CVA, and later mentioned Volume overload, HFpEF, and Normocytic Anemia). Initially, the patient was on minoxidil 10mg daily. However, during the hospital stay, due to persistently hypertensive readings, the dose of minoxidil was adjusted to 5mg, alongside increases in carvedilol to 50mg BID and continuation of amlodipine 10mg QD, aiming for a goal SBP <130 as an outpatient.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Context:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Conditions Relevant to Minoxidil Usage:** Hypertension (HTN), among other comorbidities (Diabetes Mellitus Type 2, Chronic/Acute on Chronic Kidney Disease, Acute on Chronic Anemia)

**Minoxidil Usage in HTN and Comorbidities:**

* **Indication for Minoxidil:** While the primary documents (2, 3, and 5) do not explicitly state the indication for Minoxidil beyond listing it under **Hypertension** management, Minoxidil is commonly used in the treatment of severe hypertension that is symptomatic or associated with target organ damage and is not manageable with maximal therapeutic doses of a diuretic plus two other antihypertensive drugs.
* **Dose:** Consistently listed across relevant documents as **10 mg PO DAILY**.
* **Dose Adjustments:** There is **no mention of dose adjustments** for Minoxidil in any of the provided documents (Document 1 through Document 5). The dose remains constant at 10 mg PO DAILY across all references.

**Additional Observations:**

* **Consistency Across Documents:** The patient's ID (13180007), Note ID (13180007-DS-19), and Admission ID (20774429) are consistent across all five documents, indicating they pertain to the same patient event.
* **Minoxidil in the Context of Other Medications for HTN:** It is used in conjunction with other antihypertensive medications (Amlodipine and Carvedilol) as part of the patient's hypertension management plan, suggesting a regimen for complex or resistant hypertension.

**Metadata Values for Reference:**

* **Patient/Subject ID:** 13180007
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)
* **Chart Time and Store Time:** Refer to individual documents for these details, but notably, the **Store Time** is consistent across all documents as **21/06/62 9:56**.","['* **Admission Medications:**\n\t1. Albuterol Inhaler\n\t2. Amlodipine 10 mg PO DAILY\n\t3. Atorvastatin 80 mg PO QPM\n\t4. Carvedilol 50 mg PO BID\n\t5. Furosemide 80 mg PO DAILY\n\t6. Insulin (70/30) 30 Units Br', '1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the prescribed dosage and administration schedule for Polyethylene Glycol in the provided patient discharge information, and what is the indicated use for this medication?","['784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:', '8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast']","According to the discharge medications list (not explicitly mentioned but inferred from the context of medications) and the medications on admission list, Polyethylene Glycol is prescribed as follows: **Dosage:** 17 g **Administration Schedule:** PO (orally) DAILY:PRN (as needed) **Indicated Use:** Constipation - First Line treatment.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

* **Prescribed Dosage for Polyethylene Glycol:** 17 g
* **Administration Schedule for Polyethylene Glycol:** PO (Orally) DAILY:PRN (as needed)
* **Indicated Use for Polyethylene Glycol:** For Constipation - Listed as First Line treatment

**Source Documents for Answer:**
* Primary Source: **Document 1** (Initial mention with full admission medications list) and **Document 5** (Detailed view of specific medications including Polyethylene Glycol)
* Cross-Reference: **Document 3** implies continuation of medications not explicitly changed at discharge, but for precise dosage and indication, Documents 1 and 5 are referenced.

**Metadata Consistency Note:**
* The **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)** are consistent across all provided documents (**Documents 1 through 5**), indicating these documents pertain to the same patient's hospital admission. 
* **Chart Time** and **Store Time** are also consistent, suggesting these documents were generated or updated at the same time, reflecting a single point of care or discharge summary.","['* **Admission Medications:**\n\t1. Albuterol Inhaler\n\t2. Amlodipine 10 mg PO DAILY\n\t3. Atorvastatin 80 mg PO QPM\n\t4. Carvedilol 50 mg PO BID\n\t5. Furosemide 80 mg PO DAILY\n\t6. Insulin (70/30) 30 Units Br', 'Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula', '11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ', '10. **Polyethylene Glycol**\n\t* Dose: 17 g\n\t* Frequency: PO DAILY:PRN (as needed) for Constipation - First Line\n11. **Sevelamer Carbonate**\n\t* Dose: 800 mg\n\t* Frequency: PO TID (three times a day) W/ME']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the role of Aspirin in the medication regimen of patients with chronic conditions, as observed in the provided medical records, and what are the associated health conditions?","['499f5ec0-b3d8-4161-93fa-07c1b6a6de75\n\ncolonoscopy report in our system previously. Iron studies from \n___ with low normal ferritin (53), low iron, low normal \nTIBC - possibly consistent with anemia of chronic disease or \ninflammation, however hard to rule out concomitant iron \ndeficiency.\n# Hypothyroidism: TSH wnl. Continued home levothyroxine.\n# Asthma: Albuterol inhaler prn continued.\nTRANSITIONAL ISSUES:\n- consideration of outpatient colonoscopy referral if not up to \ndate with screening, particularly iso chronic anemia\n- re-check BP at next PCP appointment, decision on further med \ntitration as above (?increase BB, resuming another home agent\n- ?resume Veltassa if K elevated\n- PCP: consider referral to ___ clinic\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Aspirin 81 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.4 mg PO BID \n4. HydrALAZINE 100 mg PO TID \n5. Levothyroxine Sodium 100 mcg PO DAILY', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","Based on the provided medical context, Aspirin (81 mg PO DAILY) is consistently present in the medication lists. Associated health conditions and considerations include:  - **Chronic Anemia**: Aspirin is mentioned alongside considerations for outpatient colonoscopy referral for screening, particularly in the context of chronic anemia. - **Cardiovascular Health**: The presence of Aspirin, alongside medications like Atorvastatin (for cholesterol), CARVedilol and HydrALAZINE (for blood pressure), and amLODIPine (for hypertension), suggests its role in managing cardiovascular risk. - **Diastolic Heart Failure Exacerbation**: Aspirin is part of the discharge medication list for a patient with a primary diagnosis of acute on chronic diastolic heart failure exacerbation, indicating its continued use in heart failure management. - **General Health Maintenance**: Aspirin's antiplatelet properties are beneficial for overall cardiovascular health, which is a common theme across the observed medical conditions.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Role of Aspirin and Associated Health Conditions:**

Based on the provided medical records, Aspirin plays a role in the management of a specific chronic condition in the patient's medication regimen.

* **Medication:** Aspirin
* **Dosage:** 81 mg PO (orally) DAILY (Document 1) / **Note:** Only the medication name is mentioned in Documents 2 and 5, without dosage, which is provided in Document 1 for completeness.
* **Associated Health Condition:** History of **CVA (Cerebrovascular Accident)**

**Observations Across Documents:**

* The same patient is referenced across all documents, as indicated by the consistent **Patient/Subject ID: 13180007**.
* All documents share the same **Note ID (13180007-DS-19)** and **Admission ID (20774429)**, suggesting they are part of the same medical note or admission record.
* The **Chart Time** and **Store Time** are also consistent across all documents, further supporting this observation.

**Relevant Documents for This Answer:**

* **Primary Document:** Document 1 (Provides detailed medication information including dosage)
* **Secondary Documents:** Documents 2 and 5 (Mention Aspirin in the context of CVA management, without specifying dosage)","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '**Additional Chronic Conditions Mentioned Elsewhere in the Document (not explicitly under *CHRONIC PROBLEMS*)**', '* **Related Information from Other Sections (for context):**\n\t+ **Family History:** Parents have heart disease; Mother has heart problems and diabetes; Father has diabetes\n\t+ **Chronic Problems Sectio']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the trends and implications of CK-MB levels in the provided patient data, considering the fluctuations observed across different time points, and how do these levels correlate with other diagnostic findings such as cardiac silhouette size and pulmonary vascular congestion?","[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'db1f4cbf-c584-4ec8-b5c0-1cf04afe2fb4\n\n___ 07:44AM BLOOD CK-MB-7 cTropnT-0.03*\n___ 05:00PM BLOOD CK-MB-7 cTropnT-0.03*\n___ 07:00AM BLOOD CK-MB-6 cTropnT-0.02*\nTFTs:\n___ 09:10AM BLOOD TSH-9.6*\n___ 07:44AM BLOOD T4-6.5 T3-118 Free T4-1.0\nIMAGING:\n========\nCXR (___):\nFINDINGS:  \nThe lung volumes are low-normal.  There is no focal \nconsolidation.  There is mild prominence of the bilateral \npulmonary vessels suggestive of volume \noverload.  The heart is top-normal in size.  There is no large \neffusion or a pneumothorax.  There is no acute osseous \nabnormality, chronic left rib \nfractures are noted. \n  \nIMPRESSION:  \nStable top-normal heart size with mild pulmonary vascular \ncongestion. \nTTE (___):\nThe left atrial volume index is normal. There is no evidence for']","Based on the provided context, here are the observations and implications of CK-MB levels in relation to other diagnostic findings:           **CK-MB Levels Over Time:**      - **11:00 AM (initial context node):** CK-MB = 4, indicating a relatively low level of cardiac muscle damage.      - **07:44 AM, 05:00 PM, and 07:00 AM (subsequent context node):** CK-MB levels were consistently higher, at 7 (07:44 AM and 05:00 PM) and slightly lower at 6 (07:00 AM), suggesting an increase in cardiac muscle damage or stress over the initial measurement.           **Correlation with Cardiac Silhouette Size:**      - **Initial Context Node:** Describes a 'borderline size of the cardiac silhouette without pulmonary edema,' which, coupled with a CK-MB of 4, might suggest minimal to no acute cardiac injury at the time of the initial assessment.      - **Subsequent Context Node:** Mentions a 'top-normal heart size' with 'mild pulmonary vascular congestion.' The increased CK-MB levels (6 and 7) here could imply worsening cardiac function or additional cardiac stress, though the heart size is described as only top-normal.           **Implications and Considerations:**      - The fluctuations in CK-MB levels, particularly the increase observed in the subsequent measurements, warrant close monitoring of cardiac function.      - The correlation between CK-MB levels and cardiac silhouette size/pulmonary vascular congestion suggests that as CK-MB increases, there is a noticeable, though mild, impact on cardiac function and pulmonary vascular status.      - Further diagnostic workup, including but not limited to serial CK-MB measurements, detailed cardiac imaging (e.g., more frequent TTE), and clinical assessment, is crucial for accurately determining the prognosis and guiding management.",custom_multi_hop_query_synthesizer,"**CK-MB Trends and Implications Analysis**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**CK-MB Levels Across Documents:**

| **Document** | **CK-MB Level** | **Time Point(s)** |
| --- | --- | --- |
| Document 1 | 4 | 09:01 AM & 07:35 PM |
| Document 2 | 4 | Multiple timestamps (matches with 09:01 AM & 07:35 PM from Doc 1) |
| Document 3 | 4 | 02:28 PM, 07:35 PM, 09:01 AM (comprehensive timeline) |
| Document 4 | 4 | 09:01 AM & 07:35 PM (consistent with previous docs) |
| Document 5 | **Not Specifically Listed as CK-MB, but Troponin T (cTropnT) is mentioned** | - |

**Trends and Implications:**

1. **Stability of CK-MB Levels:** The CK-MB level remains consistently at 4 across all time points (09:01 AM and 07:35 PM) and documents (1, 2, 3, and 4), indicating no significant fluctuation in the measured timeframe.
2. **Correlation with Other Diagnostic Findings:**
   - **Cardiac Silhouette Size:** Not directly mentioned in the provided documents. However, the consistent CK-MB level suggests a stable cardiac condition in terms of myocardial damage, but without direct imaging data, the cardiac silhouette size's implications are speculative.
   - **Pulmonary Vascular Congestion (from Document 5, Chest X-Ray):** The presence of mild pulmonary vascular congestion with small bilateral pleural effusions could imply heart failure or fluid overload, which is supported by the elevated proBNP (784) in Documents 2, 3, and 5. The stable CK-MB level, however, does not indicate acute myocardial infarction but could be consistent with chronic cardiac stress or other non-acute cardiac conditions.

**Considerations:**

- **CK-MB in Context:** While CK-MB is elevated (considering a typical reference range of 0-3.6 ng/mL, though not provided), its stability across time points may not indicate an acute coronary event but rather could reflect ongoing cardiac stress or other conditions.
- **Comprehensive Diagnostic Approach:** The combination of CK-MB, elevated proBNP, and imaging findings (pulmonary vascular congestion) suggests a cardiac condition, potentially heart failure, but a definitive diagnosis requires integrating these findings with clinical presentation and possibly additional diagnostic tests.

**Recommendations for Further Analysis:**

1. **Clinical Presentation Review:** Integrate laboratory findings with the patient's symptoms, medical history, and physical examination results.
2. **Additional Diagnostic Tests:** Consider echocardiography to assess cardiac function, further troponin assays for serial monitoring, and other tests as clinically indicated to elucidate the cardiac condition.
3. **Longitudinal Monitoring:** Continue to monitor CK-MB, proBNP, and other relevant markers over time to assess the progression of the cardiac condition and response to treatment.","['- **09:01 AM & 07:35 PM**\n\t\t\t- CK-MB: 4\n\t\t- **09:01 AM**\n\t\t\t- proBNP: 784* (High)', '- **Glucose:** 287* (09:01 AM)\n\t\t- **UreaN:** 39* (09:01 AM), 51* (Discharge)\n\t\t- **Creat:** 2.6 (Admission), 2.9 (Discharge)\n\t\t- **CK(CPK):** 257 (02:28 PM)\n\t\t- **ALT:** 9 (05:53 AM)\n\t\t- **AST:** 13 ', '### **Cardiac Biomarkers**\n\n* **Date/Time:**\n\t+ ___ 02:28PM (CK, cTropnT, CK-MB)\n\t+ ___ 07:35PM (CK-MB, cTropnT)\n\t+ ___ 09:01AM (cTropnT, proBNP, CK-MB)\n* **Results:**\n\t+ CK (CPK): 257\n\t+ cTropnT: 0.0', '- AnGap: 13\n\t\t- **05:53 AM**\n\t\t\t- Calcium: 8.4\n\t\t\t- Phos: 4.9* (High)\n\t\t\t- Mg: 2.0\n\t\t\t- Iron: 28*\n\t\t\t- calTIBC: 294\n\t\t\t- Ferritn: 73\n\t\t\t- TRF: 226\n\t\t\t- %HbA1c: 11.4* (High)\n\t\t\t- eAG: 280*\n\t\t\t- TSH: 4.', '- Creatinine (Cr): 2.6\n\t\t- pro-B-type Natriuretic Peptide (proBNP): 784\n\t\t- Troponin T (TropT): 0.03\n\t+ **Imaging:**\n\t\t- **Chest X-Ray (CXR):** Mild pulmonary vascular congestion with small bilateral ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"Whats the plan for Asthma management for this patient, espeshally with Albuterol inhaler?","['499f5ec0-b3d8-4161-93fa-07c1b6a6de75\n\ncolonoscopy report in our system previously. Iron studies from \n___ with low normal ferritin (53), low iron, low normal \nTIBC - possibly consistent with anemia of chronic disease or \ninflammation, however hard to rule out concomitant iron \ndeficiency.\n# Hypothyroidism: TSH wnl. Continued home levothyroxine.\n# Asthma: Albuterol inhaler prn continued.\nTRANSITIONAL ISSUES:\n- consideration of outpatient colonoscopy referral if not up to \ndate with screening, particularly iso chronic anemia\n- re-check BP at next PCP appointment, decision on further med \ntitration as above (?increase BB, resuming another home agent\n- ?resume Veltassa if K elevated\n- PCP: consider referral to ___ clinic\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Aspirin 81 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.4 mg PO BID \n4. HydrALAZINE 100 mg PO TID \n5. Levothyroxine Sodium 100 mcg PO DAILY']","According to the patient's record, for Asthma management, the Albuterol inhaler is to be continued on an as-needed basis (prn). No changes or additional instructions are noted in the provided context beyond this continuation.",custom_multi_hop_query_synthesizer,"**Asthma Management Plan for Patient 13180007, focusing on Albuterol Inhaler:**

**Patient Identification:**
- **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)
- **Chart Time:** 20/06/62 0:00 (consistent across all documents)
- **Store Time:** 21/06/62 9:56 (consistent across all documents)

**Asthma Management with Albuterol Inhaler:**

1. **Medication:** Albuterol Inhaler
2. **Dose:** 2 PUFF
3. **Frequency/Indication:** IH Q8H:PRN (every 8 hours as needed) for **shortness of breath**
   - **Source Documents:** This regimen is consistently mentioned across:
     - Document 1 (under **Asthma**)
     - Document 2 (under **Discharge Medications**)
     - Document 3 (dedicated section for **Albuterol Inhaler**)
     - Document 4 (under **Medications on Admission**)
     - Document 5 (dedicated section for **Albuterol Inhaler**)

**Observations and Insights:**

- **Consistency:** The Albuterol Inhaler dosage and administration instructions for asthma management are **consistent** across all provided documents.
- **Continuation:** The medication is noted as ""continued"" in Document 2, indicating it was part of the patient's pre-admission regimen and is being continued post-admission.
- **No Adjustments Mentioned:** There is no mention of any adjustments to the Albuterol Inhaler dosage or frequency in the provided documents, suggesting the current regimen is deemed appropriate for the patient's asthma management at the time of these records.","['3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '* **Discharge Medications:**\n\t1. **Torsemide**: 100 mg PO DAILY (newly prescribed)\n\t2. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath (continued)\n\t3. **Amlodipine**: 10 mg PO DAILY (cont', '1. **Albuterol Inhaler**\n\t* Dose: 2 PUFF IH Q8H\n\t* Indication: PRN shortness of breath\n2. **Amlodipine**\n\t* Dose: 10 mg PO DAILY\n3. **Atorvastatin**\n\t* Dose: 80 mg PO QPM\n4. **Carvedilol**\n\t* Dose: 50', '* **Medications on Admission (Pre-admission List):**\n\t1. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath\n\t2. **Amlodipine**: 10 mg PO DAILY\n\t3. **Atorvastatin**: 80 mg PO QPM\n\t4. **Carved', '1. **Torsemide**\n\t* Dose: 100 mg\n\t* Frequency: PO DAILY\n\t* Additional Info: *torsemide 20 mg 5 tablet(s) by mouth once a day, Disp #*70, Tablet Refills:*0\n2. **70/30 Insulin**\n\t* Dose: \n\t\t+ 30 Units w']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the patient's vital signs (VS) upon discharge, and are there any notable findings in the cardiovascular examination?","['0070a23b-dc9f-483f-a66d-a8d84a4b995b\n\nCARDIOVASCULAR: Regular rate and rhythm with late ___ systolic\nmurmur at RUSB, no rubs or gallops\nLUNGS: clear to auscultation bilaterally without rhonchi,\nwheezes, or crackles\nGI: soft, nontender, without rebounding or guarding, \nnondistended\nwith normal active bowel sounds, no hepatomegaly\nEXTREMITIES: no clubbing, cyanosis, or edema\nGU: no foley\nSKIN: no rashes, petechia, lesions, or echymoses; warm to\npalpation\nNEURO: Alert and interactive to person, ___ (daughters\nstated that this is a hospital before pt named it), ___, but\nthinks that it is ___, cranial nerves II-XII intact, strength \nis\n___ in RUE, RLE, LLE, ___ in LUE elbow flexion/extension and\nhand grip. Gait is WNL, negative Romberg, negative pronator\ndrift.\nPSYCH: normal mood and affect\nDISCHARGE EXAM\nVS: 97.9 PO 151 / 65 64 18 99 RA \nGEN: Alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor', '29d118b8-9203-4616-bc9a-07f5566771d6\n\nVS: \n24 HR Data (last updated ___ @ 817)\n    Temp: 98.3 (Tm 98.4), BP: 136/56 (135-164/56-69), HR: 78\n(57-84), RR: 20 (___), O2 sat: 97% (95-97), O2 delivery: RA  \n24 HR Data (last updated ___ @ 817)\n    Temp: 98.3 (Tm 98.4), BP: 136/56 (135-164/56-69), HR: 78\n(57-84), RR: 20 (___), O2 sat: 97% (95-97), O2 delivery: RA  \nFluid Balance (last updated ___ @ 600) \n  Last 8 hours  Total cumulative -405ml\n    IN: Total 120ml, PO Amt 120ml\n    OUT:  Total 525ml, Urine Amt 525ml\n  Last 24 hours  Total cumulative -725ml\n    IN: Total 1000ml, PO Amt 900ml, IV Amt Infused 100ml\n    OUT:  Total 1725ml, Urine Amt 1725ml     \nWEIGHT: 74.3 kg (75.6 kg)\n \nGENERAL: Sitting up in a chair next to bed. NAD.\nNECK: JVP 7-8 cm. \nCARDIAC: Regular rate and rhythm. Normal S1, S2. Right upper\nborder systolic murmur III/VI. \nLUNGS: Respiration is unlabored with no accessory muscle use.\nCTAB. No wheezes/rales/rhonchi. \nABDOMEN: +BS. Distended but soft. Non-tender to palpation.\nEXTREMITIES: Warm. 1+ edema L > RLE.']","Upon discharge, the patient's vital signs (VS) were: Temperature (Temp) = 97.9, Pulse (PO) = 151, Blood Pressure (BP) = 65/64, Respiratory Rate (RR) = 18, Oxygen Saturation (O2 sat) = 99% on Room Air (RA). Notably, the cardiovascular examination revealed a regular rate and rhythm with a late systolic murmur at the Right Upper Sternal Border (RUSB), but no rubs or gallops were detected.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's the answer to the question following the specified instructions:

**Question:** What are the patient's vital signs (VS) upon discharge, and are there any notable findings in the cardiovascular examination?

**Answer:**

1. **Vital Signs (VS) upon Discharge:**
	* **Not explicitly provided** in any of the documents (1 through 5) under the content sections related to discharge. Typically, vital signs would include temperature, pulse, blood pressure, respiratory rate, and oxygen saturation. Without a dedicated ""Vital Signs"" section in the provided documents, especially under discharge observations, this information cannot be accurately reported from the given content.

2. **Notable Findings in the Cardiovascular Examination upon Discharge:**
	* **Document 2 (Discharge Physical Exam)** provides relevant information:
		+ **Cardiac:** ""(same as Admission Physical Exam, except no PMI location mentioned)"" - **No new or specific discharge-related cardiac findings are noted** beyond the comparison to admission.
		+ **Neck:** ""JVP 12 cm"" - This is a notable finding, as a Jugular Venous Pressure (JVP) of 12 cm is elevated, suggesting potential fluid overload or cardiac dysfunction, which aligns with the patient's discharge diagnosis of ""Acute on chronic diastolic heart failure exacerbation"".
		+ **Lower Extremity Edema (under Extremities):** ""present, to ankles (Left > Right)"" - While not a direct cardiovascular examination finding, edema is relevant to the patient's cardiac condition, indicating possible fluid retention.

**Metadata Observations (as per instruction 3):**
- The **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)** are consistent across all five documents, indicating they pertain to the same patient event.","['+ **Symptoms to Report (Danger Signs)**: Not explicitly listed under Discharge Condition, but implied to be monitored based on hospital course (e.g., worsening edema, shortness of breath, chest pain)', '* **Discharge Physical Exam**\n\t+ **General**: NAD, Mood and affect appropriate\n\t+ **HEENT**: (same as Admission Physical Exam)\n\t+ **Neck**: JVP 12 cm\n\t+ **Cardiac**: (same as Admission Physical Exam, ', '### **DISCHARGE DIAGNOSIS & CONDITION**\n\n* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation\n* **Secondary Diagnoses:**\n\t1. Acute kidney injury\n\t2. Acute on chronic anemia\n\t', '+ Diastolic dysfunction (grade indeterminate)\n\t+ Small pericardial effusion\n\t+ Other findings: Detailed in the original document under ""PERTINENT STUDIES/RESULTS""\n* **Laboratory Results - mentioned in', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What happen to patient come to ED for asthma but family say no asthma, have weight loss, chills, hand and leg cramping, and history of CVA, what all test and meds patient have in ED?","['33441964-a7d6-441d-ac8e-c600d6bf9f69\n\nED Course:\nExam: no focal neuro deficits. \nVS: T96.1, HR 80, BP 114/50, RR 16, 99% on room air. \nLabs: TropT 0.04, proBNP: 754, Cr 2.3, WBC 5.6, Hgb 10.6\nCultures: urine culture pending. \nMeds: acetaminophen 1g, NS 500mL.\nImaging: CT head: no acute intracranial abnormality. chronic\ninfarcts. \nOn arrival to the floor, pt states that he came to the ED \nbecause\nof his asthma. His daughters are present and state that asthma \nis\nnot, in fact, the reason for his ED presentation. They also\ndescribe anorexia with weight loss. They believe that he looks\nlike he has lost weight, but no clear idea of how much. He\nendorses chills without fevers, which seems to be chronic since\nhis CVA. He has not mentioned chest pain, but has endorsed hand\nand leg cramping. He did have a transient headache which has now\nresolved. \nAt baseline, ___ work full time jobs and have\ntheir own families; pt lives with his wife, who is on HD. ___\ncomes to the house once a week, and pt is followed by RN/BSN \nfrom', ""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin.""]","Patient, with history of CVA, presented to ED with claimed asthma, but family denied this, reporting anorexia with weight loss instead. Key findings and actions in ED include:      * **Exam:** No focal neuro deficits.      * **Vital Signs (VS):** T96.1, HR 80, BP 114/50, RR 16, 99% on room air.      * **Labs:** TropT 0.04 (indicating no acute myocardial infarction), proBNP 754 (elevated, suggesting heart failure), Cr 2.3 (elevated, indicating renal impairment), WBC 5.6 (within normal range), Hgb 10.6 (mild anemia). Urine culture pending.      * **Meds Administered in ED:** Acetaminophen 1g, Normal Saline (NS) 500mL.      * **Imaging:** CT head showed no acute intracranial abnormality but chronic infarcts.      * **Symptoms:** Chills without fevers (chronic since CVA), hand and leg cramping, transient headache (now resolved). No chest pain.      * **Pre-ED Context:** Had an episode of confusion, slurred speech, and hyperglycemia (FSBG>500, HbA1c 15.0%) before ED arrival. Was on Tresiba 50u. History of similar neurological episodes, including dysarthria, confusion, and aphasia, during last hospitalization with unrevealing MRI/MRA and EEG, leading to continued ASA and atorvastatin.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and the content of the documents, I must point out that the scenario described in the ""Current Question"" does not match the information provided in the documents (Document 1 through Document 5). The scenario mentions:

- Presenting to the ED for asthma (contradicted by family)
- Symptoms: weight loss, chills, hand and leg cramping
- History of CVA (consistent with the documents)

However, the documents provided describe a patient with:

- Presenting symptoms of dyspnea on exertion, chest discomfort on exertion, worsening lower extremity edema, and wheeze (Document 1)
- A history that includes CVA, among other conditions (consistent across documents, especially detailed in Document 5)
- No mention of asthma as a presenting complaint in the ED, but asthma is listed as part of the past medical history (Document 5)
- No mention of weight loss, chills, or hand and leg cramping as presenting symptoms
- Tests and medications mentioned are in the context of the symptoms and conditions described in the documents, not the scenario

Given the discrepancy, I will answer based on the information provided in the documents (since the scenario's details are not found within them) and then address the scenario's questions to the extent possible.

**Based on the Documents (for the patient with ID 13180007, consistent across all documents):**

- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)
- **Chart Time & Store Time:** As listed, but note all documents have the same timestamps, indicating they pertain to the same period.

**Tests Mentioned in the ED Context:**

1. **Creatinine (Cr):** 2.6 (Document 3)
2. **pro-B-type Natriuretic Peptide (proBNP):** 784 (Document 3)
3. **Troponin T (TropT):** 0.03 (Documents 3 and 4)
4. **Chest X-Ray (CXR):** Showing mild pulmonary vascular congestion with small bilateral pleural effusions (left > right) (Documents 3 and 4)

**Medications Mentioned in the ED:**

1. **IV Lasix (Furosemide) 80mg** (Documents 3 and 4)

**Regarding the Scenario's Questions (to the extent information is available or can be inferred):**

- **Presenting to ED for asthma but family says no asthma:** There is no mention of this scenario in the provided documents. Asthma is listed as part of the patient's past medical history (Document 5), but it's not indicated as a presenting complaint.
  
- **Symptoms (weight loss, chills, hand and leg cramping):** Not mentioned in the documents as presenting symptoms.

- **History of CVA:** Consistent, mentioned in Document 1 and detailed in Document 5.

- **Tests and Meds for the Scenario:** Since the scenario's symptoms (weight loss, chills, hand and leg cramping, and the context of asthma contradicted by family) are not described in the documents, we cannot accurately determine the tests and medications specifically for this scenario based on the provided information. The tests and medication listed above are for the symptoms and conditions described in the documents (dyspnea on exertion, chest discomfort, etc.).","['* **Patient Profile**: ___ male with history of:\n\t+ HFpEF (EF 55-60%)\n\t+ Prior CVA\n\t+ CKD\n\t+ DM\n\t+ Hypertension\n\t+ Carotid artery disease\n* **Presenting Symptoms**:\n\t+ 2 days of dyspnea on exertion\n\t+', '* **Summary:** 10-point review of systems is negative except as noted above (referring to the History of Present Illness section, which mentioned dyspnea on exertion, chest discomfort on exertion, wor', '- Creatinine (Cr): 2.6\n\t\t- pro-B-type Natriuretic Peptide (proBNP): 784\n\t\t- Troponin T (TropT): 0.03\n\t+ **Imaging:**\n\t\t- **Chest X-Ray (CXR):** Mild pulmonary vascular congestion with small bilateral ', '- TropT: 0.03\n\t+ Notable Studies:\n\t\t- CXR: Mild pulmonary vascular congestion with small bilateral pleural effusions (left > right)\n\t+ Treatment in ED: IV Lasix 80mg\n* **Symptom Progression on Medical', '**PAST MEDICAL HISTORY**\n\n* **Conditions:**\n\t1. **Hypertension**\n\t2. **Dyslipidemia**\n\t3. **Diabetes Mellitus Type 2**\n\t4. **Cerebrovascular Disease**, status post CVA (date: **[REDACTED]**)\n\t5. **Ext']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
Wha CK-MB level mean for patient wit chest pain but no ischemia sign?,"[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","Patient have flat CK-MB with mild troponin elevation. CK-MB level specifically mentioned as 4. This, combined with other findings, not suggestive of ischemia. Patient continued on ASA and atorvastatin. Note: CK-MB interpretation in context of patient's Chronic Kidney Disease (CKD) should be considered, though direct implications not detailed in provided context.",custom_multi_hop_query_synthesizer,"**Answer to Current Question**

**Question:** What does the CK-MB level mean for a patient with chest pain but no ischemia sign?

**Relevant Documents:** 
- **Document 1** (contains initial lab results, including CK-MB)
- **Document 3** (provides clinical interpretation of chest pain and related lab findings)
- **Document 4** (additional lab results, including CK-MB at different times)

**Patient/Subject ID:** 13180007 (consistent across all documents)
**Note ID:** 13180007-DS-19 (consistent across all documents)
**Admission ID:** 20774429 (consistent across all documents)

**CK-MB Levels:**
- **Document 1:** CK-MB: 4 (at **09:01 AM & 07:35 PM**)
- **Document 4:** CK-MB: 4 (at **09:01 AM & 07:35 PM**, consistent with Document 1)

**Clinical Interpretation (from Document 3):**
- **Chest Pain Presentation:** Mild troponin elevation (0.03) but difficult to interpret due to Chronic Kidney Disease (CKD).
- **Findings Relevant to CK-MB:**
  - **Flat CK-MB** (implying no significant change or elevation indicative of ischemia)
  - No focal wall motion abnormalities or signs of ischemia on TTE (Transthoracic Echocardiogram)

**Meaning of CK-MB Level in This Context:**
- The CK-MB level of 4, in the context of this patient's chest pain but without signs of ischemia, is described as ""flat"" in **Document 3**. This suggests that the level is not indicative of acute myocardial infarction (heart attack) or significant cardiac ischemia.
- The stability of CK-MB levels at 4 across different measurement times (**09:01 AM & 07:35 PM**) further supports the interpretation that there is no acute cardiac event as evidenced by CK-MB.
- The patient's mild troponin elevation (0.03) is noted but considered possibly not indicative of ischemia due to the patient's CKD, as mentioned in **Document 1** and interpreted in **Document 3**.","['- AnGap: 13\n\t\t- **05:53 AM**\n\t\t\t- Calcium: 8.4\n\t\t\t- Phos: 4.9* (High)\n\t\t\t- Mg: 2.0\n\t\t\t- Iron: 28*\n\t\t\t- calTIBC: 294\n\t\t\t- Ferritn: 73\n\t\t\t- TRF: 226\n\t\t\t- %HbA1c: 11.4* (High)\n\t\t\t- eAG: 280*\n\t\t\t- TSH: 4.', '- Normal oropharynx\n\t+ Lungs: Non-labored breathing, Clear to Auscultation Bilaterally (CTAB)\n\t+ Cardiovascular (CV):\n\t\t- Regular Rate and Rhythm (RRR)\n\t\t- Systolic murmur\n\t\t- Normal S1, S2\n\t+ Abdomen', '### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d', '- **09:01 AM & 07:35 PM**\n\t\t\t- CK-MB: 4\n\t\t- **09:01 AM**\n\t\t\t- proBNP: 784* (High)', '* **Summary:** 10-point review of systems is negative except as noted above (referring to the History of Present Illness section, which mentioned dyspnea on exertion, chest discomfort on exertion, wor']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the key findings from the patient's Transthoracic Echocardiogram (TTE) regarding ventricular function, valve conditions, and comparisons to prior TTE results, from a medical researcher's analytical perspective?","['6947fbec-1aff-4c0a-8eb5-fe9953adbb08\n\nventricular cavity size with normal free wall motion. The aortic \nsinus diameter is normal for gender with normal ascending aorta \ndiameter for gender. The aortic valve leaflets (3) appear \nstructurally normal. There is no aortic valve stenosis. There is \ntrace aortic regurgitation. The mitral valve leaflets appear \nstructurally normal with no mitral valve prolapse. There is \ntrivial mitral regurgitation. The pulmonic valve leaflets are \nnormal. The tricuspid valve leaflets appear structurally normal. \nThere is physiologic tricuspid regurgitation. The pulmonary \nartery systolic pressure could not be estimated. There is a \ntrivial pericardial effusion.\nIMPRESSION: Mild symmetric left ventricular hypertrophy with \nnormal cavity size and regional/global biventricular systolic \nfunction. No significant mitral regurgitation.\nCompared with the prior TTE ___, the findings are \nsimilar.\nMRI/MRA HEAD AND NECK (___)\nIMPRESSION:\n \n \n1. No hemorrhage or acute infarct.\n2. Chronic infarcts within the subcortical right frontal lobe \nand left\ntemporal and occipital lobes.\n3. Atrophic pons likely a sequela of prior infarcts.', 'db1f4cbf-c584-4ec8-b5c0-1cf04afe2fb4\n\n___ 07:44AM BLOOD CK-MB-7 cTropnT-0.03*\n___ 05:00PM BLOOD CK-MB-7 cTropnT-0.03*\n___ 07:00AM BLOOD CK-MB-6 cTropnT-0.02*\nTFTs:\n___ 09:10AM BLOOD TSH-9.6*\n___ 07:44AM BLOOD T4-6.5 T3-118 Free T4-1.0\nIMAGING:\n========\nCXR (___):\nFINDINGS:  \nThe lung volumes are low-normal.  There is no focal \nconsolidation.  There is mild prominence of the bilateral \npulmonary vessels suggestive of volume \noverload.  The heart is top-normal in size.  There is no large \neffusion or a pneumothorax.  There is no acute osseous \nabnormality, chronic left rib \nfractures are noted. \n  \nIMPRESSION:  \nStable top-normal heart size with mild pulmonary vascular \ncongestion. \nTTE (___):\nThe left atrial volume index is normal. There is no evidence for']","Based on the provided TTE findings, the key observations include:  1. **Mild symmetric left ventricular hypertrophy** with normal cavity size. 2. **Normal regional/global biventricular systolic function**. 3. **Structurally normal valve leaflets** for aortic, mitral, pulmonic, and tricuspid valves. 4. **Trace aortic regurgitation** and **trivial mitral regurgitation** with **physiologic tricuspid regurgitation**. 5. A **trivial pericardial effusion** was noted. 6. **Comparison to prior TTE** shows similar findings, indicating stability in the observed conditions. These findings suggest a relatively stable cardiac condition with some minor abnormalities, but no significant deterioration or new major issues compared to the previous TTE.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)

**Relevant Note ID for TTE Findings:** 13180007-DS-19 (consistent across all documents, indicating these are related entries for the same patient and admission)

**Key Findings from Transthoracic Echocardiogram (TTE):**

### **Ventricular Function:**
- **Left Ventricular Findings (Document 1):**
  - Mild symmetric hypertrophy with normal cavity size
  - Normal regional and global systolic function
  - Visually estimated Left Ventricular Ejection Fraction (LVEF): 65%
- **Right Ventricular Findings (Implicit in Documents 4 and 5, via context):**
  - No right ventricular diastolic collapse noted in the context of increased respiratory variation in transtricuspid inflow

### **Valve Conditions:**
- **Mitral Valve Leaflets (Document 5):**
  - Mildly thickened
  - Trivial regurgitation
  - No prolapse
- **Pulmonic Valve Leaflets (Documents 4 and 5):**
  - Normal
- **Tricuspid Valve Leaflets (Documents 4 and 5):**
  - Structurally normal
  - Physiologic regurgitation

### **Comparisons to Prior TTE Results:**
- **No Direct Comparisons Provided in Any Document:** There is no explicit mention of comparisons to prior TTE results in the provided documents (Document 1 through Document 5).

### **Additional Notable Findings Relevant to TTE Context:**
- **Pericardial Effusion (Documents 2, 4, and 5):**
  - Characterized as Small
- **Pulmonary Artery Systolic Pressure (Documents 4 and 5):**
  - Normal
- **Diastolic Dysfunction (Document 2):**
  - Grade indeterminate, which might relate to the increased respiratory variation in transmitral/transtricuspid inflow without right atrial/right ventricular diastolic collapse (Documents 4 and 5)","['* **EKG:**\n\t+ Finding: TWI (T-wave inversion) in lateral leads\n* **Echocardiogram (TTE) - mentioned in ""PERTINENT STUDIES/RESULTS"" and ""ACUTE PROBLEMS"":**\n\t+ Left atrial volume index: Normal\n\t+ Estima', '+ Diastolic dysfunction (grade indeterminate)\n\t+ Small pericardial effusion\n\t+ Other findings: Detailed in the original document under ""PERTINENT STUDIES/RESULTS""\n* **Laboratory Results - mentioned in', '+ **Diagnostic Procedures:** Various lab tests, imaging studies (e.g., CXR, TTE), and EKG were performed (detailed under ""Labs notable for:"", ""Studies notable for:"", ""PERTINENT RESULTS:"", and ""DISCHAR', '+ Pulmonic Valve Leaflets: Normal\n\t+ Tricuspid Valve Leaflets: Structurally normal, physiologic regurgitation\n\t+ Pulmonary Artery Systolic Pressure: Normal\n\t+ Pericardial Effusion: Small\n\t+ Respirator', '+ **Mitral Valve Leaflets**: Mildly thickened, trivial regurgitation, no prolapse\n\t+ **Pulmonic Valve Leaflets**: Normal\n\t+ **Tricuspid Valve Leaflets**: Structurally normal, physiologic regurgitation']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the key considerations and current plans for managing the patient's cardiovascular health, particularly regarding the known inducible ischemia in the LCX distribution, in the context of their complex medical history including CKD and recent medication adjustments?","['3854e9c9-f299-4327-94b1-3dc260a4fc6f\n\nLying HR: 68 RR: 20 O2 sat: 98% O2 delivery: 3LNC Dyspnea: 3\nRASS: 0 Pain Score: ___ \n \n  Of note, since ___, he has had known inducible ischemia on\nLCX distribution from stress test. The risks (including dialysis\nafter contrast load) and benefits were discussed with primary\ncardiologist Dr. ___. Coronary angiogram was deferred. \n  He also had a recent admission to the heart failure service\nwith uptitration of blood pressure control agents. Coronary\nangiogram was deferred at that time. ACEi was stopped (prior\nlisinopril 40mg) given worsened CKD vs ___.  Low dose lisinopril\nwas reinitiated at last visit with Dr. ___. \n  Multiple notes in OMR describe issues with ensuring consistent\nsupply of medications. The patient and his family confirm this.\nHowever, they state recently no change in medications, ___ comes\nonce per week.  He describes his diet as healthy but family\nconcerned about salt intake. No h/o arrhythmia, no palpitations. \n On the floor, he reports ongoing mild wheeze, improving\nshortness of breath, no current chest pain. \nREVIEW OF SYSTEMS:  \nPositive per HPI.', '4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:']","The patient has known inducible ischemia in the LCX distribution from a previous stress test, alongside multiple risk factors. Management considerations include:         - **Coronary Angiogram Deferral**: Recently deferred due to risks, including dialysis after contrast load, as discussed with Dr. ___.        - **Medication Adjustments**:           - **ACEi (Lisinopril)**: Initially stopped due to worsened CKD, then reinitiated at a low dose.          - **Continued Medications**: Home aspirin, atorvastatin, and carvedilol are continued.          - **Discontinued**: Jardiance, due to contraindication with chronic kidney disease.        - **Future Plans**: Potential switch to a more sustainable insulin regimen (e.g., 70/30 mix BID) if the patient can be placed in a day program, emphasizing close follow-up and compliance services upon discharge.        - **Additional Recommendations**: Outpatient neurocognitive evaluation for subacute mental status decompensation.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's a structured answer to the question, following the given instructions:

**Key Considerations and Current Plans for Managing Cardiovascular Health:**

* **Patient/Subject ID:** 13180007 (consistent across all documents: **Document 1**, **Document 2**, **Document 3**, **Document 4**, and **Document 5**)
* **Admission ID:** 20774429 (consistent across all documents, same as above)

**Key Considerations:**

1. **Complex Medical History:**
	* **CKD (Chronic Kidney Disease):** Elevated Cr levels (admission: 2.6, discharge: 2.9) as per **Document 5**.
	* **Cardiovascular Conditions:**
		+ **Acute on Chronic HFpEF (Heart Failure with preserved Ejection Fraction):** Primary diagnosis as per **Document 5**.
		+ **Cerebrovascular Disease, status post CVA:** Mentioned in **Document 3** and managed with aspirin and atorvastatin 80 as per **Document 4**.
		+ **Extensive Intracranial Atherosclerosis, Carotid Artery Disease, Secundum Atrial Septal Defect (ASD), Mild Aortic Regurgitation (AR):** Listed in **Document 3**.
2. **Recent Medication Adjustments:**
	* No direct mentions of recent medication adjustments specifically for cardiovascular health in the context of inducible ischemia in the LCX distribution. However:
		+ **Sevelamer Carbonate** for CKD (continued from home) as per **Document 2**.
		+ **Aspirin and Atorvastatin 80** for history of CVA as per **Document 4**.

**Current Plans for Managing Cardiovascular Health (Specific to Inducible Ischemia in LCX Distribution):**
* **No Specific Plans Mentioned:** The documents provided do not explicitly mention inducible ischemia in the LCX distribution or specific plans for managing it in the context of the patient's complex medical history and recent medication adjustments.

**Recommendation for Further Analysis:**
Given the absence of direct information on inducible ischemia in the LCX distribution and its management within the provided documents, it is recommended to:
- Consult additional medical records or documents that may specifically address cardiovascular interventions, stress test results, or cardiology consultation notes.
- Review medication lists for any adjustments to cardiovascular medications that might not be highlighted in the provided documents.
- Consider seeking input from the patient's cardiologist or primary care physician for a comprehensive management plan.","['* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '**PAST MEDICAL HISTORY**\n\n* **Conditions:**\n\t1. **Hypertension**\n\t2. **Dyslipidemia**\n\t3. **Diabetes Mellitus Type 2**\n\t4. **Cerebrovascular Disease**, status post CVA (date: **[REDACTED]**)\n\t5. **Ext', '* **Related Information from Other Sections (for context):**\n\t+ **Family History:** Parents have heart disease; Mother has heart problems and diabetes; Father has diabetes\n\t+ **Chronic Problems Sectio', '* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
What is the prescribed dosage of hydralazine for a patient with acute on chronic heart failure and hypertension?,"['5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia', '71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:']","According to the provided medical context, the patient was previously on hydralazine but it was stopped by the PCP just prior to admission. However, a past prescription for hydralazine is mentioned in one of the discharge medications lists as: '12. HydrALAZINE 100 mg PO TID' which translates to 'hydralazine 100 mg, 1 tablet by mouth three times a day'. Please note, this might not reflect the current treatment plan as the medication was stopped prior to the described hospital stay.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the response to the current question:

**Answer to the Current Question:**
There is **no prescribed dosage of hydralazine** mentioned in any of the provided documents for a patient with acute on chronic heart failure and hypertension.

**Reasoning:**

1. **Medication Mentioned for Heart Failure and Hypertension:**
   - For Heart Failure (specifically HFpEF): The mentioned treatment involves diuretics (IV Lasix 80, torsemide 100 daily for active diuresis).
   - For Hypertension: The patient is continued on home medications including Amlodipine 10, Coreg 50 BID, and Minoxidil 10 daily (Document 2, Section 4).

2. **Hydralazine Not Mentioned:**
   - A thorough review of all provided documents (1 through 5) does not yield any mention of hydralazine as part of the patient's treatment regimen for either acute on chronic heart failure or hypertension.

**Additional Observations (as per instructions):**

- **Patient/Subject ID Consistency:** The Patient/Subject ID `13180007` is consistent across all documents (1 through 5), indicating they pertain to the same patient.
- **Note ID, Admission ID, Chart Time, and Store Time Consistency:** These metadata fields are also identical across all documents, suggesting they are part of the same medical note or admission record. 
  - **Note ID:** `13180007-DS-19`
  - **Admission ID:** `20774429`
  - **Chart Time:** `20/06/62 0:00`
  - **Store Time:** `21/06/62 9:56`","['### 5. **Acute on Chronic Anemia**\n\n* **Presentation:** Hb 7.4 on admission\n* **Possible Causes:** Worsening renal function or dilutional iso heart failure\n* **Management:**\n\t+ Received 3 doses of Fer', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '+ 2 hospitalizations in the past year for HF exacerbations\n* **Medication Compliance**:\n\t+ Typically on Lasix 80mg daily\n\t+ Endorses compliance with medications\n* **Initial Assessment in ED**:\n\t+ Init', '* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa', '**ACUTE PROBLEMS**\n=====================\n\n### 1. **Acute on Chronic HFpEF (Heart Failure with Preserved Ejection Fraction)**']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the key considerations for a Clinical Care Coordinator managing a patient with Mild Aortic Regurgitation (Mild AR) alongside other cardiac risk factors and extensive intracranial atherosclerosis, in terms of preventing repeated hospital admissions and managing home medications?","['07c9a41e-be29-4f49-810c-9cfabe64e237\n\nInterventions: \n3L LR, Vanc/Cefepime/Flagyl, insulin gtt, Propofol (changed to\nmidazolam for hypotension), fentanyl \nVS Prior to Transfer: temp 96.2, HR 61, BP 109/54, RR 24, O2 sat\n99% Intubation \nROS: Positives as per HPI; otherwise negative.  \n \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '2fefbd11-fef9-45c9-8e5f-7c57ff45ef50\n\nCase Management, ___, as outpatient. ___ and\n___ both feel that their father needs increased services at\nhome to prevent repeated admissions. They are both providing as\nmuch support as they can, in the setting of having their own \nfull\ntime jobs and families. ___ expresses concern that his home\nmedications will be resumed/uptitrated without the understanding\nthat he is not, in fact, taking them as prescribed; she\nrecognizes that this could result in major adverse events, if \nall\nhome medications were to be resumed at the same time in the\nhospital.\n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.']","Based on the provided context, key considerations for managing such a patient include:  1. **Close Monitoring of Cardiac Condition**: Given the patient's history of Mild AR, Secondary ASD, Type 2 Diabetes Mellitus, Hypertension, Dyslipidemia, and Coronary Artery Disease, careful monitoring of cardiac health is crucial. 2. **Management of Intracranial Atherosclerosis**: The patient's extensive intracranial atherosclerosis, particularly worse in the right MCA territory, and history of CVA, necessitate careful management to prevent further cerebrovascular events. 3. **Preventing Repeated Admissions**: Increasing home services, as suggested by the patient's family, could help in preventing repeated hospital admissions by providing adequate support and monitoring. 4. **Safe Management of Home Medications**: It is critical to understand the patient's adherence to prescribed medications before resuming or uptitrating them post-hospitalization to avoid major adverse events. A tailored approach to medication management, possibly including education on proper medication use, is essential.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Patient Context:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Relevant Conditions for Consideration:**
	+ Mild Aortic Regurgitation (Mild AR)
	+ Secundum Atrial Septal Defect (ASD)
	+ Extensive Intracranial Atherosclerosis
	+ Carotid Artery Disease
	+ Hypertension
	+ Dyslipidemia
	+ Diabetes Mellitus Type 2
	+ Cerebrovascular Disease (post-CVA)
	+ Chronic Kidney Disease (CKD)
	+ Asthma
	+ Osteoarthritis
	+ Hypothyroidism

**Key Considerations for Clinical Care Coordinator:**

1. **Multidisciplinary Care Team Engagement:**
	* Collaborate with cardiologists for managing Mild AR and ASD.
	* Involve neurologists for extensive intracranial atherosclerosis and post-CVA care.
	* Engage nephrologists for CKD management.
	* Coordinate with endocrinologists for Diabetes Mellitus Type 2 and Hypothyroidism.

2. **Medication Management at Home:**
	* **List of Medications to Monitor:**
		- For Hypothyroidism: Levothyroxine Sodium 100 mcg PO DAILY
		- For History of CVA: Aspirin 81 mg PO DAILY, Atorvastatin 80 mg PO QPM
		- For CKD: Sevelamer Carbonate 800 mg PO TID W/MEALS
		- For Asthma: Albuterol Inhaler 2 PUFF IH Q8H:PRN
		- **Note:** No medications listed for Mild AR, ASD, Extensive Intracranial Atherosclerosis, Carotid Artery Disease, Hypertension, Dyslipidemia, Osteoarthritis in provided documents. **Recommendation:** Verify and potentially adjust medications with the care team to ensure comprehensive management.
	* **Adherence Monitoring:** Regularly check patient adherence to prescribed medications to prevent complications.

3. **Preventing Repeated Hospital Admissions:**
	* **Regular Follow-Ups:** Schedule frequent outpatient appointments with the multidisciplinary care team.
	* **Symptom Monitoring:** Educate the patient to recognize and report early signs of heart failure exacerbation, kidney injury, or stroke.
	* **Lifestyle Modifications:** Encourage dietary changes, regular exercise (tailored to the patient's capabilities), smoking cessation (if applicable), and stress reduction techniques.

4. **Extensive Intracranial Atherosclerosis Management:**
	* **Close Neurological Monitoring:** Regular assessments for signs of neurological deterioration.
	* **Optimize Risk Factors:** Aggressively manage hypertension, dyslipidemia, and diabetes to slow disease progression.

5. **Patient Education and Support:**
	* **Disease Awareness:** Provide comprehensive education on all conditions, focusing on Mild AR and extensive intracranial atherosclerosis.
	* **Emergency Preparedness:** Ensure the patient knows when and how to seek emergency care.
	* **Support Network:** Facilitate connections with support groups for patients with similar conditions.","['6. **Secundum ASD (Atrial Septal Defect)**, **Mild AR (Aortic Regurgitation)**, **Carotid Artery Disease** (mentioned in Past Medical History, no medications or updates listed)', '**PAST MEDICAL HISTORY**\n\n* **Conditions:**\n\t1. **Hypertension**\n\t2. **Dyslipidemia**\n\t3. **Diabetes Mellitus Type 2**\n\t4. **Cerebrovascular Disease**, status post CVA (date: **[REDACTED]**)\n\t5. **Ext', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
What are the key findings from the patient's Transthoracic Echocardiogram (TTE) regarding left ventricular function and structure?,"['81401d7e-0074-4c95-b4cf-e031f6b09906\n\nFindings are compatible with moderate pulmonary edema with a \nmoderate left\npleural effusion.  Underlying bibasilar atelectasis and/or \npneumonia in the\nappropriate clinical setting should also be considered.\nCT HEAD WO CON (___)\nIMPRESSION: \n \nArea of low-density left occipital ___ represent subacute \ninfarct, if there are clinical symptoms, consider brain MRI \nwithout contrast. Small chronic lacunar infarct right basal \nganglia. Few calcifications at the pons, nonspecific, may be \nsequela of prior\ninflammatory or ischemic process, cavernoma cannot be excluded.\nTTE (___)\n---------------\nCONCLUSION: The left atrial volume index is mildly increased. \nThere is mild symmetric left ventricular hypertrophy with a \nnormal cavity size. There is normal regional and global left \nventricular systolic function. The visually estimated left \nventricular ejection fraction is 55-60%. There is no resting \nleft ventricular outflow tract gradient. Normal right', 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","According to the TTE findings, the patient has:               1. **Mildly increased left atrial volume index**.              2. **Mild symmetric left ventricular hypertrophy** with a normal cavity size.              3. **Normal regional and global left ventricular systolic function**.              4. A **visually estimated left ventricular ejection fraction of 55-60%**.              5. **No resting left ventricular outflow tract gradient**.              Additionally, the TTE did not show evidence of focal wall motion abnormalities or other findings suggestive of ischemia.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Identification (from METADATA, as per instruction 1):**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Key Findings from Transthoracic Echocardiogram (TTE) regarding Left Ventricular Function and Structure:**

Combining information from **Document 1**, **Document 2**, and **Document 3** (as these provide the most relevant TTE findings):

* **Left Ventricular (LV) Structure:**
	+ **Hypertrophy:** Mild, symmetric (Document 1, Document 2, and Document 3 concur)
	+ **Cavity Size:** Normal (Document 1, Document 2, and Document 3 concur)
* **Left Ventricular (LV) Function:**
	+ **Systolic Function:** Normal (regional and global) (Document 1 and Document 2 concur; Document 3 mentions ""Normal (visually estimated LVEF 65%)"")
	+ **Visually Estimated Left Ventricular Ejection Fraction (LVEF):** 65% (Document 1, Document 2, and Document 3 concur)
* **Additional Finding (not directly asked but relevant to LV function in the context of overall heart function):**
	+ **Left Ventricular Filling Pressure (PCWP):** Elevated (>18 mmHg) (Document 3 only)
	+ **Diastolic Dysfunction:** Grade indeterminate (Document 3 and mentioned in Document 5, though without specifics in the latter)","['* **EKG:**\n\t+ Finding: TWI (T-wave inversion) in lateral leads\n* **Echocardiogram (TTE) - mentioned in ""PERTINENT STUDIES/RESULTS"" and ""ACUTE PROBLEMS"":**\n\t+ Left atrial volume index: Normal\n\t+ Estima', '* **Echocardiogram (TTE) Findings:**\n\t+ Left Atrial Volume Index: Normal\n\t+ Estimated Right Atrial Pressure: **[NOT PROVIDED]**\n\t+ Left Ventricular (LV) Characteristics:\n\t\t- Mild symmetric LV hypertro', '* **Echocardiogram (TTE) Findings:**\n\t+ Left Atrial Volume Index: Normal\n\t+ Estimated Right Atrial Pressure: [NOT PROVIDED]\n\t+ Left Ventricular Hypertrophy: Mild, symmetric\n\t+ Left Ventricular Cavity ', '+ Pulmonic Valve Leaflets: Normal\n\t+ Tricuspid Valve Leaflets: Structurally normal, physiologic regurgitation\n\t+ Pulmonary Artery Systolic Pressure: Normal\n\t+ Pericardial Effusion: Small\n\t+ Respirator', '+ Diastolic dysfunction (grade indeterminate)\n\t+ Small pericardial effusion\n\t+ Other findings: Detailed in the original document under ""PERTINENT STUDIES/RESULTS""\n* **Laboratory Results - mentioned in']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the prescribed dosage and administration schedule for HydrALAZINE in the provided medical discharge instructions, and what are the primary and secondary diagnoses associated with its prescription?","['058d90f2-3d7b-4d29-bca6-e70e3cb19e4d\n\n4.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times daily \nDisp #*90 Tablet Refills:*0 \n5.  Glargine 30 Units Breakfast \n6.  Albuterol Inhaler 2 PUFF IH Q4H  \n7.  amLODIPine 10 mg PO DAILY  \n8.  Atorvastatin 80 mg PO QPM  \n9.  CloNIDine 0.2 mg PO BID  \n10.  Gabapentin 400 mg PO TID  \n11.  Levothyroxine Sodium 100 mcg PO DAILY  \n12.  MetFORMIN (Glucophage) 850 mg PO TID  \n13.  Vitamin D ___ UNIT PO WEEKLY  \n14. HELD- Lisinopril 40 mg PO DAILY  This medication was held. \nDo not restart Lisinopril until told to do so by your doctor\n15.Outpatient Lab Work\nChem-7 to be draw ___\nICD 10: I50.3: Diastolic (congestive) heart failure\nFax results to: ___ ATTN: ___\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___', '5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia']","According to the discharge instructions, HydrALAZINE is prescribed as follows: 100 mg PO (by mouth) TID (three times a day). This medication regimen is associated with the following diagnoses: **PRIMARY DIAGNOSIS** - Acute on chronic heart failure with preserved ejection fraction, and **SECONDARY DIAGNOSES** - Acute kidney injury, Coronary artery disease, Type 2 Diabetes Mellitus, and Hyperkalemia. The prescription details are consistent across both provided medical records (Disp #*90 Tablet Refills:*0 in one record and implied in the other with #*60 Tablet Refills:*0 for a different medication, suggesting a similar dispensing approach might be intended for HydrALAZINE despite the specific refill number not being directly mentioned in the second record for HydrALAZINE).",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the response to the current question:

**Question:** What is the prescribed dosage and administration schedule for HydrALAZINE in the provided medical discharge instructions, and what are the primary and secondary diagnoses associated with its prescription?

**Answer:**

1. **Prescribed Dosage and Administration Schedule for HydrALAZINE:**
	* **Dosage:** NOT MENTIONED
	* **Administration Schedule:** NOT MENTIONED
	* **Reason:** HydrALAZINE is not mentioned at all in the provided documents (Document 1 through Document 5).

2. **Primary and Secondary Diagnoses (General, since HydrALAZINE is not mentioned):**
	* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation
	* **Secondary Diagnoses:**
		1. Acute kidney injury
		2. Acute on chronic anemia
		3. Type 2 diabetes mellitus
	* **Source for Diagnoses:** Document 1, Document 4, and Document 5 (consistent across these documents)

**Additional Observations Based on Instructions:**

* **Patient/Subject ID Consistency:** The Patient/Subject ID `13180007` is consistent across all provided documents (Document 1 through Document 5).
* **Note ID, Admission ID, Chart Time, and Store Time Consistency:** These metadata elements are also consistent across all documents, indicating they all pertain to the same patient event.
* **Medications Mentioned (not including HydrALAZINE):** 
	+ Levothyroxine (for Hypothyroidism) - Document 5
	+ Aspirin and Atorvastatin (for History of CVA) - Document 5
	+ Medications for the primary and secondary diagnoses are mentioned in summary in Document 2 but not specified by name, dosage, or administration schedule.","['### **DISCHARGE DIAGNOSIS & CONDITION**\n\n* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation\n* **Secondary Diagnoses:**\n\t1. Acute kidney injury\n\t2. Acute on chronic anemia\n\t', 'Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula', '22. BRIEF HOSPITAL COURSE\n23. SUMMARY\n24. TRANSITIONAL ISSUES\n25. ACUTE PROBLEMS\n26. CHRONIC PROBLEMS\n27. MEDICATIONS ON ADMISSION\n28. DISCHARGE MEDICATIONS\n29. DISCHARGE DISPOSITION\n30. DISCHARGE DIA', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', '#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What me worry bout wen patient hav small left pleural effusion, borderline cardiac silhouette, and chronic infarcts in brain CT, but no acute intracranial abnormality? Should i look into somethin else wit dis patient?","[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'a0523bf3-a15e-4abc-bd78-1c98b6c5dc7e\n\nedema.  No\nevidence of displaced fracture.\nCT head ___:\nThere is no evidence of infarction, hemorrhage, edema,or midline \nshift.  There\nis prominence of the ventricles and sulci suggestive of \ninvolutional changes.\n \nThere is no evidence of fracture.  Opacification of the mastoid \nair cells. \nThe visualized portion of the paranasal sinuses, mastoid air \ncells, and middle\near cavities are clear.  The visualized portion of the orbits \nare\nunremarkable.\nCT abd/pelvis ___:\n1. Bilateral lower lobe opacities, concerning for aspiration or \npneumonia.\n2. No acute finding in the abdomen or pelvis.\nCT C spine ___:\nNG tube and endotracheal tube are noted.  Alignment is normal. \nNo fractures\nare identified. There is no evidence of high-grade spinal canal']","Based on provided CT scans and blood work, key concerns for the patient include:      1. **Small left pleural effusion and borderline size of the cardiac silhouette** observed in the chest X-ray (CXR), suggesting potential cardiac or pulmonary issues, but **no pneumonia or pneumothorax**.     2. **Chronic infarcts** within the right frontal lobe, left occipital lobe, and right basal ganglia, as well as **calcifications in the pons**, indicating past ischemic or inflammatory processes, but **no evidence of acute intracranial abnormality** on the Head CT.     3. **Elevated %HbA1c (14.4)** and **eAG (367)**, indicating poorly controlled diabetes.     4. **proBNP of 754**, which may suggest heart failure or other cardiac conditions.     **Recommendation**: Further investigation into the patient's cardiac health (given the borderline cardiac silhouette and proBNP levels) and management of diabetes are warranted. Monitoring for any signs of neurological deterioration, despite the current lack of acute intracranial abnormalities, is also advisable.",custom_multi_hop_query_synthesizer,"**Response as a Medical Document Assistant**

**Addressing the Current Question:**
The question posed doesn't directly correlate with the provided documents' content, which focus on a patient's (ID: **13180007**) admission, treatment, and findings related to pulmonary and cardiac issues. However, I'll provide a structured response to guide further investigation based on the hypothetical scenario you've outlined (small left pleural effusion, borderline cardiac silhouette, and chronic infarcts in brain CT, but no acute intracranial abnormality).

**Concerns Based on Hypothetical Scenario:**

1. **Small Left Pleural Effusion:**
	* **Monitoring:** Regular chest X-rays to monitor the size of the effusion.
	* **Investigate Underlying Cause:** Given the patient's other conditions (as per the hypothetical scenario), consider if the effusion is related to cardiac issues (e.g., heart failure) or other causes (infection, malignancy).
2. **Borderline Cardiac Silhouette:**
	* **Cardiac Evaluation:** Echocardiogram to assess cardiac function, particularly focusing on signs of heart failure or structural abnormalities that could explain the ""stiff left ventricle"" mentioned in Documents 4 and 5.
3. **Chronic Infarcts in Brain CT with No Acute Intracranial Abnormality:**
	* **Neurological Assessment:** Comprehensive neurological examination to evaluate for any deficits that could be attributed to the chronic infarcts.
	* **Risk Factor Management:** Aggressive management of vascular risk factors (e.g., hypertension, diabetes, hyperlipidemia) to prevent further cerebral vascular events.

**Additional Recommendations:**

* **Holistic Review:** Conduct a thorough review of the patient's medical history, including all previous diagnoses, treatments, and hospital admissions (utilizing the provided IDs for coherence):
	+ **Patient/Subject ID:** **13180007** (consistent across all documents)
	+ **Note ID:** **13180007-DS-19** (consistent across all documents, indicating these are related notes)
	+ **Admission ID:** **20774429** (consistent across all documents, confirming they pertain to the same admission)
* **Multidisciplinary Team (MDT) Review:** Given the complexity of the patient's condition (cardiac, pulmonary, and neurological aspects), consider an MDT review involving cardiology, neurology, and possibly palliative care to ensure comprehensive management.

**Metadata Observations:**

* The **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)** are consistent across all documents, indicating they relate to the same patient and admission.
* **Chart Time** and **Store Time** are also consistent, suggesting these documents were generated and stored as part of the same clinical episode.","['- Creatinine (Cr): 2.6\n\t\t- pro-B-type Natriuretic Peptide (proBNP): 784\n\t\t- Troponin T (TropT): 0.03\n\t+ **Imaging:**\n\t\t- **Chest X-Ray (CXR):** Mild pulmonary vascular congestion with small bilateral ', 'Here is the extracted and summarized information for the subheading ""* STUDIES NOTABLE FOR"":\n\n* **Study Type:** CXR (Chest X-Ray)\n* **Findings:**\n\t+ Mild pulmonary vascular congestion\n\t+ Small bilater', '- TropT: 0.03\n\t+ Notable Studies:\n\t\t- CXR: Mild pulmonary vascular congestion with small bilateral pleural effusions (left > right)\n\t+ Treatment in ED: IV Lasix 80mg\n* **Symptom Progression on Medical', '* **Impression:** Suboptimal image quality, Stiff Left Ventricle, Small Pericardial Effusion, No frank tamponade.', '**IMPRESSION**\n\n* **Image Quality**: Suboptimal\n* **Key Findings**: Stiff left ventricle, small pericardial effusion, no frank tamponade.']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What medikashuns shud patient wit Type 2 Diabetes Mellitus, heart failure, and acute kidney injury take when goin home from hospital, espeshally for diabetis?","['281ec1ee-1c32-43a3-8667-6c9eaa2f4734\n\nEKG:  SR, NL axis, NIs, TWIs laterally (c/w prior) \nLabs/studies notable for:  proBNP: 1140, Cr 1.9\nPatient was given:  IV Furosemide 10mg\nOn the floor...  \n---------------\nStates that he feels better than he did when he came to the\nhospital. No SOB, CP, or palpitations. Only complaint is the\nburning/itching in his lower extremities. \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia']","Based on provided context, for a patient with Type 2 Diabetes Mellitus discharged home, the specified medications do not directly target diabetes management at home. However, medications listed in the context that the patient was on or discharged with, which might be relevant or need monitoring in the context of their diabetes and other conditions, include:  - **HydrALAZINE 100 mg PO TID** (primarily for hypertension, a cardiac risk factor for diabetes patients) - **Levothyroxine Sodium 100 mcg PO DAILY** (for thyroid conditions, not directly related to diabetes but important for overall metabolic health) - **IV Furosemide 10mg** was administered in the hospital (for acute kidney injury and heart failure, not a home medication in this context but important for managing conditions that impact diabetes care).  **Direct Diabetes Management Medication:** Not specified in the discharge or hospital administration context provided. Typically, a patient with Type 2 Diabetes Mellitus would be on medications such as Metformin, Sulfonylureas, or other classes depending on their specific condition and health status, but these are not mentioned in the given context.",custom_multi_hop_query_synthesizer,"**Answering the Question with Provided Guidelines**

**Patient Identification for Context:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, 2, 3, 4, 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Medications for Type 2 Diabetes Mellitus, Heart Failure, and Acute Kidney Injury upon Discharge:**

1. **Type 2 Diabetes Mellitus:**
	* **70/30 Insulin**: Specifically dosed as 30 Units at Breakfast, 10 Units at Lunch (Document 3, Discharge Medications List, Item 2)
	* **Note:** No Victoza (Liraglutide) is listed in the discharge medications (Document 3), although it was continued from home in Document 1. **Only Insulin is specified for discharge.**

2. **Heart Failure (Acute on Chronic Diastolic Heart Failure Exacerbation):**
	* **Torsemide 100 mg PO DAILY** (Document 3, Discharge Medications List, Item 1) - Typically used for managing fluid overload associated with heart failure.
	* **Carvedilol 50 mg PO BID** (Document 3, Discharge Medications List, Item 7) - A beta-blocker for heart failure management.

3. **Acute Kidney Injury (AKI):**
	* **No specific medication** is listed in the discharge medications (Document 3) that is uniquely targeted at AKI. Management of AKI often involves careful fluid management and adjustment of medications that could be nephrotoxic, which might explain the absence of specific AKI medications and the presence of **Torsemide** for fluid management.

**Additional Discharge Medications (for comprehensive context, though not specifically asked):**
- **Amlodipine 10 mg PO DAILY** (for Hypertension, Document 3, Item 4)
- **Aspirin 81 mg PO DAILY** (Document 3, Item 5)
- **Atorvastatin 80 mg PO QPM** (Document 3, Item 6)
- **Albuterol Inhaler 2 PUFF IH Q8H:PRN** (Document 3, Item 3)
- **Levothyroxine Sodium 100 mcg PO DAILY** (Document 3, Item 8)

**Important Note:**
- The discharge medications list (Document 3) mentions ""Take all medications as prescribed"" but only explicitly lists 8 medications. Document 5 lists admission medications, which include some not found in the discharge list (e.g., Furosemide, Liraglutide (Victoza), Minoxidil, Polyethylene Glycol). The discrepancy suggests that not all admission medications were continued at discharge, highlighting the importance of following the discharge instructions specifically for post-hospital care.","['1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '### **DISCHARGE DIAGNOSIS & CONDITION**\n\n* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation\n* **Secondary Diagnoses:**\n\t1. Acute kidney injury\n\t2. Acute on chronic anemia\n\t', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', '* **Admission Medications:**\n\t1. Albuterol Inhaler\n\t2. Amlodipine 10 mg PO DAILY\n\t3. Atorvastatin 80 mg PO QPM\n\t4. Carvedilol 50 mg PO BID\n\t5. Furosemide 80 mg PO DAILY\n\t6. Insulin (70/30) 30 Units Br']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"Whats the deal with the Asprin perscription for a patient with a history of CAD and CKD stage III, shouldnt they be on somethin els?","['4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","According to the patient's care plan, **Aspirin** is indeed continued at home, alongside **atorvastatin** and **carvedilol**, despite the patient's history of CAD (with a past stress test showing inducible ischemia in LCx distribution) and CKD stage III. This decision was made as part of medically optimizing the patient, with close follow-up planned. Specifically, the patient is to take **Aspirin 81mg once daily** as prescribed upon discharge, with no indication in the provided context to switch to an alternative due to these conditions.",custom_multi_hop_query_synthesizer,"Based on the provided instructions, I'll address the question to the best of my abilities with the given documents. Please note that:

* The question mentions a patient with a history of CAD (Coronary Artery Disease), but the provided documents primarily highlight conditions such as heart failure with preserved ejection fraction (HFpEF), acute kidney injury, and others. CAD is not explicitly mentioned in the documents provided, but there are mentions of carotid artery disease and a secundum atrial septal defect (ASD), among other cardiovascular conditions.
* The question also mentions CKD stage III, but the documents provided do not explicitly state the stage of Chronic Kidney Disease (CKD); they only discuss acute on chronic kidney disease (CKD) and provide lab values.

**Addressing the Question:**

1. **Patient/Subject ID**: The patient in question across all documents has a consistent **Patient/Subject ID: 13180007**. This ID is uniform across Documents 1 through 5.
   
2. **Aspirin Prescription for CAD and CKD Stage III**:
   - **CAD**: Not explicitly mentioned in the provided documents. However, there's a discussion about chest pain with mild troponin elevation in **Document 4**, which might imply some cardiac concern, but it's managed with ASA (Aspirin) and Atorvastatin, suggesting a cardiovascular aspect to their care.
   - **CKD Stage III**: Not explicitly stated in the documents. The focus is on managing acute on chronic kidney disease, with **Document 5** discussing elevated creatinine levels and management with Sevelamer.

3. **Shouldnât They Be on Something Else?**
   - **Current Management for Relevant Conditions**:
     - **Cardiovascular Aspect (implied, not explicitly CAD)**: ASA (Aspirin) and Atorvastatin (**Document 4**).
     - **CKD**: Sevelamer for elevated creatinine levels (**Document 5**). Hypertension is managed with Amlodipine, Coreg, and Minoxidil (**Document 5**), which is relevant for CKD patients to control blood pressure.
   - **Consideration for Alternative Medications**: Without explicit mention of CAD or CKD stage III, and considering the provided management plans align with general practices for heart failure, hypertension, and CKD (though specific stage-driven recommendations might vary), it's challenging to definitively state an alternative without more specific diagnostic information. However, for patients with CKD, especially if progressing or at stage III, careful consideration of medications affecting renal function is crucial. The use of Aspirin in patients with CKD, especially if there's a cardiovascular benefit (e.g., secondary prevention in CAD), is generally weighed against the risk of bleeding and potential renal effects, often under close monitoring.

**Recommendation Based on Provided Information**:
- **Consult Recent Guidelines**: For CKD management, refer to the latest KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, and for cardiovascular aspects, consider guidelines from bodies like the ACC (American College of Cardiology) or ESC (European Society of Cardiology), ensuring alignment with the patient's specific conditions and stages.
- **Multidisciplinary Review**: Given the complexity and potential interactions between the patientâs conditions (HFpEF, CKD, hypertension, etc.), a multidisciplinary team review could provide a more tailored approach, ensuring all aspects of care are optimized.

**IDs and Dates for Reference**:
- **Patient/Subject ID**: 13180007 (Consistent across Documents 1-5)
- **Note ID**: 13180007-DS-19 (Consistent across Documents 1-5)
- **Admission ID**: 20774429 (Consistent across Documents 1-5)
- **Chart Time**: 20/06/62 0:00 (Consistent across Documents 1-5)
- **Store Time**: 21/06/62 9:56 (Consistent across Documents 1-5)","['* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi', '- AnGap: 13\n\t\t- **05:53 AM**\n\t\t\t- Calcium: 8.4\n\t\t\t- Phos: 4.9* (High)\n\t\t\t- Mg: 2.0\n\t\t\t- Iron: 28*\n\t\t\t- calTIBC: 294\n\t\t\t- Ferritn: 73\n\t\t\t- TRF: 226\n\t\t\t- %HbA1c: 11.4* (High)\n\t\t\t- eAG: 280*\n\t\t\t- TSH: 4.', '**PAST MEDICAL HISTORY**\n\n* **Conditions:**\n\t1. **Hypertension**\n\t2. **Dyslipidemia**\n\t3. **Diabetes Mellitus Type 2**\n\t4. **Cerebrovascular Disease**, status post CVA (date: **[REDACTED]**)\n\t5. **Ext', '### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
What is the prescribed administration schedule for Albuterol Inhaler upon hospital admission for a patient experiencing shortness of breath?,['8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast'],"According to the preadmission medication list, Albuterol Inhaler is prescribed as 2 puffs, inhaled (IH) every 8 hours as needed (Q8H:PRN) specifically for shortness of breath.",custom_multi_hop_query_synthesizer,"Based on the provided documents, to answer the question about the prescribed administration schedule for Albuterol Inhaler upon hospital admission for a patient experiencing shortness of breath, we'll analyze the relevant information:

**Question Breakdown:**
- **Medication of Interest:** Albuterol Inhaler
- **Specific Query:** Prescribed administration schedule upon hospital admission for shortness of breath
- **Relevant Documents:** Primarily looking at admission-related documents

**Analysis:**

1. **Metadata Consistency for Patient Context:**
   - **Patient/Subject ID:** Consistently listed as `13180007` across all documents.
   - **Admission ID:** Consistently listed as `20774429` across all documents, confirming these documents pertain to the same hospital admission.

2. **Albuterol Inhaler Administration Schedule:**
   - **Document 1 (Content):** Lists ""2 PUFF IH Q8H"" with an indication for ""PRN shortness of breath"". **PRN** stands for ""pro re nata,"" meaning as needed.
   - **Document 2 (Content - Medications on Admission):** Mirrors Document 1, specifying ""2 PUFF IH Q8H:PRN shortness of breath"".
   - **Document 4 (Content - Admission Medications):** Simply lists ""Albuterol Inhaler"" without the detailed administration schedule, but given the consistency with Documents 1 and 2, we can infer the schedule is as previously stated.
   - **Document 5 (Content):** While it discusses medications, it seems more focused on discharge or a specific point in time rather than admission protocols, and its details on Albuterol align with previous documents but don't add new admission-specific information.

**Answer:**
- **Prescribed Administration Schedule for Albuterol Inhaler upon Hospital Admission for Shortness of Breath:**
  - **Dose:** 2 PUFF
  - **Frequency:** IH (Inhalation) Q8H (Every 8 Hours)
  - **Additional Instruction:** PRN (Pro Re Nata, meaning as needed) for shortness of breath.

**Metadata Confirmation (as per instruction 2 & 3):**
- The **Patient/Subject ID** (`13180007`) and **Admission ID** (`20774429`) are consistently mentioned across all documents, confirming the context of these answers.","['1. **Albuterol Inhaler**\n\t* Dose: 2 PUFF IH Q8H\n\t* Indication: PRN shortness of breath\n2. **Amlodipine**\n\t* Dose: 10 mg PO DAILY\n3. **Atorvastatin**\n\t* Dose: 80 mg PO QPM\n4. **Carvedilol**\n\t* Dose: 50', '* **Medications on Admission (Pre-admission List):**\n\t1. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath\n\t2. **Amlodipine**: 10 mg PO DAILY\n\t3. **Atorvastatin**: 80 mg PO QPM\n\t4. **Carved', '* **Discharge Medications:**\n\t1. **Torsemide**: 100 mg PO DAILY (newly prescribed)\n\t2. **Albuterol Inhaler**: 2 PUFF IH Q8H:PRN shortness of breath (continued)\n\t3. **Amlodipine**: 10 mg PO DAILY (cont', '* **Admission Medications:**\n\t1. Albuterol Inhaler\n\t2. Amlodipine 10 mg PO DAILY\n\t3. Atorvastatin 80 mg PO QPM\n\t4. Carvedilol 50 mg PO BID\n\t5. Furosemide 80 mg PO DAILY\n\t6. Insulin (70/30) 30 Units Br', '1. **Torsemide**\n\t* Dose: 100 mg\n\t* Frequency: PO DAILY\n\t* Additional Info: *torsemide 20 mg 5 tablet(s) by mouth once a day, Disp #*70, Tablet Refills:*0\n2. **70/30 Insulin**\n\t* Dose: \n\t\t+ 30 Units w']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What adjustments were made to the patient's medication regimen for managing Type 2 Diabetes Mellitus (T2DM) and Hypertension, and what follow-up actions were recommended upon discharge?","['386e4975-89d1-411a-99a3-9d225138df6c\n\n[] Ensure that patient was able to adhere to a diabetic diet\nPCP:\n[] Had elevated SBP in 130s-150s. Increased minoxidil to 5mg and \ncarvedilol to 50 mg BID. Please follow-up on blood pressures. \n[] Follow up on diuretics and volume status. Please get \nfollow-up labs BUN/Cr at follow-up appointment.\nNew meds: 70-30 novolog (30 units in AM, 20 units at dinner)\nStopped meds: none\nChanged meds: Carvedilol 50 mg twice a day, increased minoxidil \n5 mg daily \nACUTE ISSUES: \n=============== \n# HHS\n# T2DM\nPatient has history of poorly-controlled DM w/ A1c ~14. Based on \nlabs, determined to be in HHS likely precipitated by med \nnon-adherence or difficulty understanding multi-step process. No \nclear infection was identified. Of note, he tends to have high \ninsulin requirements. Pt was continued on insulin basal/bolus \nwhile inpatient. There was significant efforts to have him bring \nin home Victoza but he only had a half dose so he was continued \non basal/bolus course and made a plan for close outpatient \nfollow up and home 2 injections (Victoza and pre-mixed insulin).']","Adjustments made to the patient's medication regimen include: increasing minoxidil to 5mg daily and carvedilol to 50mg twice a day (BID) to manage elevated Systolic Blood Pressure (SBP); continuation of basal/bolus insulin due to high insulin requirements and the patient's difficulty with multi-step medication processes. Specifically for T2DM, the patient was started on 70-30 novolog (30 units in the morning, 20 units at dinner). Upon discharge, recommended follow-up actions include: monitoring blood pressures, assessing diuretics and volume status, and obtaining follow-up labs for BUN/Cr at the next appointment. Additionally, plans were made for close outpatient follow-up and administering two injections at home (Victoza and pre-mixed insulin).",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, 2, 3, 4, and 5)
**Note ID:** 13180007-DS-19 (consistent across all documents)
**Admission ID:** 20774429 (consistent across all documents)
**Relevant Time Frames:** Chart Time - 20/06/62 0:00, Store Time - 21/06/62 9:56 (consistent across all documents)

**Adjustments to Medication Regimen for T2DM and Hypertension:**

1. **Type 2 Diabetes Mellitus (T2DM) Management:**
	* **Initial Medication (Document 1):** 
		+ 70/30 Insulin (dosage and timing not specified)
	* **Adjustment (Document 2 & Further Clarified in Document 4):**
		- Insulin regimen adjusted to home regimen, with specific dosages provided in **Document 4:**
			- 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)
	* **Additional T2DM Relevant Medication (Document 2):**
		- No direct T2DM medications added beyond insulin adjustments, but **Vitamin D 1000 UNIT PO DAILY** was added, which can be beneficial for overall health but is not directly targeted at T2DM management.
2. **Hypertension Management:**
	* **Initial Medications (Document 1):**
		+ Amlodipine 10 mg PO DAILY
		+ Carvedilol 50 mg PO BID
		+ (Indirectly related) Torsemide 100 mg PO DAILY for fluid accumulation, often associated with heart failure, a potential complication of hypertension.
	* **Adjustments:**
		- No direct adjustments to hypertension medications are noted across the documents. **Torsemide** is mentioned as ""New/Changed"" in **Document 2**, but the change specifics are not detailed beyond being part of the discharge regimen, implying its continuation or initiation for managing fluid accumulation, which can be related to heart failure, a condition often linked to hypertension.

**Follow-up Actions Recommended Upon Discharge:**

* **Specific Follow-up Appointments:** Not Provided in any of the documents (as indicated in **Document 1** under **Follow-up Appointments**: [NOT PROVIDED])
* **General Post-Discharge Instructions (Document 5):**
	+ **Reason for Hospital Admission** and **Summary of Hospital Stay** are provided for context, but specific follow-up actions (e.g., follow-up appointments, monitoring instructions) beyond taking all medications as prescribed (**Document 4**) are not detailed in the provided documents.

**Note:** For comprehensive follow-up actions and any additional adjustments not captured in the provided documents, consulting the original patient chart or discharge paperwork not included here may be necessary.","['+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ', 'Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What are the current management strategies for a patient with Coronary Artery Disease (CAD) presenting with inducible ischemia and a recent Non-ST Elevation Myocardial Infarction (NSTEMI), given the presence of chronic kidney disease (CKD)?","['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', '5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,']","According to the provided context, for a patient with CAD, inducible ischemia, and recent NSTEMI (troponin peaked at 0.02, suspected as type 2 due to volume overload), the management includes:  - Continuation of aspirin, atorvastatin, and carvedilol.  - A decision was made to hold off on the coronary angiogram due to compromised kidney function and the suspicion of a type 2 myocardial infarction.  Additionally, the patientâs hypertension is being managed with multiple anti-hypertensives, aiming for <130/80, and a secondary hypertension workup was conducted, which included an aldosterone to renin ratio and 24-hour urine metanephrines and catecholamines, all within normal limits.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I'll address the question to the best of my abilities. However, please note the following:

1. **CAD and NSTEMI are not explicitly mentioned** in the provided documents as current conditions for the patient. The documents mention chest pain with mild troponin elevation, which is interpreted as possibly not indicative of ischemia due to the presence of CKD.
2. **CKD is confirmed** across multiple documents.

Given these points, I'll provide an answer that aligns with the instructions and the information available in the documents, while highlighting the assumptions needed to address the question directly.

**Assumptions for Direct Answering:**
- Assuming the patient has or is suspected to have CAD with a recent NSTEMI, as per the question (not explicitly stated in the documents).
- Focusing on management strategies for a patient with CKD, as this is confirmed.

**Answer Based on Provided Documents and Assumptions:**

### Patient/Subject ID: 13180007 (Consistent across all documents)
### Note ID: 13180007-DS-19 (Consistent across all documents)
### Admission ID: 20774429 (Consistent across all documents)

**Management Strategies for Assumed CAD/NSTEMI with Confirmed CKD:**

1. **Cardiovascular Management (Assumed based on the question, not directly from documents):**
   - Typically, for CAD with NSTEMI, management would include antiplatelet therapy (e.g., ASA, as mentioned in **Document 1** for chest pain), statins (e.g., Atorvastatin, also mentioned in **Document 1**), beta-blockers (e.g., Coreg 50 BID mentioned in **Document 4** for hypertension), and possibly ACE inhibitors or ARBs, which are not explicitly mentioned for cardiovascular purposes but are common in CKD and heart failure management.

2. **CKD Management (Directly from documents):**
   - **Sevelamer** (mentioned in **Document 4**) for phosphate control.
   - Monitoring of renal function (evidenced by Cr levels in **Documents 3, 4, and 5**).
   - Management of complications (e.g., anemia, as noted in **Documents 2 and 4**, with iron supplementation possibly implied but not directly stated for treatment during this admission).

3. **Heart Failure and Hypertension Management (Relevant given the patient's profile, though not directly answering the assumed CAD/NSTEMI question):**
   - **Amlodipine** and **Minoxidil** for hypertension (**Document 4**).
   - Management of heart failure with preserved ejection fraction (HFpEF) as per **Document 5**, though specific treatments beyond those for hypertension and CKD are not detailed in the provided documents.

**Limitations:**
- The direct question about CAD, NSTEMI, and their management with CKD cannot be fully addressed due to the absence of explicit mentions in the documents.
- The provided management strategies are inferred based on standard practices for patients with CKD and assumed cardiovascular conditions, supplemented with actual treatments mentioned for the patient's confirmed conditions.","['### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '- AnGap: 13\n\t\t- **05:53 AM**\n\t\t\t- Calcium: 8.4\n\t\t\t- Phos: 4.9* (High)\n\t\t\t- Mg: 2.0\n\t\t\t- Iron: 28*\n\t\t\t- calTIBC: 294\n\t\t\t- Ferritn: 73\n\t\t\t- TRF: 226\n\t\t\t- %HbA1c: 11.4* (High)\n\t\t\t- eAG: 280*\n\t\t\t- TSH: 4.', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the prescribed dosage and administration schedule for sevelamer CARBONATE in the provided patient discharge information, and how might it relate to the patient's diagnosed conditions, particularly those affecting kidney function (e.g., CKD)?","['080dba33-29e9-4409-89cb-54a03af0e470\n\n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Torsemide 100 mg PO DAILY  \n13.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n14.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNSOIS:\n==================\nAcute Hypoxemic Respiratory Failure\nAcute on Chronic Diastolic Heart Failure\nHyperglycemia, Type 2 Diabetes \n___ on CKD \nSECONDARY DIAGNOSIS:', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","According to the discharge medication lists (nodes: 080dba33-29e9-4409-89cb-54a03af0e470 and 784a4f17-941d-40ee-a5aa-7471e6a5f600), the prescribed dosage for sevelamer CARBONATE is 800 mg, administered orally three times a day (PO TID) with meals. Sevelamer carbonate is often used to treat high phosphate levels in patients with chronic kidney disease (CKD). Given the patient's secondary diagnosis includes '___ on CKD' in one discharge summary and no explicit mention in the other, but both indicating the presence of kidney issues through CKD, the sevelamer carbonate is likely prescribed to manage hyperphosphatemia associated with CKD, thereby supporting the patient's renal health alongside other treatments for diagnosed conditions like Acute on Chronic Diastolic Heart Failure and Type 2 Diabetes.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Prescribed Dosage and Administration Schedule for Sevelamer Carbonate:**

* **Dosage:** 800 mg
* **Administration Schedule:** PO (Orally) TID (Three Times a Day) W/MEALS

**Source Documents:** This information is consistently reported across:
1. **Document 1** (CONTENT, under *Discharge Medications*, implied continuation with no changes mentioned)
2. **Document 2** (CONTENT, listed as #11)
3. **Document 3** (CONTENT, listed as #11 with detailed format)
4. **Document 4** (CONTENT, listed under *Chronic Kidney Disease (CKD)*, mentioned as ""continued from home"")

**Relation to Diagnosed Conditions, Particularly Affecting Kidney Function (e.g., CKD):**

* **Condition:** Chronic Kidney Disease (CKD)
* **Source Document:** **Document 4** (CONTENT, under #3)
* **Implication:** Sevelamer Carbonate is prescribed for the management of CKD. Sevelamer is a phosphate binder used to treat high phosphate levels in the blood, which is a common complication in patients with CKD. The continuation of this medication from home, as noted in **Document 4**, suggests its ongoing importance in the patient's CKD management plan.

**Metadata Consistency for Patient/Subject ID, Note ID, and Admission ID:**
All five documents (**Document 1** to **Document 5**) share the same:
- **Patient/Subject ID:** 13180007
- **Note ID:** 13180007-DS-19
- **Admission ID:** 20774429
- **Chart Time:** 20/06/62 0:00
- **Store Time:** 21/06/62 9:56

This consistency indicates that all documents pertain to the same patient's hospital admission and note.","['11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '11. Sevelamer CARBONATE 800 mg PO TID W/MEALS\n\t12. Victoza (Liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Follow-up Appointments:**\n\t+ **Lab Follow-u', '10. **Polyethylene Glycol**\n\t* Dose: 17 g\n\t* Frequency: PO DAILY:PRN (as needed) for Constipation - First Line\n11. **Sevelamer Carbonate**\n\t* Dose: 800 mg\n\t* Frequency: PO TID (three times a day) W/ME', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', 'Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
"What is the significance of continuing ASA (Aspirin) in the patient's treatment plan, given their medical history and recent hospitalization?","[""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin."", 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","The patient was continued on ASA (Aspirin) and atorvastatin, indicating that these medications are crucial for managing the patient's condition. Given the patient's history of CVA (Cerebrovascular Accident) with episodes of dysarthria, confusion, and aphasia, ASA is likely prescribed for its antiplatelet effects to prevent further cerebrovascular events. Additionally, the patient has risk factors for ischemia, although recent findings were not suggestive of ischemia. ASA's continuation suggests its importance in primary or secondary prevention of cardiovascular events, aligning with the patient's overall cardiovascular and cerebrovascular risk management.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Significance of Continuing ASA (Aspirin) in the Patient's Treatment Plan:**

Based on the provided documents, the continuation of Aspirin (ASA) in the patient's treatment plan is significant due to its role in managing two critical aspects of the patient's medical history:

1. **History of CVA (Cerebrovascular Accident)**: Aspirin is commonly used as an antiplatelet agent to prevent future strokes in patients with a history of CVA. Its continuation (as noted in **Document 1** under ""CHRONIC PROBLEMS"" and **Document 3** under ""#History of CVA"") suggests an ongoing effort to reduce the risk of subsequent cerebrovascular events.

2. **Cardiovascular Implications of Other Conditions**: Although not directly stated for all conditions, Aspirin's antiplatelet effects are also beneficial for patients with cardiovascular diseases. Given the **Primary Diagnosis of Acute on chronic diastolic heart failure exacerbation** (as seen in **Document 3** under ""DISCHARGE DIAGNOSIS""), continuing Aspirin may help manage the cardiovascular aspects of this condition, though this is somewhat inferred as the direct link to heart failure management isn't explicitly stated in the provided documents.

**Additional Observations from Metadata and Content:**

- **Consistency in Patient/Subject ID, Note ID, and Admission ID**: All documents (**1** through **5**) share the same:
	* **Patient/Subject ID**: 13180007
	* **Note ID**: 13180007-DS-19
	* **Admission ID**: 20774429
	* **Chart Time** and **Store Time**, indicating these documents pertain to the same patient's single hospital admission, with updates or different sections of the medical record.

- **Medication Consistency**: Aspirin's dosage (81 mg PO DAILY) is consistently mentioned across **Document 1** and **Document 2**, reinforcing its established role in the patient's long-term management plan.

**Recommendation for Further Analysis:**
For a more comprehensive understanding of Aspirin's role in this patient's care, reviewing documents that explicitly link medications to the **Primary** and **Secondary Diagnoses** (as listed in **Document 3**) would be beneficial. Additionally, analyzing the patient's response to Aspirin and any potential side effects or interactions with other medications (like Torsemide, which was newly added or changed as per **Document 2**) could provide further insights into the treatment plan's efficacy and safety.","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t12. Aspirin 81 mg PO DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Discharge Medications:**\n\t(Similar to Admission with the following changes/notable menti', '#### 26. CHRONIC PROBLEMS\n* **#Hypothyroidism:**\n\t+ **Medication:** Levothyroxine 100mcg daily\n* **#History of CVA:**\n\t+ **Medications:** Aspirin, Atorvastatin 80\n\n#### 30. DISCHARGE DIAGNOSIS\n* **Pri', ""**Additional Relevant Information (not explicitly under Social History but related to patient's social context):**"", '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]",,,,
